Taimei
太美医疗科技

浙江太美醫療科技股份有限公司
Zhejiang Taimei Medical Technology Co., Ltd.

(A joint stock company incorporated in the People's Republic of China with limited liability)
（於中華人民共和國註冊成立的股份有限公司）

Stock Code 股份代號：2576

2026
INTERIM REPORT 中期報告

CONTENTS 目錄

CORPORATION INFORMATION
公司資料

BOARD OF DIRECTORS
董事會

Executive Directors
執行董事

Dr. ZHAO Lu (Chairman of the Board) 趙璐博士(董事長)
Ms. WAN Yunyun (General Manager) 萬韞鋆女士(總經理)
Mr. MA Dong 馬東先生
Mr. ZHANG Hongwei 張宏偉先生
Mr. LU Yiming 陸一鳴先生
Ms. NI Xiaomei 倪曉梅女士

Independent Non-Executive Directors
獨立非執行董事

Dr. JIANG Xiao 蔣驍博士
Mr. FUNG Che Wai Anthony 馮志偉先生
Dr. GONG Yan 龔焱博士

AUDIT COMMITTEE
審計委員會

Mr. FUNG Che Wai Anthony (Chairman) 馮志偉先生(主席)
Dr. JIANG Xiao 蔣驍博士
Dr. GONG Yan 龔焱博士

REMUNERATION AND APPRAISAL COMMITTEE
薪酬與考核委員會

Dr. GONG Yan (Chairman) 龔焱博士(主席)
Dr. ZHAO Lu 趙璐博士
Mr. FUNG Che Wai Anthony 馮志偉先生

NOMINATION COMMITTEE
提名委員會

Dr. ZHAO Lu (Chairman) 趙璐博士(主席)
Dr. JIANG Xiao 蔣驍博士
Dr. GONG Yan 龔焱博士
Ms. NI Xiaomei 倪曉梅女士
Mr. FUNG Che Wai Anthony 馮志偉先生

SUPERVISORY COMMITTEE
監事會

Ms. DONG Xiaohan (Chairlady) 董曉晗女士(主席)
Mr. WEN Gang 文綱先生
Mr. CAI Xin 蔡鑫先生

AUDITOR

PricewaterhouseCoopers
Certified Public Accountants and
Registered Public Interest Entity Auditor
22/F Prince's Building Central
Hong Kong SAR, China

核數師

羅兵咸永道會計師事務所
執業會計師及註冊
公眾利益實體核數師
中國香港特別行政區
中環太子大廈22樓

JOINT COMPANY SECRETARIES

Ms. NI Xiaomei
Mr. POON Ping Yeung

聯席公司秘書

倪曉梅女士
潘秉揚先生

AUTHORISED REPRESENTATIVES

Ms. NI Xiaomei
Mr. POON Ping Yeung

授權代表

倪曉梅女士
潘秉揚先生

REGISTERED OFFICE, HEADQUARTERS AND PRINCIPAL PLACE OF BUSINESS IN CHINA

3/F, Building 9
Smart Industry Innovation Park
36 Changsheng South Road, Jiaxing
Zhejiang
PRC

中國註冊辦事處、總部及主要營業地點

中國
浙江省
嘉興市昌盛南路36號
智慧產業創新園
9號樓3樓

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

19/F, Golden Centre
188 Des Voeux Road Central
Hong Kong

香港主要營業地點

香港
德輔道中188號
金龍中心19樓

H SHARE REGISTRAR

Computershare Hong Kong Investor Services Limited
Shops 1712–1716, 17th Floor
Hopewell Centre
183 Queen's Road East
Wan Chai
Hong Kong

H股證券登記處

香港中央證券登記有限公司
香港
灣仔
皇后大道東183號
合和中心
17樓1712–1716號舖

CORPORATION INFORMATION
公司資料

PRINCIPAL BANKERS

China Minsheng Banking Corp., Ltd., Jiaxing Sub-branch
1818 Zuili Road
Nanhu District, Jiaxing
Zhejiang
PRC

Bank of Hangzhou Co., Ltd., Jiaxing Sub-branch
1/F, Yihong Building
1029 Chengnan Road
Nanhu District, Jiaxing
Zhejiang
PRC

主要往來銀行

中國民生銀行股份有限公司嘉興分行
中國
浙江省
嘉興市南湖區
檇李路1818號

杭州銀行股份有限公司嘉興分行
中國
浙江省
嘉興市南湖區
城南路1029號
億鴻大廈1樓

LEGAL ADVISER

As to Hong Kong Laws
Jingtian & Gongcheng LLP
Suites 3203–3209, 32/F.
Edinburgh Tower, The Landmark
15 Queen's Road Central
Central
Hong Kong

As to PRC Laws
Jingtian & Gongcheng
34/F, Tower 3, China Central Place
77 Jianguo Road
Chaoyang District
Beijing
PRC

法律顧問

有關香港法律
競天公誠律師事務所有限法律責任合夥
香港
中環
皇后大道中15號
置地廣場公爵大廈
32樓3203–3209室

有關中國法律
競天公誠律師事務所
中國
北京市
朝陽區
建國路77號
華貿中心3號寫字樓34樓

STOCK CODE

2576

股份代號

2576

COMPANY WEBSITE

www.taimei.com

公司網站

www.taimei.com

DEFINITIONS
釋義

In this interim report, unless the context otherwise requires, the following terms shall have the following meanings:

在本中期報告中，除非另有所指，下列詞彙具有下列涵義：

"affiliate(s)"		with respect to any specified person, any other person, directly or indirectly, controlling or controlled by or under direct or indirect common control with such specified person
「聯屬人士」	指	就任何特定人士而言，直接或間接控制或受控於該特定人士或與該特定人士直接或間接受共同控制的任何其他人士
"AGM"		the 2025 annual general meeting of the Company held on Tuesday, June 23, 2026
「股東週年大會」	指	本公司於2026年6月23日(星期二)舉行的2025年年度股東會
"Articles" or "Articles of Association"		the articles of association of the Company currently in force
「章程」或「公司章程」	指	現時生效的本公司章程
"associate(s)"		has the meaning ascribed thereto under the Listing Rules
「聯繫人」	指	具有上市規則賦予該詞的涵義
"Audit Committee"		the audit committee of the Board
「審計委員會」	指	董事會審計委員會
"Board" or "Board of Directors"		the board of Directors
「董事會」	指	董事會
"CG Code"		the Corporate Governance Code as set out in Appendix C1 to the Listing Rules
「企業管治守則」	指	上市規則附錄C1所載的企業管治守則
"China" or "the PRC"		the People's Republic of China, excluding, for the purposes of this interim report, Hong Kong, the Macau Special Administrative Region of the People's Republic of China and Taiwan
「中國」	指	中華人民共和國，就本中期報告而言不包括香港、中華人民共和國澳門特別行政區及台灣
"Companies Ordinance"		the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
「公司條例」	指	香港法例第622章公司條例(經不時修訂、補充或以其他方式修改)

DEFINITIONS
釋義

"Company" "our Company" or "Taimei Medical Technology"		Zhejiang Taimei Medical Technology Co., Ltd. (浙江太美醫療科技股份有限公司), a joint stock company with limited liability incorporated in the PRC, the predecessor of which was Jiaxing Taimei Medical Technology Co., Ltd. (嘉興太美醫療科技有限公司), a limited liability company established in the PRC on June 6, 2013, and if the context requires, includes its predecessor
「本公司」或「太美醫療科技」	指	浙江太美醫療科技股份有限公司，一家於中國註冊成立的股份有限公司(其前身為嘉興太美醫療科技有限公司，一家於2013年6月6日在中國成立的有限責任公司)，以及若文義有所指則包括其前身
"CRO"		a contract research organization, which provides professional services to pharmaceutical companies and research institutions during the drug development process through contractual agreements
「CRO」	指	受託研究機構，其透過受託協議在藥物開發過程中為製藥公司及研究機構提供專業服務
"Director(s)"		the director(s) of our Company
「董事」	指	本公司董事
"Domestic Share(s)"		ordinary share(s) in the share capital of our Company, with a nominal value of RMB1.00 each, which are subscribed for in Renminbi
「內資股」	指	本公司股本中每股面值人民幣1.00元的普通股，以人民幣認購
"Global Offering"		has the meaning ascribed thereto in the Prospectus
「全球發售」	指	具有招股章程所賦予之涵義
"Group", "our Group", "we", "us" or "our"		our Company and all of its subsidiaries, or any one of them as the context may require
「本集團」或「我們」	指	本公司及其所有附屬公司，或按文義指其中任何一家公司
"H Share(s)"		overseas listed foreign invested ordinary share(s) in the ordinary share capital of our Company, with a nominal value of RMB1.00 each, which are listed on the Stock Exchange
「H股」	指	本公司普通股股本中每股面值人民幣1.00元的境外上市外資普通股，於聯交所上市
"H Share Registrar"		Computershare Hong Kong Investor Services Limited
「H股證券登記處」	指	香港中央證券登記有限公司

"Hong Kong" or "HK" 「香港」	指	Hong Kong Special Administrative Region of the PRC 中國香港特別行政區
"Hong Kong dollars" or "HK$" 「港元」	指	Hong Kong dollars, the lawful currency of Hong Kong 香港法定貨幣港元
"Hong Kong Stock Exchange" or "Stock Exchange" 「香港聯交所」或「聯交所」	指	The Stock Exchange of Hong Kong Limited, a wholly owned subsidiary of Hong Kong Exchanges and Clearing Limited 香港聯合交易所有限公司，為香港交易及結算所有限公司的全資附屬公司
"IFRS" 「國際財務報告準則」	指	IFRS Accounting Standards 國際財務報告會計準則
"Listing" 「上市」	指	the listing of the H Shares on the Main Board of the Hong Kong Stock Exchange H股於香港聯交所主板上市
"Listing Date" 「上市日期」	指	October 8, 2024, on which the H Shares were first listed and dealings in the H Shares first commenced on the Stock Exchange 2024年10月8日，H股首次在聯交所上市及首次開始交易的日期
"Listing Rules" or "Hong Kong Listing Rules" 「上市規則」或「香港上市規則」	指	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (as amended, supplemented or otherwise modified from time to time) 香港聯合交易所有限公司證券上市規則(經不時修訂、補充或以其他方式修改)
"Main Board" 「主板」	指	the stock market (excluding the option market) operated by the Hong Kong Stock Exchange which is independent from and operated in parallel with the GEM of the Hong Kong Stock Exchange 香港聯交所運作的股票市場(不包括期權市場)，獨立於香港聯交所GEM且與其並行運作
"Model Code" 「標準守則」	指	the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules 上市規則附錄C3所載的上市發行人董事進行證券交易的標準守則
"Nomination Committee" 「提名委員會」	指	the nomination committee of the Board 董事會提名委員會

"PRC Company Law"		the Company Law of the People's Republic of China (《中華人民共和國公司法》), as amended, supplemented or otherwise modified from time to time
「《中國公司法》」	指	《中華人民共和國公司法》，經不時修訂、補充或以其他方式修改
"Prospectus"		the prospectus issued by the Company and published on the websites of the Company and the Stock Exchange on September 27, 2024
「招股章程」	指	本公司於2024年9月27日刊發並登載於本公司及聯交所網站之招股章程
"Remuneration and Appraisal Committee"		the remuneration and appraisal committee of the Board
「薪酬與考核委員會」	指	董事會薪酬與考核委員會
"Renminbi" or "RMB"		Renminbi, the lawful currency of the PRC
「人民幣」	指	中國的法定貨幣人民幣
"Reporting Period"		for the six months ended June 30, 2026
「報告期間」	指	截至2026年6月30日止六個月
"Ruansu Enterprise Management"		Xinyu Ruansu Enterprise Management Partnership (Limited Partnership) (新余軟素企業管理合夥企業(有限合夥)) (formerly known as Shanghai Ruansu Enterprise Management Partnership (Limited Partnership) (上海軟素企業管理合夥企業(有限合夥)))
「軟素企業管理」	指	新余軟素企業管理合夥企業（有限合夥）（前稱上海軟素企業管理合夥企業（有限合夥））
"R&D"		research and development
「研發」	指	研究與開發
"SFO"		the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
「《證券及期貨條例》」	指	香港法例第571章《證券及期貨條例》（經不時修訂、補充或以其他方式修改）
"Shanghai Kunrui"		Shanghai Kunrui Enterprise Management Partnership (Limited Partnership) (上海昆鋭企業管理合夥企業(有限合夥)) (formerly known as Shanghai Kunrui Investment Management Partnership (Limited Partnership) (上海昆鋭投資管理合夥企業(有限合夥)))
「上海昆鋭」	指	上海昆鋭企業管理合夥企業（有限合夥）（前稱上海昆鋭投資管理合夥企業（有限合夥））

"Taimei Intelligence"		Taimei Intelligence Pharmaceutical (Shanghai) R&D Co., Ltd. (formerly named " 聖方(上海)醫藥研發有限公司"," **Taimei Intelligence**")
「太美智研」	指	太美智研醫藥研發(上海)有限公司(前稱聖方(上海)醫藥研發有限公司，「**太美智研**」)
"Shanghai Xiaoju"		Shanghai Xiaoju Enterprise Management Partnership (Limited Partnership) (上海小橘企業管理合夥企業(有限合夥)) (formerly known as Shanghai Xiaoju Investment Management Partnership (Limited Partnership) (上海小橘投資管理合夥企業(有限合夥)))
「上海小橘」	指	上海小橘企業管理合夥企業(有限合夥)(前稱上海小橘投資管理合夥企業(有限合夥))
"Share(s)"		ordinary share(s) in the capital of our Company with a nominal value of RMB1.00 each, including both Domestic Shares and H Shares
「股份」	指	本公司股本中每股面值人民幣1.00元的普通股，包括內資股及H股
"Shareholder(s)"		holder(s) of our Share(s)
「股東」	指	股份持有人
"subsidiary(ies)"		has the meaning ascribed thereto under the Listing Rules
「附屬公司」	指	具有上市規則賦予該詞的涵義
"substantial shareholder(s)"		has the meaning ascribed thereto under the Listing Rules
「主要股東」	指	具有上市規則賦予該詞的涵義
"Supervisor(s)"		member(s) of the Supervisory Committee
「監事」	指	監事會成員
"Supervisory Committee"		the supervisory committee of our Company
「監事會」	指	本公司監事會
"Taimei Digital Technology"		Shanghai Taimei Digital Technology Co., Ltd. (上海太美數字科技有限公司) (formerly known as Shanghai Taimei Hongsheng Intelligent Technology Limited (上海太美弘聖智能科技有限公司))
「太美數字科技」	指	上海太美數字科技有限公司(前稱上海太美弘聖智能科技有限公司)
"Taimei International"		Shanghai Taimei International Consulting Co., Ltd. (上海太美星際企業諮詢有限公司)
「太美星際」	指	上海太美星際企業諮詢有限公司

"Taimei Xingcheng"		Hangzhou Taimei Xingcheng Pharmaceutical Technology Co., Ltd. (杭州太美星程醫藥科技有限公司)
「太美星程」	指	杭州太美星程醫藥科技有限公司
"Taimei Xinghuan"		Shanghai Taimei Xinghuan Digital Technology Co., Ltd. (上海太美星環數字科技有限公司) (formerly known as Shanghai Softium Technology Ltd. (上海軟素科技有限公司) and Shanghai Softium Technology Co., Ltd. (上海軟素科技股份有限公司))
「太美星環」	指	上海太美星環數字科技有限公司(前稱上海軟素科技有限公司及上海軟素科技股份有限公司)
"Taimei Xingyun"		Shanghai Taimei Xingyun Digital Technology Co., Ltd. (上海太美星雲數字科技有限公司) (formerly known as Shanghai Yikai Intelligent Technology Co., Ltd. (上海億鐦智能科技有限公司))
「太美星雲」	指	上海太美星雲數字科技有限公司(前稱上海億鐦智能科技有限公司)
"Treasury Shares"		has the meaning ascribed thereto under the Listing Rules
「庫存股份」	指	具有上市規則賦予該詞的涵義
"United States" or "U.S."		the United States of America, its territories, its possessions and all areas subject to its jurisdiction
「美國」	指	美利堅合眾國、其國土、屬地及受其司法管轄的所有地區
"U.S. dollars", "US$" or "USD"		United States dollars, the lawful currency of the United States
「美元」	指	美國法定貨幣美元
"Xinyu Haolin"		Xinyu Haolin Enterprise Management Partnership (Limited Partnership) (新余浩霖企業管理合夥企業(有限合夥)) (formerly known as Jiaxing Haolin Enterprise Management Partnership (Limited Partnership) (嘉興浩霖企業管理合夥企業(有限合夥)))
「新余浩霖」	指	新余浩霖企業管理合夥企業(有限合夥)(前稱嘉興浩霖企業管理合夥企業(有限合夥))
"Xinyu Nuoming"		Xinyu Taimei Nuoming Enterprise Management Partnership (Limited Partnership) (新余太美諾銘企業管理合夥企業(有限合夥))
「新余諾銘」	指	新余太美諾銘企業管理合夥企業(有限合夥)

"Xinyu Qiwushi"		Xinyu Qiwushi Medical Technology Partnership (Limited Partnership) (新余七武士醫療科技合夥企業(有限合夥)) (formerly known as Jiaxing Qiwushi Medical Technology Partnership (Limited Partnership) (嘉興七武士醫療科技合夥企業(有限合夥))
「新余七武士」	指	新余七武士醫療科技合夥企業(有限合夥)(前稱嘉興七武士醫療科技合夥企業(有限合夥))
"Xinyu Shenkong"		Xinyu Shenkong Enterprise Management Partnership (Limited Partnership) (新余深空企業管理合夥企業(有限合夥))
「新余深空」	指	新余深空企業管理合夥企業(有限合夥)
"Xinyu Xingmeng"		Xinyu Taimei Xingmeng Enterprise Management Partnership (Limited Partnership) (新余太美星盟企業管理合夥企業(有限合夥))
「新余星盟」	指	新余太美星盟企業管理合夥企業(有限合夥)
"Zhoushan Yijin"		Zhoushan Yijin Investment Management Partnership (Limited Partnership) (舟山憶瑾投資管理合夥企業(有限合夥)) (formerly known as Jiaxing Yijin Enterprise Management Consulting Partnership (Limited Partnership) (嘉興憶瑾企業管理諮詢合夥企業(有限合夥)))
「舟山憶瑾」	指	舟山憶瑾投資管理合夥企業(有限合夥)(前稱嘉興憶瑾企業管理諮詢合夥企業(有限合夥))
"2026 H Share Award Scheme"		the share award scheme adopted by our Company on February 14, 2026
「2026年H股獎勵計劃」	指	本公司於2026年2月14日採納的股份獎勵計劃
"%"		per cent
「%」	指	百分比

Note: The English translation of Chinese names of entities included in this interim report is prepared for identification purpose only.

*附註：*本中期報告所載實體的中文名稱之英文譯名僅供識別。

FINANCIAL HIGHLIGHTS
財務摘要

		Six months Ended June 30, 截至6月30日止六個月				
		2026 2026年		2025 2025年		
		RMB'000 人民幣千元	**% of Revenue 收入百分比**	RMB'000 人民幣千元	% of Revenue 收入百分比	Year-on-year change (%) 同比變動 (%)
Revenue	收入	**263,639**	**100.0**	244,221	100.0	8.0
Gross profit	毛利	**117,750**	**44.7**	100,188	41.0	17.5
Operating loss	經營虧損	**(62,369)**	**-23.7**	(48,710)	-19.9	28.0
Loss for the period	期內虧損	**(48,161)**	**-18.3**	(29,309)	-12.0	64.3
Non-IFRS measures[(1)]:	非國際財務報告準則計量[(1)]：					
Adjusted net loss	經調整虧損淨額	**(30,907)**	**-11.7**	(28,696)	-11.8	7.7
Adjusted EBITDA	經調整EBITDA	**(3,424)**	**-1.3**	(20,708)	-8.5	-83.5

		As at June 30, 2026 於2026年6月30日 RMB'000 人民幣千元	As at December 31, 2025 於2025年12月31日 RMB'000 人民幣千元
Total assets	資產總值	**1,498,737**	1,556,327
Total liabilities	負債總額	**348,400**	365,468
Equity attributable to equity holders of the Company	本公司權益持有人應佔權益	**1,084,446**	1,121,867
Non-controlling interests	非控股權益	**65,891**	68,992
Cash and cash equivalents	現金及現金等價物	**477,324**	625,185

(1) See the section headed "Non-IFRS measures" for more information about the non-IFRS Accounting Standards measures.

(1) 有關非國際財務報告會計準則計量的更多資料，請參閱「非國際財務報告準則計量」一節。

BUSINESS OVERVIEW

As a leader in AI clinical development, Taimei Medical Technology is built upon a full-chain AI infrastructure and integrated with deep clinical development expertise, accelerating the clinical development and commercialization of innovative drugs and improving the success rate of clinical development. Taimei Medical Technology has participated in over 10,000 clinical development projects in aggregate.

業務回顧

太美醫療科技作為AI臨床開發的領導者，以全鏈路AI基礎設施為核心，融合深厚的臨床開發經驗，加速創新藥的臨床開發與商業化進程，提升臨床開發成功率。太美醫療科技已累計參與逾10,000項臨床開發項目。

1. Operating Performance

During the Reporting Period, the Company recorded new contract value of approximately RMB363.5 million, representing a year-on-year increase of 14.9%, which serves as a leading indicator of our business development and reflects the continued expansion of customer demand. By business segment:

– The **AI Clinical Development Platform** segment recorded a year-on-year increase of 46.9% in new contract value to approximately RMB266.1 million, primarily driven by the Wiz.AI Platform, which recorded new contract value of approximately RMB122.8 million during the Reporting Period, representing a year-on-year growth of 67.4%. Segment revenue increased by 22.2% year-on-year to approximately RMB158.8 million, of which revenue from the Wiz.AI Platform reached approximately RMB61.8 million, representing a year-on-year increase of 48.0%. Segment gross profit margin was 63.6%.

– The **AI-enabled CRO** segment recorded a year-on-year decrease of 27.9% in new contract value to approximately RMB97.4 million, and segment revenue decreased by 8.3% year-on-year to approximately RMB104.9 million, primarily due to the Company's proactive adjustment of its business structure during the Reporting Period and the orderly scaling down of certain historically low-margin contracts. Segment gross profit margin improved to 15.9%. As the business restructuring period gradually concludes, the continued penetration of AI capabilities in this segment is expected to contribute to the improvement of its revenue and earnings quality.

1. 經營表現

於報告期內，公司新增合同金額達約人民幣363.5百萬元，同比增長14.9%，作為公司業務發展的先行指標，反映客戶需求持續擴大。按業務分部劃分：

— **AI臨床開發平台**分部新簽合同金額同比增長46.9%至約人民幣266.1百萬元，主要由「Wiz.AI文思智能平台」帶動，該AI智能體平台報告期內新增合同金額達約人民幣122.8百萬元，同比增長67.4%。分部收入同比增長22.2%至約人民幣158.8百萬元，其中「Wiz.AI文思智能平台」收入達約人民幣61.8百萬元，同比增長48.0%。分部毛利率為63.6%。

— **AI賦能的臨床開發服務**分部新增合同金額同比下降27.9%至約人民幣97.4百萬元，分部收入同比下降8.3%至約人民幣104.9百萬元，主要由於公司於報告期內主動調整業務結構，有序壓縮部分歷史低毛利業務合同規模。分部毛利率提升至15.9%。隨著業務結構調整期逐步完成，AI能力於該分部的持續滲透將有助於改善其收入及盈利質量。

The Company recorded total revenue of approximately RMB263.6 million for the Reporting Period, representing a year-on-year increase of 8.0%, while overall gross profit margin increased from 41.0% for the corresponding period in 2025 to 44.7%.

公司報告期內總收入為約人民幣263.6百萬元，同比增長8.0%；整體毛利率由2025年同期的41.0%提升至44.7%。

During the Reporting Period, the Company recorded an adjusted EBITDA loss of approximately RMB3.4 million, representing a decline in the loss of approximately 83.5% as compared with the corresponding period in the last year. The Company's Non-IFRS adjusted net loss before the impact of foreign exchange gains or losses was approximately RMB2.0 million, representing a decline in the loss of approximately 84.0% as compared with the corresponding period in the last year. The optimization of revenue mix, enhancement of product capabilities and realization of economies of scale were the key drivers of the improvement in operating performance, while the Company's cash flow position continued to improve.

報告期內，公司經調整EBITDA虧損約人民幣3.4百萬元，較去年同期虧損收窄約83.5%。公司非國際財務報告準則計量經調整淨虧損（未計及匯兑損益影響）約人民幣2.0百萬元，較去年同期虧損收窄約84.0%。收入結構優化、產品力提升以及規模效應釋放為經營表現改善的主要驅動因素，公司現金流狀況持續改善。

2. Market Position

During the Reporting Period, more than 60% of innovative drugs of all Class 1 new drugs approved by the National Medical Products Administration (NMPA) were developed through Taimei's AI Clinical Development Platform. AI-empowered endpoint intelligence services have supported the approval of over 65 projects, including multiple "First-in-Class" innovative drug assets. The penetration of the Company's products and services in innovative drug development and customer recognition continued to increase, further consolidating Taimei's market position as a key partner in the clinical development of innovative drugs.

2. 市場地位

報告期內，國家藥品監督管理局(NMPA)批准的一類新藥中，逾60%的創新藥通過太美AI臨床開發平台完成開發。AI驅動的終點評估服務已助力65+項目獲批，含多款「First in Class」（同類首創）創新藥資產。公司產品及服務在創新藥開發領域的滲透程度及客戶認可度持續提升，進一步鞏固太美作為新藥臨床開發關鍵合作夥伴的市場地位。

3. Client Collaboration and International Expansion

During the Reporting Period, the Company reached cooperation consensus with several multinational pharmaceutical companies on end-to-end AI clinical development solutions, further deepening its international business presence. In South Korea, the Company entered into an enterprise-level strategic cooperation agreement with C&R Research, a leading local CRO, to collaborate on the development of an AI-powered clinical trial operation system. In Australia, the Company formed a strategic partnership with GreenLight Clinical, a renowned CRO; its AI-driven Electronic Data Capture System (EDC) and pharmacovigilance (eSafety) solutions have been integrated into GreenLight Clinical's clinical research service system, and relevant projects have been successfully delivered. In the Indian market, the Company partnered with Glenmark, a leading local pharmaceutical company, on trial endpoint intelligence services, leveraging AI technology to improve the efficiency, quality, and consistency of imaging assessments. The Company also entered into a strategic cooperation agreement with Shanghai United Imaging Healthcare Advanced Technology Research Institute (上海聯影醫療高新技術研究院) to jointly develop AI-driven imaging endpoint assessment solutions.

3. 客戶合作及國際化拓展

報告期內，公司與數家跨國製藥企業就AI臨床開發端到端解決方案達成合作共識，國際化業務佈局持續深化：於韓國，公司與當地頭部CRO企業C&R Research訂立企業級戰略合作協議，就人工智能臨床試驗運營體系建設展開合作；於澳大利亞，公司與知名CRO企業GreenLight Clinical達成戰略合作，其AI驅動的電子數據採集系統(EDC)與藥物警戒(eSafety)解決方案已集成至GreenLight Clinical的臨床研究服務體系，相關項目已順利完成交付；於印度市場，公司與當地頭部製藥企業Glenmark就臨床研究終點評估服務展開合作，以AI技術提升影像評估效率、質量與一致性。公司亦與上海聯影醫療高新技術研究院訂立戰略合作協議，共同開發AI驅動的影像終點評估解決方案。

4. Innovative Drug Pipeline Equity Fund

The Company has established the Innovative Drug Pipeline Equity Fund to continuously advance the assessment and selection of clinical assets investment. Leveraging the Company's proprietary AI selection and prediction model and professional clinical development capabilities, it has so far evaluated more than 150 clinical assets in total, covering multiple therapeutic areas and technological paths. The first pipeline investment is expected to be completed in the third quarter of 2026.

4. 創新藥管線權益基金

公司設立的創新藥管線權益基金持續推進臨床資產投資的評估與篩選工作。依託公司獨有的AI篩選及預測模型和臨床開發專業能力，目前已累計評估管線超過150個，覆蓋多個治療領域和技術路徑。首筆管線投資有望於2026年第三季度完成。

BUSINESS OUTLOOK

Looking ahead to the second half of the year, the management will continue to promote the Company's business development as follows:

(I) Continuously invest in the R&D of products on the AI Clinical Development Platform, and further advance the functional iteration and commercialization implementation of the Wiz.AI platform;

(II) Steadily push forward the business structure optimization of the AI-enabled CRO segment, continuously embed AI capabilities to upgrade the delivery quality and efficiency of development services, and enhance the profitability of this segment;

(III) Deepen international presence, and expand the Company's business network and customer partnerships in Europe, the United States and other key markets; and

(IV) Promote the implementation and deployment of clinical asset investments, and strengthen the business synergy model of "platform development services + clinical asset investments".

業務展望

展望下半年，管理層將繼續圍繞以下方向推進公司業務發展：

(一) 持續投入AI臨床開發平台產品研發，繼續推動Wiz.AI文思智能平台(Wiz.AI)的功能迭代與商業化落地；

(二) 穩步推進AI賦能的臨床開發服務分部的業務結構優化，持續嵌入AI能力，升級開發服務的交付效果和交付效率，提升該分部盈利能力；

(三) 深化國際化佈局，拓展公司於歐美及其他重點市場的業務網絡及客戶合作；及

(四) 推進創新藥管線權益投資的落地部署，強化「平台開發服務+權益投資」的業務協同模式。

FINANCIAL REVIEW

財務回顧

Revenues

收入

		Six Months Ended June 30, 截至6月30日止六個月				
		2026 2026年		2025 2025年		
		RMB'000 人民幣千元	% of Revenue 收入百分比	RMB'000 人民幣千元	% of Revenue 收入百分比	Year-on-year change (%) 同比變動 (%)
AI Clinical Development Platforms	AI臨床開發平台	158,782	60.2	129,888	53.2	22.2
AI-enabled CRO	AI賦能的臨床開發服務	104,857	39.8	114,333	46.8	-8.3
Total	總計	263,639	100.0	244,221	100.0	8.0

We primarily derive our revenue from two sectors: AI Clinical Development Platforms as well as AI-enabled CRO.

我們主要從兩個業務分部獲得收入：AI臨床開發平台以及AI賦能的臨床開發服務。

Our revenue increased by 8.0% from RMB244.2 million in the six months ended June 30, 2025 to RMB263.6 million in the six months ended June 30, 2026, reflecting our proactive efforts to optimize the revenue mix and focus on margin accretive businesses.

我們的收入由截至2025年6月30日止六個月的人民幣244.2百萬元增加8.0%至截至2026年6月30日止六個月的人民幣263.6百萬元，反映我們主動優化收入組合，聚焦於利潤率較高的業務。

AI Clinical Development Platforms. Our revenue from sales of AI Clinical Development Platforms increased by 22.2% from RMB129.9 million in the six months ended June 30, 2025 to RMB158.8 million in the six months ended June 30, 2026. This growth was primarily attributable to the expansion in sales of AI products, together with steady growth in repeat purchases and up-sell/cross-sell demand from existing customers.

AI臨床開發平台。我們AI臨床開發平台的銷售收入由截至2025年6月30日止六個月的人民幣129.9百萬元增加22.2%至截至2026年6月30日止六個月的人民幣158.8百萬元，該增長主要得益於AI產品銷售規模擴大，以及現有客戶複購與增購需求保持穩定增長所致。

AI-enabled CRO. Our revenue from AI-enabled CRO decreased by 8.3% from RMB114.3 million in the six months ended June 30, 2025 to RMB104.9 million in the six months ended June 30, 2026, mainly due to our proactive adjustment of business structure and systematic scaling down of certain low gross margin businesses.

AI賦能的臨床開發服務。我們來自AI賦能的臨床開發服務的收入由截至2025年6月30日止六個月的人民幣114.3百萬元減少8.3%至截至2026年6月30日止六個月的人民幣104.9百萬元，主要由於我們主動調整業務架構，並有系統地縮減若干低毛利率業務所致。

Cost of sales

Our cost of sales slightly increased by 1.3% from RMB144.0 million in the six months ended June 30, 2025 to RMB145.9 million in the six months ended June 30, 2026. This increase was primarily attributable to an increase of RMB1.1 million in share-based payments to certain employees.

銷售成本

我們的銷售成本由截至2025年6月30日止六個月的人民幣144.0百萬元輕微增加1.3%至截至2026年6月30日止六個月的人民幣145.9百萬元。該增加主要歸因於向若干僱員支付的以股份為基礎的付款增加人民幣1.1百萬元所致。

Gross profit and gross margin

Our gross profit increased by 17.5% from RMB100.2 million in the six months ended June 30, 2025 to RMB117.8 million in the six months ended June 30, 2026, mainly due to the increase in revenue. Our gross profit margin increased from 41.0% in the six months ended June 30, 2025 to 44.7% in the six months ended June 30, 2026, primarily driven by further improvement in the profitability of AI-enabled CRO, whose gross margin rose by 3.3 percentage points and the consistently high profitability of AI clinical development platforms.

毛利及毛利率

我們的毛利由截至2025年6月30日止六個月的人民幣100.2百萬元增加17.5%至截至2026年6月30日止六個月的人民幣117.8百萬元，主要由於收入增加所致。我們的毛利率由截至2025年6月30日止六個月的41.0%上升至截至2026年6月30日止六個月的44.7%，主要受AI賦能的臨床開發服務盈利能力進一步提升所推動，其毛利率上升3.3個百分點，且AI臨床開發平台持續保持高盈利能力。

Selling expenses

Our selling expenses increased by 17.5% from RMB37.6 million in the six months ended June 30, 2025 to RMB44.2 million in the six months ended June 30, 2026, primarily due to (i) an increase of RMB4.0 million in advertising costs and conference fee; and (ii) an increase of RMB1.1 million in share-based payments to certain employees.

銷售開支

我們的銷售開支由截至2025年6月30日止六個月的人民幣37.6百萬元增加17.5%至截至2026年6月30日止六個月的人民幣44.2百萬元，主要是由於(i)廣告成本及會議費用增加人民幣4.0百萬元；及(ii)向若干僱員支付的以股份為基礎的付款增加人民幣1.1百萬元。

Administrative expenses

Our administrative expenses increased by 21.3% from RMB57.7 million in the six months ended June 30, 2025 to RMB70.0 million in the six months ended June 30, 2026, primarily due to an increase of RMB11.5 million in share-based payments to certain employees.

行政開支

我們的行政開支由截至2025年6月30日止六個月的人民幣57.7百萬元增加21.3%至截至2026年6月30日止六個月的人民幣70.0百萬元，主要由於向若干僱員支付的以股份為基礎的付款增加人民幣11.5百萬元。

Research and development expenses

Our research and development expenses increased by 5.9% from RMB37.7 million in the six months ended June 30, 2025 to RMB39.9 million in the six months ended June 30, 2026, primarily attributable to an increase of RMB2.9 million in share-based payments to certain employees.

研發開支

我們的研發開支由截至2025年6月30日止六個月的人民幣37.7百萬元增加5.9%至截至2026年6月30日止六個月的人民幣39.9百萬元，主要歸因於向若干僱員支付的以股份為基礎的付款增加人民幣2.9百萬元。

Net impairment losses on financial and contract assets

We recorded net impairment losses on financial and contract assets of RMB5.5 million in the six months ended June 30, 2025 and RMB5.1 million in the six months ended June 30, 2026. Such change was primarily driven by a decrease in the credit risk.

金融及合約資產減值虧損淨額

我們於截至2025年6月30日止六個月及截至2026年6月30日止六個月錄得金融及合約資產減值虧損淨額分別為人民幣5.5百萬元及人民幣5.1百萬元。該變動主要由於信貸風險降低所致。

Other income

Our other income increased from RMB2.4 million in the six months ended June 30, 2025 to RMB6.3 million in the six months ended June 30, 2026, primarily due to the increase of RMB4.0 million in government grants.

其他收入

我們的其他收入由截至2025年6月30日止六個月的人民幣2.4百萬元增加至截至2026年6月30日止六個月的人民幣6.3百萬元，主要是由於政府補助增加人民幣4.0百萬元所致。

Other losses – net

We recorded net other losses of RMB27.2 million in the six months ended June 30, 2026, including net foreign exchange losses of RMB28.9 million, and we recorded net other losses of RMB12.9 million in the six months ended June 30, 2025, which included net foreign exchange losses of RMB16.1 million. The swing was primarily driven by significant volatility in the US$ to RMB exchange rate and US$ to SGD exchange rate.

其他虧損淨額

我們於截至2026年6月30日止六個月錄得其他虧損淨額人民幣27.2百萬元，包括外匯虧損淨額人民幣28.9百萬元，而我們於截至2025年6月30日止六個月錄得其他虧損淨額人民幣12.9百萬元，包括外匯虧損淨額人民幣16.1百萬元。此波動主要是由於美元兑人民幣匯率及美元兑新加坡元匯率大幅波動所致。

Finance income – net

Our net finance income decreased from RMB19.4 million in the six months ended June 30, 2025 to RMB14.2 million in the six months ended June 30, 2026 primarily due to a decrease of RMB4.8 million in interest income.

財務收入淨額

我們的財務收入淨額由截至2025年6月30日止六個月的人民幣19.4百萬元減少至截至2026年6月30日止六個月的人民幣14.2百萬元，乃主要由於利息收入減少人民幣4.8百萬元。

Loss for the period

As a result of the above, our loss for the period increased by 64.3% from RMB29.3 million for the six months ended June 30, 2025 to RMB48.2 million for the six months ended June 30, 2026.

期內虧損

由於上述原因，我們的期內虧損由截至2025年6月30日止六個月的人民幣29.3百萬元增加64.3%至截至2026年6月30日止六個月的人民幣48.2百萬元。

Non-IFRS measures

To supplement our consolidated financial statements, which are presented in accordance with IFRS, we also use adjusted net loss and adjusted EBITDA as an additional non-IFRS measure, which are not required by, or presented in accordance with, IFRS.

非國際財務報告準則計量

為補充我們根據國際財務報告準則呈列的合併財務報表，我們亦使用國際財務報告準則並無規定或並無根據國際財務報告準則呈列的經調整虧損淨額及經調整EBITDA作為額外的非國際財務報告準則計量。

Adjusted net loss represents the loss for the period adjusted by adding back share-based payments.

經調整虧損淨額定義為通過加回以股份為基礎的付款的期內虧損。

Adjusted EBITDA represents the loss for the period adjusted for: i) finance income, finance costs, certain items in other losses – net including fair value gains on financial assets at fair value through profit or loss, net foreign exchange losses and fair value gains on warrant liabilities; ii) certain non-cash items, including share-based compensation expenses, depreciation of right-of-use assets depreciation of property, plant and equipment and amortisation of intangible assets; and iii) certain expense provision.

經調整EBITDA定義為期內虧損，就以下各項作出調整：i)財務收入、財務成本及其他虧損淨額的若干項目，包括按公允價值計量且其變動計入當期損益的金融資產的公允價值收益、匯兑虧損淨額及認股權證負債的公允價值收益；ii)若干非現金項目，包括以股份為基礎的薪酬開支、使用權資產折舊、物業、廠房及設備折舊及無形資產攤銷；及iii)若干開支撥備。

We believe the presentation of these non-IFRS measures provides useful information to investors and management in facilitating a comparison of our operating performance from year to year by eliminating potential impacts of these items. However, our presentation of adjusted net loss and adjusted EBITDA may not be comparable to similarly titled measures presented by other companies. The use of these non-IFRS measures has limitations as an analytical tool, and you should not consider them in isolation from, or as substitutes for, an analysis of our results of operations or financial condition as reported under IFRS.

我們認為，該等非國際財務報告準則計量的呈列為投資者及管理層提供有用資料，以通過消除該等項目的潛在影響來促進比較我們各年度的經營表現。然而，我們呈列的經調整虧損淨額及經調整EBITDA可能無法與其他公司呈列的類似計量指標進行比較。使用該等非國際財務報告準則計量作為分析工具存在局限性， 閣下不應將彼等視為獨立於或可替代我們根據國際財務報告準則所呈報經營業績或財務狀況的分析。

The tables below set forth the reconciliation of our non-IFRS measures to the corresponding IFRS measures for the six months ended June 30, 2026 and 2025:

下表載列截至2026年及2025年6月30日止六個月非國際財務報告準則計量與相應國際財務報告準則計量的對賬：

		Six Months Ended June 30, 截至6月30日止六個月	
		2026 **2026年** **RMB'000** **人民幣千元** **(Unaudited)** **（未經審計）**	2025 2025年 RMB'000 人民幣千元 (Unaudited) （未經審計）
Loss for the period	期內虧損	**(48,161)**	(29,309)
Adjustment:	調整：		
Share-based payment	以股份為基礎的付款	**17,254**	613
Adjusted net loss for the period	**期內經調整虧損淨額**	**(30,907)**	(28,696)
Adjustment:	調整：		
Finance income	財務收入	**(15,195)**	(19,980)
Finance costs	財務成本	**987**	579
Certain items in other losses – net	其他虧損淨額的若干項目	**27,608**	14,923
Depreciation of property, plant and equipment	物業、廠房及設備折舊	**2,657**	3,068
Depreciation of right-of-use assets	使用權資產折舊	**4,610**	5,223
Amortization of intangible assets	無形資產攤銷	**2,191**	2,115
Certain expense provision	若干開支撥備	**4,625**	2,060
Adjusted EBITDA	**經調整EBITDA**	**(3,424)**	(20,708)

Liquidity and capital resource

Our principal use of cash in the six months ended June 30, 2026 was for working capital purposes. Our main source of liquidity has been generated from proceeds from our business operations and bank borrowings. We do not anticipate any changes to the availability of financing to fund our operations in the future.

As at June 30, 2026, the Group had net current assets of RMB1,062.5 million (December 31, 2025: RMB1,142.2 million) of which cash and cash equivalents, short-term bank deposits, short-term treasury investments, and restricted cash were RMB477.3 million, RMB433.7 million, RMB136.3 million and RMB1.7 million (December 31, 2025: RMB625.2 million, RMB372.0 million, RMB139.2 million and RMB0.1 million), respectively. Details of the cash and cash equivalents held by the Group are set out in Note 24 to the condensed consolidated interim financial information. Total bank borrowing was RMB75.5 million (December 31, 2025: RMB48.0 million) which is repayable within one year. Details of the Group's borrowings (including the range of interest rates) are set out in Note 30 to the condensed consolidated interim financial information.

As at June 30, 2026, the Group's current ratio(1) was 4.39 (December 31, 2025: 4.48) and gearing ratio(2) was 23.2% (December 31, 2025: 23.5%). The Group has sufficient cash to meet its working capital requirements. This strong cash position enables the Group to explore potential business development opportunities to expand in China and overseas.

As of June 30, 2026, the Group did not use any financial instruments for hedging purposes.

Notes:

(1) Current ratio equals current assets divided by current liabilities as at the same date.

(2) Gearing ratio equals total liabilities divided by total assets and multiplied by 100% as at the same date.

Pledge of assets

As at June 30, 2026, the Group had no pledge of assets.

流動資金及資金來源

我們於截至2026年6月30日止六個月的主要現金用途為營運資金。我們的主要流動資金來源為業務運營的所得款項及銀行借款。我們預計日後為營運提供資金的融資渠道不會有任何變動。

於2026年6月30日，本集團擁有流動資產淨值人民幣1,062.5百萬元(2025年12月31日：人民幣1,142.2百萬元)，其中現金及現金等價物、短期銀行存款、短期國債投資及受限制現金分別為人民幣477.3百萬元、人民幣433.7百萬元、人民幣136.3百萬元及人民幣1.7百萬元(2025年12月31日：人民幣625.2百萬元、人民幣372.0百萬元、人民幣139.2百萬元及人民幣0.1百萬元)。本集團所持現金及現金等價物詳情載於簡明合併中期財務資料附註24。銀行借款總額為人民幣75.5百萬元(2025年12月31日：人民幣48.0百萬元)，須於一年內償還。本集團借款詳情(包括利率範圍)載於簡明合併中期財務資料附註30。

於2026年6月30日，本集團的流動比率(1)為4.39(2025年12月31日：4.48)，而資產負債比率(2)為23.2%(2025年12月31日：23.5%)。本集團擁有充足現金以滿足其營運資金需求。強勁的現金狀況使本集團能夠探索潛在業務發展機會，以擴展中國及海外市場。

截至2026年6月30日，本集團未使用金融工具作為對沖用途。

附註：

(1) 流動比率等於同日的流動資產除以流動負債。

(2) 資產負債比率等於同日的負債總額除以資產總值，再乘以100%。

資產抵押

於2026年6月30日，本集團並無資產抵押。

Exchange rate fluctuation risk

During the six months ended June 30, 2026, the Group mainly operated in China with most of the transactions settled in Renminbi. The functional currency of the Company and the subsidiaries that operate in the PRC, and the subsidiaries operating in the United States and Singapore are Renminbi, U.S. dollar and Singapore dollar, respectively. The Group's cash and cash equivalents are mainly denominated in Hong Kong dollars, RMB and US dollars. For the six months ended June 30, 2026, we had currency translation losses of RMB3.9 million (for the six months ended June 30, 2025: gains of RMB10.5 million) and net foreign exchange losses of RMB28.9 million (for the six months ended June 30, 2025: losses of RMB16.1 million).

We did not hedge against any fluctuation in foreign currency during the six months ended June 30, 2026.

匯率波動風險

截至2026年6月30日止六個月，本集團主要在中國經營業務，大部分交易乃以人民幣結算。本公司及在中國經營的附屬公司以及在美國及新加坡經營的附屬公司的功能貨幣分別為人民幣、美元及新加坡元。本集團所持現金及現金等價物主要以港幣、人民幣及美元計值。截至2026年6月30日止六個月，我們錄得匯兑虧損人民幣3.9百萬元(截至2025年6月30日止六個月：收益人民幣10.5百萬元)及外匯虧損淨額人民幣28.9百萬元(截至2025年6月30日止六個月：虧損人民幣16.1百萬元)。

截至2026年6月30日止六個月，我們並無對沖任何外幣波動。

Future Plan for Material Investment and Capital Asset

Save as disclosed in this report, the Group does not have any other plans for material investments and capital assets for the Reporting Period and up to the date of this report.

重大投資與資本資產的未來計劃

除本報告所披露者外，本集團於報告期及截至本報告日期並無任何其他重大投資及資本資產計劃。

Significant Investments, Material Acquisitions and Disposals of Subsidiaries, Associates and Joint Ventures during the Reporting Period

The Group did not hold or make any significant investments, material acquisitions or disposals of subsidiaries, associates and joint ventures during the Reporting Period.

報告期重大投資、重大收購及出售附屬公司、聯營公司及合營企業

本集團於報告期並無持有或作出任何重大投資、重大收購或出售附屬公司、聯營公司及合營企業。

Contingent liabilities

As at June 30, 2026, we did not have any material contingent liabilities.

或有負債

於2026年6月30日，我們並無任何重大或有負債。

Capital commitment

As at June 30, 2026, we did not have any material capital commitments.

資本承擔

於2026年6月30日，我們並無任何重大資本承擔。

Off-balance sheet commitments and arrangements

As at June 30, 2026, we had not entered into any off-balance sheet transactions.

資產負債表外承擔及安排

於2026年6月30日，我們並無訂立任何資產負債表外交易。

Employees and remuneration

As at June 30, 2026, we had 687 full-time employees, of whom 680 were based in China, 4 were based in the United States and 3 were based in Singapore. The table below sets forth a breakdown of our full-time employees by function as at June 30, 2026:

僱員及薪酬

於2026年6月30日，我們僱有687名全職僱員，其中680人就職於中國，4人就職於美國，3人就職於新加坡。下表載列我們於2026年6月30日按職能劃分的全職僱員明細：

Function	職能	Number of Employees 僱員人數	% of Total 佔總人數的百分比
R&D	研發	132	19.2%
Sales and Marketing	銷售及營銷	84	12.2%
Professional and Technical Personnel	專業及技術人員	389	56.7%
Administrative	行政	82	11.9%
Total	**總計**	**687**	**100%**

Our total remuneration cost (excluding share-based payments) for the six months ended June 30, 2026 was RMB163.9 million (for the six months ended June 30, 2025: RMB152.1 million).

截至2026年6月30日止六個月，我們的薪酬成本總額（不包括以股份為基礎的付款）為人民幣163.9百萬元（截至2025年6月30日止六個月：人民幣152.1百萬元）。

The remuneration of the Group's employees is generally fixed. The Group adopts an appraisal system for its employees and takes into account the appraisal results of individual employees when conducting remuneration reviews, determining promotions and setting bonus amounts. The Group also procures social insurance for its employees in accordance with the applicable PRC laws and the requirements of the local government.

本集團的僱員薪酬一般為固定薪酬。本集團對僱員採用評核制度，並在進行薪酬檢討、決定晉升及釐定花紅金額時考慮個別員工的評核結果。本集團亦根據適用的中國法律及當地政府的要求為僱員購買社會保險。

In recruiting employees, the Group takes into consideration various factors such as the employees' work experience, educational background and the requirements of the job vacancies. In order to enhance the overall competitiveness of its employees, attract and retain existing employees, and strengthen their knowledge, skills and qualities, the Group places great emphasis on employee training. We provide training across different operating functions, including induction training for new employees, technical training, and training to enhance employees' knowledge of safety measures in the performance of their duties.

本集團招聘員工時，會根據員工的工作經驗、教育背景及職位空缺需求等多項因素進行考慮。為了提高員工的整體競爭力，吸引並留住現有員工，強化其知識、技能水平及素質，本集團非常重視員工的培訓。我們提供跨越不同營運職能的訓練，包括新員工的入職訓練、技術訓練，以及提升員工在履行職務時的安全措施知識的訓練。

To incentivize employees, following the Listing, the Company adopted the 2026 H Share Award Scheme on February 14, 2026. The Company also adopted the H Share Award Scheme (Existing Shares) on June 8, 2026.

為激勵員工，於上市後，本公司於2026年2月14日採納了2026年H股獎勵計劃。本公司亦於2026年6月8日採納了H股獎勵計劃(現有股份)。

2026 H Share Award Scheme

The Company adopted the 2026 H Share Award Scheme (the "**Scheme**") at the extraordinary general meeting on February 14, 2026 (the "**Adoption Date**"). The award under the Scheme will be satisfied by the transfer of Treasury H Shares and/or the issue and allotment of new H Shares. For details, please refer to the Company's circular dated January 28, 2026 (the "**Circular**") and the Company's announcements dated January 28, 2026 and February 15, 2026 (collectively, the "**Announcements**"). A summary of the Scheme is set out as follows:

(1) Purpose of the Scheme

The specific objectives of the Scheme include the following: (i) to attract and retain qualified participants who have made significant contributions to the long-term growth and success of the Group, and to recognize and reward such participants for their past contributions to the Group; (ii) to motivate qualified participants to further contribute to the Company and to work towards enhancing the value of the Company and its shares for the overall benefit of the Company and its Shareholders; (iii) to strengthen the Company's long-term compensation and incentive strategy; and (iv) to align the interests of qualified participants with those of the Company and its Shareholders, thereby promoting the Group's long-term performance (whether in terms of finance, business, or operation).

(2) Participant(s) of the Scheme

Eligible Participant in respect of the Scheme represents any individual being an Employee Participant at any time during the period of the Scheme. Employee Participant represents directors (other than an independent non-executive Director), supervisor and employees (including full-time employees and part-time employees) of the Group (including persons who are granted awards under the Scheme as an inducement to enter into employment contracts with these companies).

2026年H股獎勵計劃

本公司於2026年2月14日(「**採納日期**」)的臨時股東會上採納了「2026年H股獎勵計劃」(「**本計劃**」)。本計劃的獎勵將通過轉讓庫存H股及／或發行及配發新H股來實現。有關詳情，請參閱本公司日期為2026年1月28日的通函(「**通函**」)，以及本公司日期為2026年1月28日及2026年2月15日的公告(統稱，「**該等公告**」)。本計劃的摘要概述如下：

(1) 計劃的目的

本計劃的具體目標包括：(i)吸引及挽留為本集團的長遠發展及成功作出重大貢獻的合資格參與者，並認可及獎勵該等參與者過往對本集團的貢獻；(ii)激勵合資格參與者為本公司作出進一步貢獻，並致力提升本公司及其股份的價值，以符合本公司及其股東的整體利益；(iii)加強本公司的長期薪酬及激勵策略；及(iv)將合資格參與者的利益與本公司及其股東的利益綁定，從而促進本集團的長期表現(不論在財務、業務或營運方面)。

(2) 計劃的參與者

本計劃的合資格參與者指於計劃期內任何時間作為僱員參與者的任何個人。僱員參與者指本集團的董事(獨立非執行董事除外)、監事及僱員(包括全職僱員及兼職僱員)(包括根據本計劃獲授予獎勵以吸引與該等公司簽訂僱傭合同的人士)。

(3) Total Number of Shares Available for Issue under the Scheme and its Percentage to the Issued Shares (Excluding Treasury Shares)

According to the Scheme Mandate Limit, the total number of Treasury H Shares which may be utilized and/or new H Shares which may be issued and allotted under the Scheme must not exceed 20,042,513 H Shares (representing approximately 10.37% of the total number of the issued H shares of the Company (excluding any Treasury Shares) and approximately 3.60% of the Company's total issued Share capital (excluding any Treasury Shares) as at the interim report date).

Upon the Initial Grants made during the Reporting Period (20,042,494 awards in total, for further details, please refer to the Circular and Announcements), the number of H Shares available for future grant under the Scheme Mandate Limit of the Scheme will be 19 H Shares as at this interim report date, representing approximately 0.00001% of the total number of the issued H shares of the Company (excluding any Treasury Shares) and approximately 0.000003% of the Company's total issued Share capital (excluding any Treasury Shares) as at this interim report date. However, as at the date of this interim report, the Company has not actually issued or allotted any H Shares under the Scheme as the relevant award shares have not yet vested.

(3) 計劃中可予發行的股份總數以及其佔已發行股份（不包括庫存股份）的百分比

根據本計劃的計劃授權限額，可使用的庫存H股及／或可能根據本計劃發行及配發的新H股總數不得超過20,042,513股H股（佔本中期報告日期本公司已發行H股（不包括任何庫存股份）總數的約10.37%及本公司已發行股本總額（不包括任何庫存股份）的約3.60%）。

於報告期內作出首次授予（合共20,042,494份獎勵，詳情請參閱通函及該等公告）後，於本中期報告日期，根據本計劃的計劃授權限額可供日後授予的股份總數為19股H股，佔本中期報告日期本公司已發行H股（不包括任何庫存股份）總數的約0.00001%及本公司已發行股本總額（不包括任何庫存股份）的約0.000003%。惟截至本中期報告日期，由於相關獎勵股份尚未歸屬，本公司尚未根據本計劃實際發行或配發任何H股。

(4) Maximum Entitlement for Each Participant under the Scheme

Unless shareholders' approval is obtained and the relevant requirements of the Listing Rules are complied with, the total number of shares issued and to be issued in respect of all awards and options granted to any participant (excluding any awards or options which have lapsed in accordance with the terms of the relevant scheme) during the twelve (12)-month period up to and including the date of such grant shall not exceed the individual limit of 1% of the total number of issued H Shares (excluding Treasury Shares) of the Company as at the date of grant.

(4) 計劃中每名參與者可獲授權益上限

除非獲得股東批准及符合《上市規則》的相關要求，否則任何參與者就截至有關授予日（包括該日）止十二(12)個月期間已獲授的所有獎勵及購股權（不包括根據相關計劃條款失效的任何獎勵或購股權）而已發行及將予發行的股份總數，不得超出授予日本公司已發行H股股份總數（不包括庫存股份）的1%個人限額。

(5) Period within which a Grantee may Exercise the Options under the Scheme

Not applicable. The Scheme is a share award scheme, not a share option scheme.

(6) Vesting Period of Options or Awards Granted under the Scheme

Pursuant to the terms of the Scheme Rules, the vesting period of the award shares shall not be less than 12 months.

(7) Amount Payable (if any) on Application or Acceptance of an Option or Award and the Payment Period

The consideration payable by a Grantee upon acceptance of an offer (i.e., the "**grant price**") shall be determined by the Board or its authorised designees in their sole discretion, which may be nil. In respect of the Initial Grants, the consideration/grant price for the awards granted is nil. Accordingly, the payment period is not applicable.

(8) Basis of Determining the Purchase Price of the Awarded Shares (if any)

The purchase price per H Share payable by a Grantee to the Company upon vesting of an award (i.e., the "**vesting price**") shall be determined by the Board or its authorised persons, which may be nil. In respect of the Initial Grants, the purchase price/vesting price of the award is RMB1 per award share.

(9) Remaining Term of the Scheme

The Scheme shall terminate on the earlier of the following dates: (a) the third (3rd) anniversary of the Adoption Date (February 14, 2026); or (b) any earlier termination date determined by Shareholders at a general meeting. As at this interim report date, the remaining term of the Scheme is approximately two years and six months.

(5) 獲授人可根據計劃行使期權的期限

不適用。本計劃為股份獎勵計劃，並非購股權計劃。

(6) 根據計劃授出的期權或獎勵的歸屬期

根據本計劃規則的條款，獎勵股份的歸屬期不得少於12個月。

(7) 申請或接納期權或獎勵須付金額(如有)以及付款期限

承授人接納要約時應支付的代價(即「**授予價**」)由董事會或其授權指定人士全權酌情釐定，可為零。就首次授予而言，授出的獎勵代價／授予價為零。因此付款期限不適用。

(8) 獲授股份的購買價(如有)的釐定基準

承授人於獎勵歸屬時應向本公司支付的每股H股購買價(即「**歸屬價**」)由董事會或其授權人士釐定，可為零。就首次授予而言，獎勵的購買價／歸屬價為每股獎勵股份人民幣1元。

(9) 計劃尚餘的有效期

本計劃於以下日期(以較早者為準)終止：(a)採納日期(2026年2月14日)的第三(3)個週年日；或(b)股東於股東會釐定的有關提前終止日期。於本中期報告日期，本計劃的尚餘有效期約為兩年六個月。

Details of the awarded shares under the 2026 H Share Award Scheme during the six months ended June 30, 2026 are set out below:

有關於截至2026年6月30日止六個月內2026年H股獎勵計劃下之獎勵股份詳情載列如下：

Directors, chief executive, former Director and their associate(s) 董事、最高行政人員、前董事及其聯繫人	Date of grant 授出日期	Number of awards 獎勵數目 Unvested as at January 1, 2026 於2026年1月1日未歸屬	Granted during the Reporting Period 於報告期內授出	Vested during the Reporting Period 於報告期內歸屬	Cancelled during the Reporting Period 於報告期內註銷	Lapsed during the Reporting Period 於報告期內失效	Unvested as at June 30, 2026 於2026年6月30日未歸屬	Vesting period 歸屬期	Weighted average closing price of the shares immediately before the relevant vesting date(s) during the Reporting Period (HK$) 於報告期間緊接相關歸屬日期前股份的加權平均收市價(港元)
Dr. ZHAO Lu Executive Director and chairman of the Board 趙璐博士 執行董事兼董事長	January 28, 2026 2026年1月28日	–	6,077,677	–	–	–	6,077,677	12 months(Note 1) 12個月(附註1)	N/A 不適用
Mr. MA Dong Executive Director 馬東先生 執行董事	January 28, 2026 2026年1月28日	–	593,680	–	–	–	593,680	12 months(Note 1) 12個月(附註1)	N/A 不適用
Mr. LU Yiming Executive Director 陸一鳴先生 執行董事	January 28, 2026 2026年1月28日	–	1,818,820	–	–	–	1,818,820	12 months(Note 1) 12個月(附註1)	N/A 不適用
Ms. NI Xiaomei Executive Director and joint company secretary 倪曉梅女士 執行董事兼聯席公司秘書	January 28, 2026 2026年1月28日	–	1,388,772	–	–	–	1,388,772	12 months(Note 1) 12個月(附註1)	N/A 不適用
Ms. WAN Yunyun Executive Director, Chief Executive and general manager 萬韻馧女士 執行董事、最高行政人員兼總經理	January 28, 2026 2026年1月28日	–	1,839,795	–	–	–	1,839,795	12 months(Note 1) 12個月(附註1)	N/A 不適用

Directors, chief executive, former Director and their associate(s) 董事、最高行政人員、前董事及其聯繫人	Date of grant 授出日期	Number of awards 獎勵數目 Unvested as at January 1, 2026 於2026年1月1日未歸屬	Granted during the Reporting Period 於報告期內授出	Vested during the Reporting Period 於報告期內歸屬	Cancelled during the Reporting Period 於報告期內註銷	Lapsed during the Reporting Period 於報告期內失效	Unvested as at June 30, 2026 於2026年6月30日未歸屬	Vesting period 歸屬期	Weighted average closing price of the shares immediately before the relevant vesting date(s) during the Reporting Period (HK$) 於報告期間緊接相關歸屬日期前股份的加權平均收市價(港元)
Mr. ZHANG Hongwei Executive Director 張宏偉先生 執行董事	January 28, 2026 2026年1月28日	–	35,703	–	–	–	35,703	12 months(Note 1) 12個月(附註1)	N/A 不適用
Mr. HUANG Yufei Executive Director as at the date of grant 黃玉飛先生 於授出日期為執行董事	January 28, 2026 2026年1月28日	–	89,258	–	–	–	89,258	12 months(Note 1) 12個月(附註1)	N/A 不適用
Employee participants (56 in total) 僱員參與者(共56名)	January 28, 2026 2026年1月28日	–	8,198,789	–	–	–	8,198,789	12 months(Note 1) 12個月(附註1)	N/A 不適用
Total 合計	**-**	**-**	**20,042,494**	**-**	**-**	**-**	**20,042,494**	**-**	**-**

Notes:

1. The Awards under the grants shall vest upon expiry of a 12-month vesting period and achievement of the following market capitalization targets:

   First batch: one-third of the Awards shall vest when the average closing price of the Shares as quoted in the Stock Exchange's daily quotation sheets for any 20 consecutive trading days first reaches or exceeds HK$6.21 per Share, provided that the Grantee remains an Employee Participant;

   Second batch: one-third of the Awards shall vest when the average closing price of the Shares as quoted in the Stock Exchange's daily quotation sheets for any 20 consecutive trading days first reaches or exceeds HK$7.98 per Share, provided that the Grantee remains an Employee Participant; and

附註：

1. 授予項下獎勵於12個月歸屬期滿且達成以下市值目標後歸屬：

   第一批：獎勵的三分之一，於股份在聯交所每日報價表所報收市價在任何連續20個交易日的平均值首次達到或超過每股6.21港元時歸屬，惟承授人須仍為僱員參與者；

   第二批：獎勵的三分之一，於股份在聯交所每日報價表所報收市價在任何連續20個交易日的平均值首次達到或超過每股7.98港元時歸屬，惟承授人須仍為僱員參與者；及

Third batch: one-third of the Awards shall vest when the average closing price of the Shares as quoted in the Stock Exchange's daily quotation sheets for any 20 consecutive trading days first reaches or exceeds HK$9.76 per Share, provided that the Grantee remains an Employee Participant.

If any or all of the market capitalization targets are achieved before expiry of the vesting period, the relevant Awards may vest on the day immediately following expiry of the vesting period.

2. The closing price of the H Shares on the Grant Date was HK$4.86 per H Share. The closing price of the H Shares on the trading day immediately preceding the Grant Date was HK$4.68 per H Share.

3. The fair value of each Award for the first, second, and third batches was RMB4.14, RMB3.63, and RMB3.19, respectively. Details of the accounting standard and policy, valuation methodology and assumptions adopted, and how the features of the Awards are reflected in the fair value measurement are set out in Note 28 to the condensed consolidated interim financial information in this interim report.

4. The purchase price of the Awards set out in the table above is RMB1.00 per H Share. An exercise period is not applicable; the Awards vest subject to the conditions described in Note 1.

5. As at January 1, 2026, the Share Award Scheme had not been adopted and the number of awards available for grant at the beginning of the Reporting Period was therefore not applicable. The Scheme Mandate Limit was 20,042,513 H Shares when the scheme was adopted on February 14, 2026. As at June 30, 2026, awards in respect of 19 H Shares remained available for grant under the scheme mandate. The Scheme has no service provider sublimit.

6. The number of shares that may be issued in respect of options and awards granted under all share schemes of the Company during the Reporting Period was 20,042,494 H Shares, which, divided by the weighted average number of H Shares in issue (excluding Treasury Shares) during the Reporting Period of 200,382,342 H Shares, represented 10%.

第三批：獎勵的三分之一，於股份在聯交所每日報價表所報收市價在任何連續20個交易日的平均值首次達到或超過每股9.76港元時歸屬，惟承授人須仍為僱員參與者。

倘任何或所有市值目標於歸屬期屆滿前達成，相關獎勵可於歸屬期屆滿後翌日歸屬。

2. H股於授予日的收市價為每股4.86港元。緊接授予日前一個交易日的H股收市價為每股4.68港元。

3. 第一批、第二批及第三批獎勵的每份獎勵公平值分別為人民幣4.14元、人民幣3.63元及人民幣3.19元。有關公平值計量所採用的會計準則及政策、估值方法及假設，以及獎勵特徵如何反映於公平值計量的詳情，請參閱本中期報告簡明合併中期財務資料附註28。

4. 上表所列獎勵的購買價為每股H股人民幣1.00元。行使期不適用，獎勵須按附註1所述條件歸屬。

5. 於2026年1月1日，股份獎勵計劃尚未採納，故期初可供授出的獎勵數目不適用。該計劃於2026年2月14日採納時的計劃授權限額為20,042,513股H股。於2026年6月30日，該計劃授權項下可供授出的獎勵為19股H股。該計劃不設服務提供者分項限額。

6. 報告期內，就本公司所有股份計劃授出的購股權及獎勵而可予發行的股份數目為20,042,494股H股，除以報告期內已發行H股（不包括庫存股份）的加權平均數200,382,342股H股為10%。

Use of proceeds from the Global Offering

The H Shares were first listed on the Main Board of the Stock Exchange on October 8, 2024. After deducting underwriting fees, commissions and other related listing expenses, the total net proceeds of the Global Offering amounted to approximately HK$259.6 million (the "**Net Proceeds**"). The Net Proceeds have been allocated and utilized in accordance with the intended purposes and proportions as set out in the Prospectus, and there is no change in the intended use of the Net Proceeds as disclosed in the Prospectus.

The following table sets out the status of the use of the Net Proceeds and a summary of their utilization as at June 30, 2026 together with the expected timeline of use:

全球發售所得款項用途

H股於2024年10月8日在聯交所主板首次上市。經扣除包銷費用、佣金及其他相關上市開支後，全球發售的總所得款項淨額為約259.6百萬港元(「**所得款項淨額**」)。所得款項淨額已根據招股章程所載的擬定用途及比例分配使用，且招股章程所披露的所得款項淨額擬定用途並無變動。

下表載列截至2026年6月30日所得款項淨額的動用情況及動用情況概要，以及預期動用時間表：

Intended use of Net Proceeds 所得款項淨額擬定用途	Allocation of Net Proceeds 所得款項淨額的分配	Approximate percentage of total Net Proceeds 佔總所得款項淨額的概約百分比	Balance of Net Proceeds unutilized as at December 31, 2025 於2025年12月31日未動用所得款項淨額餘額	Amount of net proceeds utilized during the Reporting Period 於報告期內已動用所得款項淨額金額	Amount of Net Proceeds utilized up to June 30, 2026 直至2026年6月30日已動用所得款項淨額金額	Balance of Net Proceeds unutilized as at June 30, 2026 於2026年6月30日未動用所得款項淨額餘額	Intended timetable for use of the unutilized Net Proceeds(note) 未動用所得款項淨額的擬定動用時間表(附註)
(i) To improve and upgrade our TrialOS Platform and PharmaOS Platform and their respective cloud-based software and digital services	HK$90.8 million	35%	HK$80.1 million	HK$5.2 million	HK$15.9 million	HK$74.9 million	Before December 31, 2029
改善及升級我們的TrialOS平台及PharmaOS平台以及彼等各自的雲端軟件及數字化服務	90.8百萬港元		80.1百萬港元	5.2百萬港元	15.9百萬港元	74.9百萬港元	2029年12月31日前
(ii) To improve our core technology and R&D capabilities	HK$77.9 million	30%	HK$65.5 million	HK$2.0 million	HK$14.4 million	HK$63.5 million	Before December 31, 2029
提升我們的核心技術及研發能力	77.9百萬港元		65.5百萬港元	2.0百萬港元	14.4百萬港元	63.5百萬港元	2029年12月31日前
(iii) To strengthen our sales and marketing capabilities	HK$26.0 million	10%	HK$26.0 million	–	–	HK$26.0 million	Before December 31, 2029
加強我們的銷售及營銷能力	26.0百萬港元		26.0百萬港元	–	–	26.0百萬港元	2029年12月31日前
(iv) To selectively pursue strategic investments and acquisitions	HK$38.9 million	15%	HK$38.9 million	–	–	HK$38.9 million	Before December 31, 2029
選擇性地尋求戰略投資及收購	38.9百萬港元		38.9百萬港元	–	–	38.9百萬港元	2029年12月31日前
(v) For our working capital and general corporate purposes	HK$26.0 million	10%	HK$24.1 million	–	HK$1.9 million	HK$24.1 million	Before December 31, 2029
營運資金及一般企業用途	26.0百萬港元		24.1百萬港元	–	1.9百萬港元	24.1百萬港元	2029年12月31日前
Total	HK$259.6 million	100%	HK$234.6 million	HK$7.2 million	HK$32.2 million	HK$227.4 million	
總計	259.6百萬港元		234.6百萬港元	7.2百萬港元	32.2百萬港元	227.4百萬港元	

Note: The expected timeline to use the remaining Net Proceeds is prepared based on the best estimate made by the Group, which is subject to change based on future developments and events which may be outside of the Group's control.

附註： 動用餘下所得款項淨額的預期時間表乃根據本集團作出的最佳估計編製，或會因未來發展及本集團無法控制的事件而出現變動。

The Group will continue to utilise the Net Proceeds in accordance with the intended use of proceeds as set out in the Prospectus.

本集團將繼續按照招股章程所載之所得款項擬定用途動用所得款項淨額。

INTERIM DIVIDEND

The Board does not recommend the payment of an interim dividend for the Reporting Period (six months ended June 30, 2025: Nil).

中期股息

董事會不建議就報告期派付中期股息（截至2025年6月30日止六個月：無）。

CORPORATE GOVERNANCE

The Group is committed to maintaining high standards of corporate governance to safeguard the interests of the Shareholders and to enhance corporate value and accountability. The Company has adopted the principles and code provisions in the CG Code as set out in Part 2 of Appendix C1 to the Listing Rules as its own code to govern its corporate governance practices. During the Reporting Period, the Company has complied with all applicable code provisions of the CG Code. The Company will continue to review and monitor its corporate governance practices to ensure compliance with the CG Code.

企業管治

本集團致力維持高水準企業管治以保障股東權益，以及提升企業價值及問責。本公司已採納上市規則附錄C1第二部分所載企業管治守則的原則及守則條文作為其自身守則以規管企業管治常規。於報告期內，本公司已遵守企業管治守則的所有適用守則條文。本公司將繼續審查及監督其企業管治常規，以確保符合企業管治守則。

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code as set out in Appendix C3 to the Listing Rules as its own code of conduct regarding dealings by Directors, Supervisors, and the Group's senior management who, by virtue of their positions or employment, is likely to possess inside information in relation to the Company's securities.

Upon specific enquiries, all Directors and Supervisors have confirmed that they have complied with the Model Code throughout the Reporting Period. In addition, the Company is not aware of any non-compliance with the Model Code by the senior management of the Group throughout the Reporting Period.

遵守證券交易標準守則

本公司已採納上市規則附錄C3所載標準守則作為董事、監事及本集團高級管理層（彼等因有關職位或受僱工作而可能擁有有關本公司證券之內幕消息）買賣本公司證券的行為守則。

經作出具體查詢後，全體董事及監事均已確認彼等於整個報告期內已遵守標準守則。此外，本公司並未獲悉本集團高級管理層於整個報告期內有任何不遵守標準守則之情況。

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES OF THE COMPANY

購買、出售或贖回本公司上市證券

During the six months ended June 30, 2026, the Company repurchased a total of 1,141,400 H Shares of the Company on the Stock Exchange at an aggregate consideration of HK$6,543,494.00 (the "**Share Repurchase**") to enhance the Shareholder value in the long run. Particulars of the Share Repurchase are as follows:

截至2026年6月30日止六個月，本公司於聯交所購回合共1,141,400股本公司H股，總代價為6,543,494.00港元(「**股份購回**」)，以提升股東的長遠價值。股份購回之詳情如下：

Month of Repurchase 購回月份	No. of H Shares Repurchased 購回之H股數目	Price Paid per H Share 已付每股H股價格 Highest 最高價 *(HK$)* *(港元)*	Lowest 最低價 *(HK$)* *(港元)*	Aggregate Consideration 總代價 *(HK$)* *(港元)*
June 2026 2026年6月	1,141,400	6.42	4.02	6,543,494

The above Share Repurchase was made by the Directors pursuant to the general mandates granted by the Shareholders at the 2024 annual general meeting of the Company held on June 13, 2025 and the 2025 annual general meeting of the Company held on June 23, 2026, respectively.

上述股份購回由董事根據股東於本公司2025年6月13日舉行之2024年股東週年大會及2026年6月23日舉行之2025年股東週年大會上分別授予的一般授權進行。

All the repurchased H Shares were held as Treasury Shares and are intended to be used for purposes such as employee incentives, sale or transfer to obtain liquid funds, etc. subject to the actual decision by the Board. As at June 30, 2026, the Company held 1,308,800 H shares which have been repurchased and retained as Treasury Shares.

所有已購回H股均以庫存股份方式持有，並擬用於僱員激勵、出售或轉讓以獲取流動資金等用途(惟須視乎董事會的實際決定)。截至2026年6月30日，本公司持有1,308,800股已購回並以庫存股份方式持有的H股。

Save as disclosed above, neither the Company nor any of its subsidiaries has purchased, sold (including the sale or transfer of Treasury Shares) or redeemed any of the Company's listed securities during the Reporting Period.

除上文所披露者外，於報告期內，本公司或其任何附屬公司概無購買、出售(包括出售或轉讓庫存股份)或贖回本公司任何上市證券。

AUDIT COMMITTEE

The Audit Committee has been established with written terms of reference in compliance with the Listing Rules and the CG Code. The Audit Committee comprises three members, including three independent non-executive Directors, namely Mr. FUNG Che Wai Anthony, Dr. JIANG Xiao and Dr. GONG Yan. Mr. FUNG Che Wai Anthony, who holds the appropriate professional qualifications as required under Rule 3.10(2) of the Listing Rules, is the chairman of the Audit Committee.

The Audit Committee has reviewed and considered that the interim financial results for the six months ended June 30, 2026 and this interim report are in compliance with the relevant accounting standards, rules and regulations and appropriate disclosures have been duly made. The Audit Committee had no disagreement with the accounting treatment adopted by the Company.

審計委員會

本公司已根據上市規則及企業管治守則成立審計委員會，並訂明其書面職權範圍。審計委員會由三名成員組成，包括三名獨立非執行董事，即馮志偉先生、蔣驍博士及龔焱博士。馮志偉先生擁有上市規則第3.10(2)條規定的適當專業資格，為審計委員會主席。

審計委員會已審閱並認為截至2026年6月30日止6個月的中期財務業績及本中期報告符合相關會計準則、規則及法規，並已作出適當披露。審計委員會對本公司所採納的會計處理並無異議。

EVENTS AFTER THE REPORTING PERIOD

Save as disclosed in Note 33 to the condensed consolidated interim financial information, there were no other material events affecting the Group after the Reporting Period and up to the date of this report.

報告期後事項

除簡明合併中期財務資料附註33所披露者外，於報告期後及直至本報告日期，並無其他影響本集團的重大事件。

DIRECTORS', SUPERVISORS' AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES

As of June 30, 2026, the interests and short positions of the Directors, Supervisors and chief executives of the Company in the shares, underlying shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which had been notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have taken under such provisions of the SFO), or which were recorded in the register required to be kept pursuant to section 352 of the SFO or which were required to be notified to the Company and the Stock Exchange pursuant to the Model Code were as follows:

董事、監事及最高行政人員於股份、相關股份及債權證中的權益及淡倉

截至2026年6月30日，本公司董事、監事及最高行政人員於本公司或其任何相聯法團(定義見《證券及期貨條例》第XV部)的股份、相關股份及債權證中擁有根據《證券及期貨條例》第XV部第7及第8分部知會本公司及聯交所的權益及淡倉(包括根據《證券及期貨條例》有關條文彼等被當作或視作擁有的權益及淡倉)、或記錄於根據《證券及期貨條例》第352條須予置存之登記冊或根據標準守則須知會本公司及聯交所之權益及淡倉如下：

Interests in Shares

於股份的權益

Name of Director 董事姓名	Position 職位	Nature of interest 權益性質	Class of Shares 股份類別	Number of Shares/ Underlying Shares held 所持股份／相關股份數目	Approximate percentage of shareholding in the class of Shares issued 佔已發行股份類別的概約持股百分比 (%)[1]	Approximate percentage of shareholding in the total Shares issued 佔已發行股份總數的概約持股百分比 (%)[1]
Dr. ZHAO Lu[2] 趙璐博士[2]	Chairman of our Board and executive Director 董事長兼執行董事	Beneficial owner; Interests in controlled corporations 實益擁有人；受控法團權益	Domestic Shares 內資股	138,545,972	38.15	24.57
		Beneficial owner; Interests in controlled corporations 實益擁有人；受控法團權益	H Shares H股	7,294,177	3.64	1.29
Ms. WAN Yunyun[3] 萬韞鋆女士[3]	General manager and executive Director 總經理兼執行董事	Interests in controlled corporations 受控法團權益	Domestic Shares 內資股	39,657,056	10.92	7.03
		Beneficial owner 實益擁有人	H Shares H股	1,839,795	0.92	0.33
Mr. MA Dong[4] 馬東先生[4]	Executive Director 執行董事	Beneficial owner 實益擁有人	H Shares H股	593,680	0.30	0.11
Mr. ZHANG Hongwei[5] 張宏偉先生[5]	Executive Director 執行董事	Interests in controlled corporations 受控法團權益	Domestic Shares 內資股	20,312,190	5.59	3.60
		Beneficial owner 實益擁有人	H Shares H股	35,703	0.02	0.01
Mr. LU Yiming[6] 陸一鳴先生[6]	Executive Director 執行董事	Beneficial owner 實益擁有人	H Shares H股	1,818,820	0.91	0.32

Name of Director 董事姓名	Position 職位	Nature of interest 權益性質	Class of Shares 股份類別	Number of Shares/ Underlying Shares held 所持股份／相關股份數目	Approximate percentage of shareholding in the class of Shares issued 佔已發行股份類別的概約持股百分比 (%)[1]	Approximate percentage of shareholding in the total Shares issued 佔已發行股份總數的概約持股百分比 (%)[1]
Ms. NI Xiaomei[7] 倪曉梅女士[7]	Executive Director 執行董事	Beneficial owner 實益擁有人	H Shares H股	1,388,772	0.69	0.25
Ms. DONG Xiaohan[8] 董曉晗女士[8]	Supervisor 監事	Beneficial owner 實益擁有人	H Shares H股	185,403	0.09	0.03
Mr. CAI Xin[9] 蔡鑫先生[9]	Supervisor 監事	Beneficial owner 實益擁有人	H Shares H股	1,290,744	0.64	0.23

Notes:

1. As of June 30, 2026, there were 563,779,000 Shares in total, including 363,186,467 Domestic Shares and 200,592,533 H Shares (including 1,308,800 Treasury Shares).

2. As of June 30, 2026, Dr. ZHAO Lu beneficially holds 93,042,388 Domestic Shares. Dr. Zhao is also deemed to beneficially hold 7,294,177 H shares, among which, 6,077,677 H shares represent the maximum number of H shares he is entitled to receive upon the expiry of a 12-month vesting period and the achievement of the market capitalization targets under the 2026 H Share Award Scheme. Dr. Zhao is the executive partner of Xinyu Haolin, Xinyu Qiwushi, Ruansu Enterprise Management, Xinyu Nuoming and Xinyu Xingmeng, and is responsible for their respective management. He also held approximately 74.94% partnership interest in Ruansu Enterprise Management. Further, Dr. Zhao is the general partner of Zhoushan Yijin and Xinyu Shenkong, and is responsible for their respective management. As such, under the SFO, Dr. Zhao is deemed to be interested in the 45,503,584 Domestic Shares and 1,216,500 H Shares held by Xinyu Haolin, Xinyu Qiwushi, Ruansu Enterprise Management, Xinyu Nuoming, Xinyu Xingmeng, Zhoushan Yijin and Xinyu Shenkong.

3. As of June 30, 2026, Ms. WAN Yunyun is deemed to beneficially hold 1,839,795 H shares which represents the maximum number of H shares she is entitled to receive upon the expiry of a 12-month vesting period and the achievement of the market capitalization targets under the 2026 H Share Award Scheme. Ms. Wan is the executive partner of Shanghai Xiaoju and Shanghai Kunrui, and is responsible for their respective management. As such, under the SFO, Ms. Wan is deemed to be interested in the 39,657,056 Domestic Shares held by Shanghai Xiaoju and Shanghai Kunrui.

附註：

1. 截至2026年6月30日，共有563,779,000股股份，包括363,186,467股內資股及200,592,533股H股（含1,308,800庫存股份）。

2. 截至2026年6月30日，趙璐博士實益持有93,042,388股內資股。趙博士亦被視為實益持有7,294,177股H股，其中6,077,677股H股為其根據2026年H股獎勵計劃於12個月歸屬期屆滿及達成市值目標後有權收取的H股最高數目。趙博士為新余浩霖、新余七武士、軟素企業管理、新余諾銘及新余星盟的執行事務合夥人，並負責彼等各自的管理。彼亦持有軟素企業管理約74.94%的合夥權益。此外，趙博士為舟山億瑾及新余深空的普通合夥人，並負責彼等各自的管理。因此，根據《證券及期貨條例》，趙博士被視為於新余浩霖、新余七武士、軟素企業管理、新余諾銘、新余星盟、舟山億瑾及新余深空持有的45,503,584股內資股及1,216,500股H股中擁有權益。

3. 截至2026年6月30日，萬韞鋆女士被視為實益持有1,839,795股H股，為其根據2026年H股獎勵計劃於12個月歸屬期屆滿及達成市值目標後有權收取的H股最高數目。萬女士為上海小橘及上海昆鋭的執行事務合夥人，並負責彼等各自的管理。因此，根據《證券及期貨條例》，萬女士被視為於上海小橘及上海昆鋭持有的39,657,056股內資股中擁有權益。

4. As of June 30, 2026, Mr. MA Dong is deemed to beneficially hold 593,680 H shares which represents the maximum number of H shares he is entitled to receive upon the expiry of a 12-month vesting period and the achievement of the market capitalization targets under the 2026 H Share Award Scheme.

5. As of June 30, 2026, Mr. ZHANG Hongwei is deemed to beneficially hold 35,703 H shares which represents the maximum number of H shares he is entitled to receive upon the expiry of a 12-month vesting period and the achievement of the market capitalization targets under the 2026 H Share Award Scheme. Mr. Zhang also held approximately 39.42% in Shanghai Xiaoju as one of its limited partners. As such, under the SFO, Mr. ZHANG Hongwei is deemed to be interested in the 20,312,190 Domestic Shares held by Shanghai Xiaoju.

6. As of June 30, 2026, Mr. LU Yiming is deemed to beneficially hold 1,818,820 H shares which represents the maximum number of H shares he is entitled to receive upon the expiry of a 12-month vesting period and the achievement of the market capitalization targets under the 2026 H Share Award Scheme.

7. As of June 30, 2026, Ms. NI Xiaomei is deemed to beneficially hold 1,388,772 H shares which represents the maximum number of H shares she is entitled to receive upon the expiry of a 12-month vesting period and the achievement of the market capitalization targets under the 2026 H Share Award Scheme.

8. As of June 30, 2026, Ms. DONG Xiaohan is deemed to beneficially hold 185,403 H shares which represents the maximum number of H shares she is entitled to receive upon the expiry of a 12-month vesting period and the achievement of the market capitalization targets under the 2026 H Share Award Scheme.

9. As of June 30, 2026, Mr. CAI Xin is deemed to beneficially hold 1,290,744 H shares which represents the maximum number of H shares he is entitled to receive upon the expiry of a 12-month vesting period and the achievement of the market capitalization targets under the 2026 H Share Award Scheme.

10. All interests are long positions.

4. 截至2026年6月30日，馬東先生被視為實益持有593,680股H股，為其根據2026年H股獎勵計劃於12個月歸屬期屆滿及達成市值目標後有權收取的H股最高數目。

5. 截至2026年6月30日，張宏偉先生被視為實益持有35,703股H股，為其根據2026年H股獎勵計劃於12個月歸屬期屆滿及達成市值目標後有權收取的H股最高數目。張先生亦作為上海小橘的有限合夥人之一持有上海小橘約39.42%的合夥權益。因此，根據《證券及期貨條例》，張宏偉先生被視為於上海小橘持有的20,312,190股內資股中擁有權益。

6. 截至2026年6月30日，陸一鳴先生被視為實益持有1,818,820股H股，為其根據2026年H股獎勵計劃於12個月歸屬期屆滿及達成市值目標後有權收取的H股最高數目。

7. 截至2026年6月30日，倪曉梅女士被視為實益持有1,388,772股H股，為其根據2026年H股獎勵計劃於12個月歸屬期屆滿及達成市值目標後有權收取的H股最高數目。

8. 截至2026年6月30日，董曉晗女士被視為實益持有185,403股H股，為其根據2026年H股獎勵計劃於12個月歸屬期屆滿及達成市值目標後有權收取的H股最高數目。

9. 截至2026年6月30日，蔡鑫先生被視為實益持有1,290,744股H股，為其根據2026年H股獎勵計劃於12個月歸屬期屆滿及達成市值目標後有權收取的H股最高數目。

10. 所有權益為好倉。

Save as disclosed above, as of June 30, 2026, none of the Directors, Supervisors or chief executives of the Company had or was deemed to have any interest or short position in the Shares, underlying Shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which was required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have taken under such provisions of the SFO), or which were required to be recorded in the register to be kept by the Company under Section 352 of the SFO, or which were required to be notified to the Company and the Stock Exchange pursuant to the Model Code.

除上文所披露者外，截至2026年6月30日，本公司董事、監事或最高行政人員概無於本公司或其任何相聯法團(定義見《證券及期貨條例》第XV部)的股份、相關股份及債權證中擁有根據《證券及期貨條例》第XV部第7及第8分部須知會本公司及聯交所的任何權益或淡倉(包括根據《證券及期貨條例》有關條文彼等被當作或視作擁有的權益及淡倉)、或須記錄於根據《證券及期貨條例》第352條須予置存之登記冊或根據標準守則須知會本公司及聯交所之任何權益或淡倉。

SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

主要股東於股份及相關股份的權益及淡倉

As of June 30, 2026, the following persons (not being a Director, Supervisor or chief executives of the Company) had interests or short positions in the shares or underlying shares which fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO as recorded in the register required to be kept by the Company pursuant to section 336 of the SFO:

截至2026年6月30日，下列人士(並非本公司董事、監事或最高行政人員)於股份或相關股份中擁有根據《證券及期貨條例》第XV部第2及第3分部之條文須向本公司披露或記錄於本公司根據《證券及期貨條例》第336條存置之登記冊之權益或淡倉：

Interests in Shares

於股份之權益

Name of Shareholder 股東名稱／名稱	Capacity/nature of interest 身份／權益性質	Number of Shares held 持有股份數目	Approximate percentage of shareholding in the relevant proportion of Shares[1] 佔相關股份份額的概約持股百分比[1] (%)	Approximate percentage of shareholding in the total issued share capital of our Company[1] 佔本公司已發行股本總額的概約持股百分比[1] (%)
Tang Lili[2] 唐麗莉[2]	Interests in controlled corporations; Interest of spouse 受控法團權益；配偶權益	138,545,972 Domestic Shares 138,545,972股內資股	38.15	24.57
	Interest of spouse 配偶權益	7,294,177 H Shares 7,294,177股H股	3.64	1.29

Name of Shareholder 股東名稱／名稱	Capacity/nature of interest 身份／權益性質	Number of Shares held 持有股份數目	Approximate percentage of shareholding in the relevant proportion of Shares[1] 佔相關股份份額的概約持股百分比[1] (%)	Approximate percentage of shareholding in the total issued share capital of our Company[1] 佔本公司已發行股本總額的概約持股百分比[1] (%)
Shanghai Kunrui 上海昆鋭	Beneficial owner 實益擁有人	19,344,866 Domestic Shares 19,344,866股內資股	5.33	3.43
Shanghai Xiaoju 上海小橘	Beneficial owner 實益擁有人	20,312,190 Domestic Shares 20,312,190股內資股	5.59	3.60
Xinyu Shenkong[2] 新余深空[2]	Beneficial owner 實益擁有人	18,204,844 Domestic Shares 18,204,844股內資股	5.01	3.23
Oriental Power Holdings Limited[3][4]	Interests in controlled corporations 受控法團權益	51,911,405 Domestic Shares 51,911,405股內資股	14.29	9.21
		12,018,451 H Shares 12,018,451股H股	5.99	2.13
Tencent Holdings Limited[3][4] 騰訊控股有限公司[3][4]	Interests in controlled corporations 受控法團權益	51,911,405 Domestic Shares 51,911,405股內資股	14.29	9.21
		12,018,451 H Shares 12,018,451股H股	5.99	2.13

Name of Shareholder 股東名稱╱名稱	Capacity/nature of interest 身份╱ 權益性質	Number of Shares held 持有股份數目	Approximate percentage of shareholding in the relevant proportion of Shares[1] 佔相關股份份額的概約持股百分比[1] (%)	Approximate percentage of shareholding in the total issued share capital of our Company[1] 佔本公司已發行股本總額的概約持股百分比[1] (%)
Tencent Technology (Shenzhen) Company Limited[3][4] 騰訊科技(深圳)有限公司[3][4]	Interests in controlled corporations 受控法團權益	51,911,405 Domestic Shares 51,911,405股內資股	14.29	9.21
		12,018,451 H Shares 12,018,451股H股	5.99	2.13
MA Huateng[3] 馬化騰[3]	Interests in controlled corporations 受控法團權益	44,880,821 Domestic Shares 44,880,821股內資股	12.36	7.96
		10,539,805 H Shares 10,539,805股H股	5.25	1.87
Linzhi Tencent Investment Management Co., Ltd.[3] 林芝騰訊投資管理有限公司[3]	Beneficial owner 實益擁有人	44,880,821 Domestic Shares 44,880,821股內資股	12.36	7.96
		10,539,805 H Shares 10,539,805股H股	5.25	1.87
Shenzhen Tencent Industrial Investment Fund Co., Ltd.[3] 深圳市騰訊產業投資基金有限公司[3]	Interests in controlled corporations 受控法團權益	44,880,821 Domestic Shares 44,880,821股內資股	12.36	7.96
		10,539,805 H Shares 10,539,805股H股	5.25	1.87

Name of Shareholder 股東名稱／名稱	Capacity/nature of interest 身份／權益性質	Number of Shares held 持有股份數目	Approximate percentage of shareholding in the relevant proportion of Shares[(1)] 佔相關股份份額的概約持股百分比[(1)] (%)	Approximate percentage of shareholding in the total issued share capital of our Company[(1)] 佔本公司已發行股本總額的概約持股百分比[(1)] (%)
Shenzhen Tencent Ruitou Enterprise Management Co., Ltd.[(3)] 深圳市騰訊睿投企業管理有限公司[(3)]	Interests in controlled corporations 受控法團權益	44,880,821 Domestic Shares 44,880,821股內資股	12.36	7.96
		10,539,805 H Shares 10,539,805股H股	5.25	1.87
Shenzhen Tencent Ruijian Investment Co., Ltd.[(3)] 深圳市騰訊睿見投資有限公司[(3)]	Interests in controlled corporations 受控法團權益	44,880,821 Domestic Shares 44,880,821股內資股	12.36	7.96
		10,539,805 H Shares 10,539,805股H股	5.25	1.87
Shenzhen Tenglv Enterprise Management Partnership (Limited Partnership)[(3)] 深圳市藤綠企業管理合夥企業（有限合夥）[(3)]	Interests in controlled corporations 受控法團權益	44,880,821 Domestic Shares 44,880,821股內資股	12.36	7.96
		10,539,805 H Shares 10,539,805股H股	5.25	1.87

Name of Shareholder 股東名稱／名稱	Capacity/nature of interest 身份／權益性質	Number of Shares held 持有股份數目	Approximate percentage of shareholding in the relevant proportion of Shares(1) 佔相關股份份額的概約持股百分比(1) (%)	Approximate percentage of shareholding in the total issued share capital of our Company(1) 佔本公司已發行股本總額的概約持股百分比(1) (%)
Shenzhen Tengyuan Enterprise Management Partnership (Limited Partnership)(3) 深圳市藤遠企業管理合夥企業（有限合夥）(3)	Interests in controlled corporations 受控法團權益	44,880,821 Domestic Shares 44,880,821股內資股	12.36	7.96
		10,539,805 H Shares 10,539,805股H股	5.25	1.87
Shenzhen Tengqing Enterprise Management Co., Ltd.(3) 深圳市藤青企業管理有限公司(3)	Interests in controlled corporations 受控法團權益	44,880,821 Domestic Shares 44,880,821股內資股	12.36	7.96
		10,539,805 H Shares 10,539,805股H股	5.25	1.87
Jingwei Chuangteng (Hangzhou) Venture Capital Partnership (Limited Partnership) ("**Jingwei Chuangteng**")(5) 經緯創騰（杭州）創業投資合夥企業（有限合夥）（「**經緯創騰**」）(5)	Beneficial owner 實益擁有人	22,349,533 Domestic Shares 22,349,533股內資股	6.15	3.96
		28,100,879 H Shares 28,100,879股H股	14.01	4.98

Name of Shareholder 股東名稱／名稱	Capacity/nature of interest 身份／權益性質	Number of Shares held 持有股份數目	Approximate percentage of shareholding in the relevant proportion of Shares[1] 佔相關股份份額的概約持股百分比[1] (%)	Approximate percentage of shareholding in the total issued share capital of our Company[1] 佔本公司已發行股本總額的概約持股百分比[1] (%)
Hangzhou Jingwei Yuanchuang Investment Management Partnership (Limited Partnership) ("**Jingwei Yuanchuang**")[5] 杭州經緯遠創投資管理合夥企業(有限合夥)(「**經緯遠創**」)[5]	Interests in controlled corporations 受控法團權益	22,349,533 Domestic Shares 22,349,533股內資股	6.15	3.96
		28,100,879 H Shares 28,100,879股H股	14.01	4.98
Shanghai Jingwei Equity Investment Management Co., Ltd. ("**Shanghai Jingwei**")[5] 上海旌威股權投資管理有限公司(「**上海旌威**」)[5]	Interests in controlled corporations 受控法團權益	22,349,533 Domestic Shares 22,349,533股內資股	6.15	3.96
		28,100,879 H Shares 28,100,879股H股	14.01	4.98
ZUO Lingye[5] 左淩燁[5]	Interests in controlled corporations 受控法團權益	23,908,953 Domestic Shares 23,908,953股內資股	6.58	4.24
		30,061,593 H Shares 30,061,593股H股	14.99	5.33
Suzhou Northern Lights Zhengyuan Venture Capital Partnership (Limited Partnership)[6] 蘇州北極光正源創業投資合夥企業(有限合夥)[6]	Beneficial owner 實益擁有人	10,139,955 H Shares 10,139,955股H股	5.06	1.80

Name of Shareholder 股東名稱／名稱	Capacity/nature of interest 身份／權益性質	Number of Shares held 持有股份數目	Approximate percentage of shareholding in the relevant proportion of Shares[(1)] 佔相關股份份額的概約持股百分比[(1)] (%)	Approximate percentage of shareholding in the total issued share capital of our Company[(1)] 佔本公司已發行股本總額的概約持股百分比[(1)] (%)
Suzhou Boyuan Venture Capital Management Partnership (Limited Partnership)[(6)] 蘇州柏源創業投資管理合夥企業（有限合夥）[(6)]	Interests in controlled corporations 受控法團權益	15,930,449 H Shares 15,930,449股H股	7.94	2.83
Suzhou Songyuan Entrepreneurship Investment Management Co., Ltd.[(6)] 蘇州松源創業投資管理有限公司[(6)]	Interests in controlled corporations 受控法團權益	15,930,449 H Shares 15,930,449股H股	7.94	2.83
ZHANG Pengpeng[(6)] 張朋朋[(6)]	Interests in controlled corporations 受控法團權益	15,930,449 H Shares 15,930,449股H股	7.94	2.83
Shanghai Chenxi Venture Capital Center (Limited Partnership) ("**5Y Chenxi**") 上海晨熹創業投資中心（有限合夥）（「**上海晨熹**」）	Beneficial owner 實益擁有人	11,514,965 H Shares 11,514,965股H股	5.74	2.04
Shanghai Yuanpan Enterprise Management Consulting Partnership (Limited Partnership) 上海源畔企業管理諮詢合夥企業（有限合夥）	Interests in controlled corporations 受控法團權益	11,514,965 H Shares 11,514,965股H股	5.74	2.04
XUE Qiong 薛琼	Interests in controlled corporations 受控法團權益	11,514,965 H Shares 11,514,965股H股	5.74	2.04
CHEN Yihai 陳怡海	Interest of spouse 配偶權益	11,514,965 H Shares 11,514,965股H股	5.74	2.04

Name of Shareholder 股東名稱╱名稱	Capacity/nature of interest 身份╱權益性質	Number of Shares held 持有股份數目	Approximate percentage of shareholding in the relevant proportion of Shares[(1)] 佔相關股份份額的概約持股百分比[(1)] (%)	Approximate percentage of shareholding in the total issued share capital of our Company[(1)] 佔本公司已發行股本總額的概約持股百分比[(1)] (%)
Shanghai Xingshang Enterprise Management Consulting Co., Ltd. (“**Shanghai Xingshang**”) 上海興尚企業管理諮詢有限公司(「**上海興尚**」)	Interests in controlled corporations 受控法團權益	13,297,378 H Shares 13,297,378股H股	6.63	2.36
WANG Zhenting 王振庭	Interests in controlled corporations 受控法團權益	13,297,378 H Shares 13,297,378股H股	6.63	2.36
LI Luqian 李璐倩	Interest of spouse 配偶權益	13,297,378 H Shares 13,297,378股H股	6.63	2.36
Shanghai Xingpan Investment Management Consulting Co., Ltd. (“**Shanghai Xingpan**”) 上海興畔投資管理諮詢有限公司(「**上海興畔**」)	Interests in controlled corporations 受控法團權益	15,538,280 H Shares 15,538,280股H股	7.75	2.76
NI Yuanyuan 倪媛媛	Interests in controlled corporations; Interest of spouse 受控法團權益；配偶權益	15,538,280 H Shares 15,538,280股H股	7.75	2.76
LIU Qin 劉芹	Interests in controlled corporations 受控法團權益	15,538,280 H Shares 15,538,280股H股	7.75	2.76
LOU Yiting 樓懿婷	Interest of spouse 配偶權益	15,538,280 H Shares 15,538,280股H股	7.75	2.76

Name of Shareholder 股東名稱／名稱	Capacity/nature of interest 身份／權益性質	Number of Shares held 持有股份數目	Approximate percentage of shareholding in the relevant proportion of Shares[1] 佔相關股份份額的概約持股百分比[1] (%)	Approximate percentage of shareholding in the total issued share capital of our Company[1] 佔本公司已發行股本總額的概約持股百分比[1] (%)
SHI Jianming 石建明	Interests in controlled corporations 受控法團權益	15,538,280 H Shares 15,538,280股H股	7.75	2.76
Tianjin SAIF Shengyuan Investment Management Center (Limited Partnership)[7] 天津賽富盛元投資管理中心（有限合夥）[7]	Interests in controlled corporations 受控法團權益	10,889,262 H Shares 10,889,262股H股	5.43	1.93
YAN Andrew Y[7] 閻焱[7]	Interests in controlled corporations 受控法團權益	10,889,262 H Shares 10,889,262股H股	5.43	1.93
Zheshang Venture Capital Co., Ltd. ("**Zheshang VC**")[8] 浙商創投股份有限公司（「**浙商創投**」）[8]	Beneficial owner; Interests in controlled corporations 實益擁有人；受控法團權益	10,094,225 H Shares 10,094,225股H股	5.03	1.79
Ningbo Meishan Bonded Area Dirui Investment Management Partnership (Limited Partnership) [9] 寧波梅山保稅港區迪鋭投資管理合夥企業（有限合夥）[9]	Interests in controlled corporations 受控法團權益	10,694,479 H Shares 10,694,479股H股	5.33	1.90
TANG Meng[9] 唐萌[9]	Interests in controlled corporations 受控法團權益	10,694,479 H Shares 10,694,479股H股	5.33	1.90
ZHANG Xu[10] 張旭[10]	Interests in controlled corporations 受控法團權益	12,285,138 H Shares 12,285,138股H股	6.12	2.18

Notes:

1. As of June 30, 2026, there were 563,779,000 Shares in total, including 363,186,467 Domestic Shares and 200,592,533 H Shares (including 1,308,800 Treasury Shares).

2. As of June 30, 2026, Dr. ZHAO Lu beneficially holds 93,042,388 Domestic Shares. Dr. Zhao is also deemed to beneficially hold 7,294,177 H shares, among which, 6,077,677 H shares represent the maximum number of H shares he is entitled to receive upon the expiry of a 12-month vesting period and the achievement of the market capitalization targets under the 2026 H Share Award Scheme. Dr. Zhao is the executive partner of Xinyu Haolin, Xinyu Qiwushi, Ruansu Enterprise Management, Xinyu Nuoming and Xinyu Xingmeng, and is responsible for their respective management. He also held approximately 74.94% partnership interest in Ruansu Enterprise Management. Further, Dr. Zhao is the general partner of Zhoushan Yijin and Xinyu Shenkong, and is responsible for their respective management. As such, under the SFO, Dr. Zhao is deemed to be interested in the 45,503,584 Domestic Shares and 1,216,500 H Shares held by Xinyu Haolin, Xinyu Qiwushi, Ruansu Enterprise Management, Xinyu Nuoming, Xinyu Xingmeng, Zhoushan Yijin and Xinyu Shenkong.

   Ms. Tang Lili held 95% partnership interest in Zhoushan Yijin and 99% partnership interest in Xinyu Shenkong as their respective sole limited partner as of June 30, 2026. As such, under the SFO, Ms. Tang is deemed to be interested in the 23,585,382 Domestic Shares held by Zhoushan Yijin and Xinyu Shenkong. Besides, Ms. Tang is the spouse of Dr. Zhao. As such, she is deemed to be interested in the Domestic Shares and H Shares in which Dr. Zhao is interested and is deemed to be interested.

3. Linzhi Tencent Investment Management Co., Ltd. is wholly owned by Shenzhen Tencent Industrial Investment Fund Co., Ltd. (深圳市騰訊產業投資基金有限公司), which is a subsidiary of Tencent Holdings Limited (a company listed on the Main Board of the Stock Exchange, stock codes: 700 (HKD counter) and 80700 (RMB counter)).

4. Suzhou Paiyi Venture Capital Partnership L.P. is managed by its general partner, Suzhou Yaoyi Enterprise Management Co., Ltd. which is wholly owned by Shenzhen Zeyi Consultancy Co., Ltd. (深圳市澤益諮詢有限公司). Suzhou Tencent Phase I Investment Fund Partnership (Limited Partnership) is the largest limited partner of Suzhou Paiyi Venture Capital Partnership L.P..

5. The general partner of Jingwei Chuangteng is Jingwei Yuanchuang, whose general partner is Shanghai Jingwei, which was in turn held as to 80% by ZUO Lingye.

附註：

1. 截至2026年6月30日，共有563,779,000股股份，包括363,186,467股內資股及200,592,533股H股（含1,308,800庫存股份）。

2. 截至2026年6月30日，趙璐博士實益持有93,042,388股內資股。趙博士亦被視為實益持有7,294,177股H股，其中6,077,677股H股為其根據2026年H股獎勵計劃於12個月歸屬期屆滿及達成市值目標後有權收取的H股最高數目。趙博士為新余浩霖、新余七武士、軟素企業管理、新余諾銘及新余星盟的執行事務合夥人，並負責彼等各自的管理。彼亦持有軟素企業管理約74.94%的合夥權益。此外，趙博士為舟山憶瑾及新余深空的普通合夥人，並負責彼等各自的管理。因此，根據《證券及期貨條例》，趙博士被視為於新余浩霖、新余七武士、軟素企業管理、新余諾銘、新余星盟、舟山憶瑾及新余深空持有的45,503,584股內資股及1,216,500股H股中擁有權益。

   截至2026年6月30日，唐麗莉女士作為其各自的唯一有限合夥人持有舟山憶瑾95%的合夥權益及新余深空99%的合夥權益。因此，根據《證券及期貨條例》，唐女士被視為於舟山憶瑾及新余深空持有的23,585,382股內資股中擁有權益。此外，唐女士為趙博士的配偶。因此，其被視為於趙博士擁有權益及被視為擁有權益的內資股及H股中擁有權益。

3. 林芝騰訊投資管理有限公司由深圳市騰訊產業投資基金有限公司全資擁有，而深圳市騰訊產業投資基金有限公司為騰訊控股有限公司(一家於聯交所主板上市的公司，股份代號：700(港幣櫃台)及80700(人民幣櫃台))的附屬公司。

4. 蘇州湃益創業投資合夥企業(有限合夥)由其普通合夥人蘇州垚益企業管理有限公司管理，而蘇州垚益企業管理有限公司由深圳市澤益諮詢有限公司全資擁有。蘇州騰訊一期跟投基金合夥企業(有限合夥)為蘇州湃益創業投資合夥企業(有限合夥)的最大有限合夥人。

5. 經緯創騰的普通合夥人為經緯遠創，其普通合夥人為上海旌威，而該公司由左凌燁持有80%。

Besides, the general partner of Suzhou Jingwei Chuangbo Investment Center (Limited Partnership) is Suzhou Weichuang Investment Management Partnership (Limited Partnership), whose general partner is Shanghai Jingyi Investment Management Co., Ltd., which was in turn held as to 80% by ZUO Lingye.

As such, under the SFO, each of Jingwei Yuanchuang and Shanghai Jingwei is deemed to be interested in the 22,349,533 Domestic Shares and 28,100,879 H Shares held by Jingwei Chuangteng, and ZUO Lingye is deemed to be interested in the 23,908,953 Domestic Shares and 30,061,593 H Shares held by Jingwei Chuangteng and Suzhou Jingwei Chuangbo Investment Center (Limited Partnership).

6. The general partner of each Suzhou Northern Lights Zhengyuan Venture Capital Partnership (Limited Partnership) and Suzhou Northern Lights Hongyuan Venture Capital Partnership (Limited Partnership) is Suzhou Boyuan Venture Capital Management Partnership (Limited Partnership), whose general partner is Suzhou Songyuan Entrepreneurship Investment Management Co., Ltd., which was held as to 50% by ZHANG Pengpeng, 25% by LI Lixin and 25% by YANG Lei, respectively. As such, under the SFO, each of Suzhou Boyuan Venture Capital Management Partnership (Limited Partnership), Suzhou Songyuan Entrepreneurship Investment Management Co., Ltd. and ZHANG Pengpeng is deemed to be interested in the 15,930,449 H Shares held by Suzhou Northern Lights Zhengyuan Venture Capital Partnership (Limited Partnership) and Suzhou Northern Lights Hongyuan Venture Capital Partnership (Limited Partnership).

7. The general partner of Suzhou SAIF Puxin Medical and Health Industry Investment Center (Limited Partnership) is Suzhou SAIF Puxin Venture Capital Center (Limited Partnership), whose general partner is Tianjin SAIF Shengyuan Investment Management Center (Limited Partnership), which is managed by its executive partner, YAN Andrew Y.

The general partner of Nanjing SAIF Hengzhun Venture Capital Fund (Limited Partnership) is Jiaxing SAIF Hengshun Investment Management Partnership (Limited Partnership), whose general partner is Tianjin SAIF Shengyuan Investment Management Center (Limited Partnership).

此外，蘇州經緯創博投資中心（有限合夥）的普通合夥人為蘇州緯創投資管理合夥企業（有限合夥），其普通合夥人為上海經熠投資管理有限公司，而該公司由左凌燁持有80%。

因此，根據《證券及期貨條例》，經緯遠創及上海旌威各自被視為於經緯創騰所持22,349,533股內資股及28,100,879股H股中擁有權益，及左凌燁被視為於經緯創騰及蘇州經緯創博投資中心（有限合夥）所持23,908,953股內資股及30,061,593股H股中擁有權益。

6. 蘇州北極光正源創業投資合夥企業（有限合夥）及蘇州北極光泓源創業投資合夥企業（有限合夥）各自的普通合夥人為蘇州柏源創業投資管理合夥企業（有限合夥），其普通合夥人為蘇州松源創業投資管理有限公司，該公司分別由張朋朋、李立新及楊磊持有50%、25%及25%。因此，根據《證券及期貨條例》，蘇州柏源創業投資管理合夥企業（有限合夥）、蘇州松源創業投資管理有限公司及張朋朋各自被視為於蘇州北極光正源創業投資合夥企業（有限合夥）及蘇州北極光泓源創業投資合夥企業（有限合夥）所持15,930,449股H股中擁有權益。

7. 蘇州賽富璞鑫醫療健康產業投資中心（有限合夥）的普通合夥人為蘇州賽富璞鑫創業投資中心（有限合夥），其普通合夥人為天津賽富盛元投資管理中心（有限合夥），該公司由其執行事務合夥人閻焱管理。

南京賽富衡准創業投資基金（有限合夥）的普通合夥人為嘉興賽富恒順投資管理合夥企業（有限合夥），其普通合夥人為天津賽富盛元投資管理中心（有限合夥）。

The general partner of Huangshan SAIF Tourism Cultural Industry Development Fund (Limited Partnership) is Mount Huangshan Saifu Fund Management Co., Ltd., which was held as to 80% by Tianjin SAIF Shengyuan Investment Management Center (Limited Partnership).

As such, under the SFO, each of Tianjin SAIF Shengyuan Investment Management Center (Limited Partnership) and YAN Andrew Y is deemed to be interested in the 10,889,262 H Shares held by Suzhou SAIF Puxin Medical and Health Industry Investment Center (Limited Partnership), Nanjing SAIF Hengzhun Venture Capital Fund (Limited Partnership) and Huangshan SAIF Tourism Cultural Industry Development Fund (Limited Partnership).

8. Zheshang VC is a limited liability company listed on the National Equities Exchange And Quotations (stock code: 834089). It beneficially holds 1,609,427 H Shares.

   The general partner of Hangzhou Yangjian Investment Partnership (Limited Partnership) is Zhejiang Haipeng Investment Management Co., Ltd., which is a wholly-owned subsidiary of Zheshang VC.

   The general partner of Hangzhou Qizhen Future Innovation Equity Investment Partnership (Limited Partnership) is Zheshang VC.

   As such, under the SFO, Zheshang VC is deemed to be interested in the 8,484,798 H Shares held by Hangzhou Yangjian Investment Partnership (Limited Partnership) and Hangzhou Qizhen Future Innovation Equity Investment Partnership (Limited Partnership).

9. The general partner of each of Aochuan Bangde Investment Partnership (Limited Partnership), Ningbo Jinjiao Langqiu Investment Partnership (Limited Partnership) and Ningbo Xuri Xinzhu Investment Partnership (Limited Partnership) is Ningbo Meishan Bonded Area Dirui Investment Management Partnership (Limited Partnership), whose general partner is TANG Meng. As such, under the SFO, each of Ningbo Meishan Bonded Area Dirui Investment Management Partnership (Limited Partnership) and TANG Meng is deemed to be interested in the 8,505,665 Domestic Shares and 10,694,479 H Shares held by Aochuan Bangde Investment Partnership (Limited Partnership), Ningbo Jinjiao Langqiu Investment Partnership (Limited Partnership) and Ningbo Xuri Xinzhu Investment Partnership (Limited Partnership).

黃山賽富旅遊文化產業發展基金(有限合夥)的普通合夥人為黃山賽富基金管理有限責任公司，該公司由天津賽富盛元投資管理中心(有限合夥)持有80%。

因此，根據《證券及期貨條例》，天津賽富盛元投資管理中心(有限合夥)及閻焱被視為於蘇州賽富璞鑫醫療健康產業投資中心(有限合夥)、南京賽富衡准創業投資基金(有限合夥)及黃山賽富旅遊文化產業發展基金(有限合夥)所持10,889,262股H股中擁有權益。

8. 浙商創投為一家於全國中小企業股份轉讓系統掛牌的有限責任公司(股票代碼：834089)。其實益持有1,609,427股H股。

   杭州仰健投資合夥企業(有限合夥)的普通合夥人為浙江海鵬投資管理有限公司，其為浙商創投的全資附屬公司。

   杭州啟真未來創新股權投資合夥企業(有限合夥)的普通合夥人為浙商創投。

   因此，根據《證券及期貨條例》，浙商創投被視為於杭州仰健投資合夥企業(有限合夥)及杭州啟真未來創新股權投資合夥企業(有限合夥)所持8,484,798股H股中擁有權益。

9. 蘇州市相城區奧傳邦德投資合夥企業(有限合夥)、寧波金蛟朗秋投資合夥企業(有限合夥)及寧波旭日新竹投資合夥企業(有限合夥)的普通合夥人為寧波梅山保稅港區迪鋭投資管理合夥企業(有限合夥)，該公司的普通合夥人為唐萌。因此，根據《證券及期貨條例》，寧波梅山保稅港區迪鋭投資管理合夥企業(有限合夥)及唐萌被視為於蘇州市相城區奧傳邦德投資合夥企業(有限合夥)、寧波金蛟朗秋投資合夥企業(有限合夥)及寧波旭日新竹投資合夥企業(有限合夥)所持8,505,665股內資股及10,694,479股H股中擁有權益。

10. The general partner of Chengdu SBCVC Tiantou Venture Capital Center (Limited Partnership) is Chongqing SBCVC Investment Management Co., Ltd., which was held as to 95% by ZHANG Xu.

    The general partner of Ningbo SBCVC Stable Growth Investment Partnership (Limited Partnership) is Shanghai Xinbo Jieyi Private Fund Management Partnership (Limited Partnership), whose general partner is Shanghai Guanhe Lanzheng Investment Management Co., Ltd, which was held as to 90% by ZHANG Xu.

    The general partner of Jiaxing SBCVC Venture Capital Partnership (Limited Partnership) is Ningbo Ruanku Investment Co., Ltd., which was held as to 60% by ZHANG Xu.

    As such, under the SFO, ZHANG Xu is deemed to be interested in the 9,770,766 Domestic Shares and 12,285,138 H Shares held by Chengdu SBCVC Tiantou Venture Capital Center (Limited Partnership), Ningbo SBCVC Stable Growth Investment Partnership (Limited Partnership) and Jiaxing SBCVC Venture Capital Partnership (Limited Partnership).

11. All interests are long positions.

Save as disclosed above, as of June 30, 2026, the Company had not been notified by any other persons (other than the Directors, Supervisors or chief executives of the Company) who had an interest or short position in the Shares or underlying Shares of the Company which would fall to be disclosed under Divisions 2 and 3 of Part XV of the SFO, or which were required to be entered in the register required to be kept by the Company pursuant to Section 336 of the SFO.

10. 成都軟銀天投創業投資中心(有限合夥)的普通合夥人為重慶軟銀投資管理有限公司，該公司由張旭持有95%。

    寧波軟銀穩定成長投資合夥企業(有限合夥)的普通合夥人為上海欣博傑益私募基金管理合夥企業(有限合夥)，該公司的普通合夥人為上海觀禾覽正投資管理有限公司，該公司由張旭持有90%。

    嘉興軟銀創業投資合夥企業(有限合夥)的普通合夥人為寧波軟庫投資有限公司，該公司由張旭持有60%。

    因此，根據《證券及期貨條例》，張旭被視為於成都軟銀天投創業投資中心(有限合夥)、寧波軟銀穩定成長投資合夥企業(有限合夥)及嘉興軟銀創業投資合夥企業(有限合夥)所持9,770,766股內資股及12,285,138股H股中擁有權益。

11. 所有權益為好倉。

除上文所披露者外，截至2026年6月30日，本公司概無獲得任何其他人士(董事、監事或本公司最高行政人員除外)知會，其於本公司股份或相關股份中擁有須根據《證券及期貨條例》第XV部第2及3分部的條文披露或須於本公司根據《證券及期貨條例》第336條存置的登記冊登記的權益或淡倉。

CHANGES IN INFORMATION OF DIRECTORS AND SUPERVISORS

Mr. FUNG Che Wai Anthony, an independent non-executive Director of the Company, has served as an independent non-executive director of Deepexi Technology Co., Ltd. (a company listed on the Stock Exchange (stock code: 1384)) since August 2026.

Mr. WEN Gang (文綱), aged 48, has been a shareholders' representative Supervisor since September 2020. He is primarily responsible for the supervision of the performance of our Directors and members of our senior management in performing their duties to our Company and performing other supervisory duties as a Supervisor.

Mr. Wen has more than 11 years of experience in investment. Besides, since November 2013, Mr. Wen has also been a partner of Ningbo Free Trade Zone Kaifeng Venture Capital Management Co., Ltd. (寧波保稅區凱風創業投資管理有限公司), an investment company, where he has been primarily responsible for managing investments in the biomedical sector.

Mr. Wen obtained his bachelor's degree in clinical medicine and his master's degree in clinical medicine in July 2000 and July 2003, respectively, from Peking Union Medical College (北京協和醫學院) (formerly known as China Union Medical College (中國協和醫科大學)) in Beijing.

Save as disclosed above, there was no change in the information of Directors and Supervisors which is required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules since the publication of the 2025 annual report of the Company and up to the date of this interim report.

董事及監事資料變動

本公司獨立非執行董事馮志偉先生自2026年8月起擔任滴普科技股份有限公司(一家於聯交所上市的公司(股份代號：1384))的獨立非執行董事。

文綱先生，48歲，自2020年9月起擔任股東代表監事。其主要負責監督董事及高級管理層成員於履行彼等對本公司的職責時的表現以及履行作為監事的其他監督職責。

文先生於投資方面擁有逾11年經驗。此外，自2013年11月起，文先生亦為投資公司寧波保稅區凱風創業投資管理有限公司的合夥人，主要負責管理生物醫藥領域的投資。

文先生分別於2000年7月及2003年7月在北京獲得北京協和醫學院(前稱中國協和醫科大學)臨床醫學學士學位及臨床醫學碩士學位。

除上文所披露者外，自本公司2025年年報刊發起及直至本中期報告日期，董事及監事資料並無須根據上市規則第13.51B(1)條予以披露之變動。

CONTINUING DISCLOSURE OBLIGATIONS PURSUANT TO THE LISTING RULES

The Company does not have any other disclosure obligations under Rules 13.20, 13.21 and 13.22 of the Listing Rules.

根據上市規則的持續披露義務

本公司並無須根據上市規則第13.20、13.21及13.22條履行任何其他披露義務。

On behalf of the Board
Dr. ZHAO Lu
Chairman of the Board
Zhejiang, the PRC, September 23, 2026

代表董事會
董事長
趙璐博士
中國浙江省，2026年9月23日

REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION
中期財務資料審閱報告

To the Board of Directors of Zhejiang Taimei Medical Technology Co., Ltd.
(incorporated in the People's Republic of China with limited liability)

致浙江太美醫療科技股份有限公司董事會

（於中華人民共和國註冊成立的有限公司）

INTRODUCTION

We have reviewed the interim financial information set out on pages 56 to 116, which comprises the interim condensed consolidated balance sheet of Zhejiang Taimei Medical Technology Co., Ltd. (the "**Company**") and its subsidiaries (together, the "**Group**") as at June 30, 2026 and the interim condensed consolidated income statement, the interim condensed consolidated statement of comprehensive loss, the interim condensed consolidated statement of changes in equity and the interim condensed consolidated statement of cash flows for the six-month period then ended, and selected explanatory notes. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of a report on interim financial information to be in compliance with the relevant provisions thereof and International Accounting Standard 34 "Interim Financial Reporting". The directors of the Company are responsible for the preparation and presentation of this interim financial information in accordance with International Accounting Standard 34 "Interim Financial Reporting". Our responsibility is to express a conclusion on this interim financial information based on our review and to report our conclusion solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

引言

我們已審閱載於第56頁至第116頁的中期財務資料，其包括浙江太美醫療科技股份有限公司(「**貴公司**」)及其附屬公司(統稱「**貴集團**」)於2026年6月30日的中期簡明合併資產負債表，以及截至該日止六個月的中期簡明合併收益表、中期簡明合併全面虧損表、中期簡明合併權益變動表及中期簡明合併現金流量表，並附選定解釋性附註。香港聯合交易所有限公司證券上市規則規定，中期財務資料報告須符合其相關條文及國際會計準則第34號「中期財務報告」。 貴公司董事負責根據國際會計準則第34號「中期財務報告」編製及列報此中期財務資料。我們的責任是根據我們的審閱對此中期財務資料發表結論，並按照我們約定的委聘條款僅向 閣下(作為一個整體)報告我們的結論，而不作任何其他用途。我們不對任何其他人士就本報告的內容承擔責任或承擔法律責任。

SCOPE OF REVIEW

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

審閱範圍

我們是根據國際審閱業務準則第2410號「由實體的獨立核數師執行的中期財務資料審閱」進行審閱。中期財務資料的審閱包括向主要負責財務及會計事務的人士作出查詢，以及應用分析和其他審閱程序。審閱的範圍較根據《國際審計準則》進行的審計大幅縮小，因此並不能使我們獲得足夠的保證，以確信在審計中可能識別的所有重大事項均會被我們察覺。因此，我們不發表審計意見。

CONCLUSION

Based on our review, nothing has come to our attention that causes us to believe that the interim financial information of the Group is not prepared, in all material respects, in accordance with International Accounting Standard 34 "Interim Financial Reporting".

結論

根據我們的審閱，我們並無注意到任何事項使我們相信　貴集團的中期財務資料並非在所有重大方面均已按照國際會計準則第34號「中期財務報告」編製。

PricewaterhouseCoopers
Certified Public Accountants
Hong Kong, August 26, 2026

羅兵咸永道會計師事務所
執業會計師
香港，2026年8月26日

INTERIM CONDENSED CONSOLIDATED INCOME STATEMENT
中期簡明合併收益表

For the six months ended June 30, 2026
截至2026年6月30日止六個月

			Six months ended June 30, 截至6月30日止六個月	
		Notes *附註*	**2026** **2026年** **RMB'000** **人民幣千元** **(Unaudited)** **（未經審計）**	2025 2025年 RMB'000 人民幣千元 (Unaudited) （未經審計）
Revenue	**收入**	*6*	**263,639**	244,221
Cost of sales	銷售成本	*7*	**(145,889)**	(144,033)
Gross profit	**毛利**		**117,750**	100,188
Selling expenses	銷售開支	*7*	**(44,159)**	(37,573)
Administrative expenses	行政開支	*7*	**(69,992)**	(57,679)
Research and development expenses	研發開支	*7*	**(39,927)**	(37,705)
Net impairment losses on financial assets and contract assets	金融及合約資產減值虧損淨額		**(5,050)**	(5,454)
Other income	其他收入	*8*	**6,250**	2,445
Other losses-net	其他虧損淨額	*9*	**(27,241)**	(12,932)
Operating loss	**經營虧損**		**(62,369)**	(48,710)
Finance income	財務收入		**15,195**	19,980
Finance cost	財務成本		**(987)**	(579)
Finance income-net	**財務收入淨額**	*10*	**14,208**	19,401
Loss before income tax	**除所得稅前虧損**		**(48,161)**	(29,309)
Income tax expenses	所得稅開支	*11*	**–**	–
Loss for the period	**期內虧損**		**(48,161)**	(29,309)

INTERIM CONDENSED CONSOLIDATED INCOME STATEMENT
中期簡明合併收益表

For the six months ended June 30, 2026
截至2026年6月30日止六個月

			Six months ended June 30, 截至6月30日止六個月	
		Notes *附註*	**2026** **2026年** **RMB'000** **人民幣千元** **(Unaudited)** **（未經審計）**	2025 2025年 RMB'000 人民幣千元 (Unaudited) （未經審計）
Loss is attributable to:	**下列各方應佔虧損：**			
Owners of the Company	本公司擁有人		**(45,107)**	(22,802)
Non-controlling interests	非控股權益		**(3,054)**	(6,507)
			(48,161)	(29,309)
Loss per share for loss attributable to equity holders of the Company	**本公司權益持有人應佔虧損之每股虧損**			
Basic and diluted loss per share (RMB)	每股基本及攤薄虧損（人民幣元）	*12*	**(0.08)**	(0.04)

The above interim condensed consolidated income statement should be read in conjunction with the accompanying notes.

上述中期簡明合併收益表應與附註一併閱讀。

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE LOSS
中期簡明合併全面虧損表

For the six months ended June 30, 2026
截至2026年6月30日止六個月

		Six months ended June 30, 截至6月30日止六個月	
		2026 **2026年** **RMB'000** **人民幣千元** **(Unaudited)** **（未經審計）**	2025 2025年 RMB'000 人民幣千元 (Unaudited) （未經審計）
Loss for the period	**期內虧損**	**(48,161)**	(29,309)
Other comprehensive (loss)/income	**其他全面（虧損）╱收益**		
Item that may be reclassified to profit or loss	*可能重新分類至損益的項目*		
Exchange differences on translation of foreign operations	因換算海外業務而產生的匯兑差額	**(3,916)**	10,539
Other comprehensive (loss)/income for the period, net of taxes	**期內其他全面（虧損）╱收益（扣除税項）**	**(3,916)**	10,539
Total comprehensive loss for the period	**期內全面虧損總額**	**(52,077)**	(18,770)
Total comprehensive loss for the period is attributable to:	**以下各方應佔期內全面虧損總額：**		
Equity holders of the Company	本公司權益持有人	**(48,976)**	(12,423)
Non-controlling interests	非控股權益	**(3,101)**	(6,347)
		(52,077)	(18,770)

The above interim condensed consolidated statement of comprehensive loss should be read in conjunction with the accompanying notes.

上述中期簡明合併全面虧損表應與附註一併閱讀。

INTERIM CONDENSED CONSOLIDATED BALANCE SHEET
中期簡明合併資產負債表

As at June 30, 2026
於2026年6月30日

		Notes 附註	As at June 30, 2026 於2026年6月30日 RMB'000 人民幣千元 (Unaudited) （未經審計）	As at December 31, 2025 於2025年12月31日 RMB'000 人民幣千元 (Audited) （經審計）
Assets	**資產**			
Non-current assets	**非流動資產**			
Property, plant and equipment	物業、廠房及設備	*14*	**9,166**	9,347
Right-of-use assets	使用權資產	*15*	**10,636**	12,982
Intangible assets	無形資產	*16*	**52,792**	54,662
Long-term receivables	長期應收款項	*21*	**9,060**	9,203
Investments accounted for using the equity method	按權益法列賬的投資	*23*	**41,000**	–
			122,654	86,194
Current assets	**流動資產**			
Contract fulfilment cost	合約履約成本	*18*	**6,532**	4,339
Contract assets	合約資產	*6(a)*	**20,222**	20,136
Trade and notes receivables	貿易應收款項及應收票據	*19*	**203,635**	181,089
Other receivables and prepayments	其他應收款項及預付款項	*20*	**62,134**	72,604
Financial assets at fair value through profit or loss	按公允價值計量且其變動計入當期損益的金融資產		**34,587**	55,451
Short-term treasury investments	短期國債投資	*22*	**136,251**	139,241
Restricted cash	受限制現金	*24*	**1,718**	70
Short-term bank deposits	短期銀行存款	*24*	**433,680**	372,018
Cash and cash equivalents	現金及現金等價物	*24*	**477,324**	625,185
			1,376,083	1,470,133
Total assets	**資產總值**		**1,498,737**	1,556,327

INTERIM CONDENSED CONSOLIDATED BALANCE SHEET
中期簡明合併資產負債表

As at June 30, 2026
於2026年6月30日

		Notes 附註	As at June 30, 2026 於2026年6月30日 RMB'000 人民幣千元 (Unaudited) (未經審計)	As at December 31, 2025 於2025年12月31日 RMB'000 人民幣千元 (Audited) (經審計)
Equity	**權益**			
Equity attributable to equity holders of the Company	**本公司權益持有人應佔權益**			
Share capital	股本	25	563,779	563,779
Other reserves	其他儲備	26	2,307,327	2,295,772
Currency translation reserves	貨幣換算儲備		4,370	8,239
Accumulated losses	累計虧損		(1,791,030)	(1,745,923)
			1,084,446	1,121,867
Non-controlling interests	**非控股權益**		65,891	68,992
Total equity	**總權益**		1,150,337	1,190,859
Liabilities	**負債**			
Non-current liabilities	**非流動負債**			
Lease liabilities	租賃負債	15	1,152	3,070
Warrant liabilities	認股權證負債	27	33,667	34,443
			34,819	37,513

		Notes 附註	As at June 30, 2026 於2026年6月30日 RMB'000 人民幣千元 (Unaudited) （未經審計）	As at December 31, 2025 於2025年12月31日 RMB'000 人民幣千元 (Audited) （經審計）
Current liabilities	**流動負債**			
Borrowings	借款	*30*	**75,489**	48,000
Trade and other payables	貿易及其他應付款項	*29*	**168,516**	200,952
Lease liabilities	租賃負債	*15*	**8,746**	10,062
Contract liabilities	合約負債	*6(b)*	**60,830**	68,941
			313,581	327,955
Total liabilities	**負債總額**		**348,400**	365,468
Total equity and liabilities	**權益及負債總額**		**1,498,737**	1,556,327

The above interim condensed consolidated balance sheet should be read in conjunction with the accompanying notes.

上述中期簡明合併資產負債表應與附註一併閱讀。

The condensed consolidated interim financial information on pages 56 to 116 was approved and authorised for issue by the Board of Directors of the Company on August 26, 2026 and was signed on its behalf by:

第56頁至第116頁的簡明合併中期財務資料已於2026年8月26日經本公司董事會批准並授權刊發，並由其代表簽署如下：

Director
董事

Director
董事

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
中期簡明合併權益變動表

For the six months ended June 30, 2026
截至2026年6月30日止六個月

			Equity attributable to owners of the Company 本公司擁有人應佔權益							
		Notes 附註	Share capital 股本 RMB'000 人民幣千元	Other reserves 其他儲備 RMB'000 人民幣千元	Treasury shares 庫存股份 RMB'000 人民幣千元	Currency translation reserves 貨幣換算儲備 RMB'000 人民幣千元	Accumulated losses 累計虧損 RMB'000 人民幣千元	Total 總值 RMB'000 人民幣千元	Non-controlling interests 非控股權益 RMB'000 人民幣千元	Total equity 權益總額 RMB'000 人民幣千元
(Unaudited)	**(未經審計)**									
As at January 1, 2026	**於2026年1月1日**		563,779	2,296,415	(643)	8,239	(1,745,923)	1,121,867	68,992	1,190,859
Comprehensive loss	**全面虧損**									
Loss for the period	期內虧損		–	–	–	–	(45,107)	(45,107)	(3,054)	(48,161)
Exchange differences on translation of foreign operations	因換算海外業務而產生的匯兑差額		–	–	–	(3,869)	–	(3,869)	(47)	(3,916)
Total comprehensive loss	**全面虧損總額**		–	–	–	(3,869)	(45,107)	(48,976)	(3,101)	(52,077)
Transactions with owners	**與擁有人的交易**									
Repurchase of ordinary shares	購回普通股		–	–	(5,699)	–	–	(5,699)	–	(5,699)
Share-based payments	以股份為基礎的付款	7, 28	–	17,254	–	–	–	17,254	–	17,254
Total transactions with owners	**與擁有人的交易總額**		–	17,254	(5,699)	–	–	11,555	–	11,555
As at June 30, 2026	**於2026年6月30日**		563,779	2,313,669	(6,342)	4,370	(1,791,030)	1,084,446	65,891	1,150,337
(Unaudited)	**(未經審計)**									
As at January 1, 2025	**於2025年1月1日**		563,779	2,295,189	–	1,919	(1,703,077)	1,157,810	76,763	1,234,573
Comprehensive loss	**全面虧損**									
Loss for the period	期內虧損		–	–	–	–	(22,802)	(22,802)	(6,507)	(29,309)
Exchange differences on translation of foreign operations	因換算海外業務而產生的匯兑差額		–	–	–	10,379	–	10,379	160	10,539
Total comprehensive loss	**全面虧損總額**		–	–	–	10,379	(22,802)	(12,423)	(6,347)	(18,770)
Transactions with owners	**與擁有人的交易**									
Share-based payments	以股份為基礎的付款	7, 28	–	613	–	–	–	613	–	613
Total transactions with owners	**與擁有人的交易總額**		–	613	–	–	–	613	–	613
As at June 30, 2025	**於2025年6月30日**		563,779	2,295,802	–	12,298	(1,725,879)	1,146,000	70,416	1,216,416

The above interim condensed consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

上述中期簡明合併權益變動表應與附註一併閱讀。

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
中期簡明合併現金流量表

For the six months ended June 30, 2026
截至2026年6月30日止六個月

			Six months ended June 30, 截至6月30日止六個月	
		Notes *附註*	**2026** **2026年** **RMB'000** **人民幣千元** **(Unaudited)** **（未經審計）**	2025 2025年 RMB'000 人民幣千元 (Unaudited) （未經審計）
Cash flows from operating activities	**經營活動所得現金流量**			
Cash used in operations	經營所用現金		**(64,580)**	(47,927)
Net cash used in operating activities	經營活動所用現金淨額		**(64,580)**	(47,927)
Cash flows from investing activities	**投資活動所得現金流量**			
Purchase of property, plant and equipment	購買物業、廠房及設備	14	**(2,483)**	(1,164)
Purchase of intangible assets	購買無形資產	16	**(321)**	(285)
Increase in investments in associates	於聯營公司投資增加	23	**(41,000)**	–
Proceeds from disposal of property, plant and equipment	出售物業、廠房及設備所得款項		**5**	5
Placement of short-term bank deposits	存入短期銀行存款		**(463,049)**	(1,357,156)
Redemption of short-term bank deposits	贖回短期銀行存款		**388,351**	1,199,585
Interest income	利息收入		**8,835**	37,318
Proceeds from disposal of short-term investments measured at fair value through profit or loss	出售按公允價值計量且其變動計入當期損益的短期投資所得款項	4(c)	**20,296**	121,915
Net cash (used in)/generated from investing activities	**投資活動（所用）╱所得現金淨額**		**(89,366)**	218

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
中期簡明合併現金流量表

For the six months ended June 30, 2026
截至2026年6月30日止六個月

		Notes 附註	Six months ended June 30, 截至6月30日止六個月 2026 2026年 RMB'000 人民幣千元 (Unaudited) （未經審計）	 2025 2025年 RMB'000 人民幣千元 (Unaudited) （未經審計）
Cash flows from financing activities	**融資活動所得現金流量**			
Proceeds from borrowings	借款所得款項		**57,489**	–
Repayments of borrowings	借款之還款情況		**(30,000)**	(10,000)
Interest paid	已付利息		**(741)**	(134)
Repurchase of ordinary shares	購回普通股		**(5,699)**	–
Principal elements of lease payments	租賃付款的本金部分		**(5,500)**	(5,982)
Interests elements of lease payments	租賃付款的利息部分		**(246)**	(449)
Net cash generated from/(used in) financing activities	融資活動所得╱（所用）現金淨額		**15,303**	(16,565)
Net decrease in cash and cash equivalents	**現金及現金等價物減少淨額**		**(138,643)**	(64,274)
Cash and cash equivalents at beginning of period	期初現金及現金等價物		**625,185**	319,297
Effect of foreign exchange rates changes	外匯匯率變動之影響		**(9,218)**	(2,010)
Cash and cash equivalents at end of period	**期末現金及現金等價物**		**477,324**	253,013

The above interim condensed consolidated statement of cash flows should be read in conjunction with the accompanying notes.

上述中期簡明合併現金流量表應與附註一併閱讀。

1 GENERAL INFORMATION

Zhejiang Taimei Medical Technology Co., Ltd. (浙江太美醫療科技股份有限公司) (the "**Company**") was established under its former name, Jiaxing Taimei Medical Technology Co., Ltd. (嘉興太美醫療科技有限公司), as a limited liability company in the People's Republic of China (the "**PRC**") on June 6, 2013. The Company completed its conversion into a joint stock limited company on September 11, 2020.

The Company and its subsidiaries (together, the "**Group**") are primarily engaged in providing digital solutions for life sciences R&D and commercialisation mainly in the PRC and certain overseas countries and regions.

The ultimate controlling shareholder of the Group is Mr. Zhao Lu (趙璐先生).

On October 8, 2024, the Company completed its IPO and was successfully listed on Main Board of the Stock Exchange of Hong Kong Limited.

The condensed consolidated interim financial information is presented in thousands of Renminbi ("**RMB'000**"), unless otherwise. The condensed consolidated interim financial information was approved for issue by the Board of Directors on August 26, 2026.

1 一般資料

浙江太美醫療科技股份有限公司(「**本公司**」)於2013年6月6日以其前稱嘉興太美醫療科技有限公司在中華人民共和國(「**中國**」)成立為有限責任公司。本公司於2020年9月11日完成股份改制。

本公司及其附屬公司(統稱「**本集團**」)主要於中國及若干海外國家及地區主要從事提供生命科學研發和營銷數字化解決方案。

本集團的最終控股股東為趙璐先生。

於2024年10月8日，本公司完成其首次公開發售並成功於香港聯合交易所有限公司主板上市。

除另有註明外，簡明合併中期財務資料乃以人民幣千元(「**人民幣千元**」)呈列。簡明合併中期財務資料已於2026年8月26日獲董事會批准刊發。

2 BASIS OF PREPARATION

This condensed consolidated interim financial information for the six months ended June 30, 2026 has been prepared in accordance with International Accounting Standards ("**IAS**") 34, "Interim Financial Reporting" issued by the International Accounting Standards Board ("**IASB**"). This report is to be read in conjunction with the consolidated financial statements of the Group for the year ended December 31, 2025, which have been prepared in accordance with IFRS Accounting Standards ("**IFRS**").

2 編製基準

截至2026年6月30日止六個月的本簡明合併中期財務資料乃根據國際會計準則理事會(「**國際會計準則理事會**」)頒佈的國際會計準則(「**國際會計準則**」)第34號「中期財務報告」編製。本報告應與本集團截至2025年12月31日止年度的合併財務報表一併閱讀，該等合併財務報表乃根據國際財務報告會計準則(「**國際財務報告準則**」)編製。

3 NEW STANDARDS AND INTERPRETATIONS

Except as described below, the accounting policies applied are consistent with those of the annual financial statements for the year ended December 31, 2025, as described in those annual financial statements.

(a) Amended standard adopted by the Group

The Group has applied the following amendment for the first time for its financial year commencing January 1, 2026:

3 新訂準則及詮釋

除下文所述者外，所採用的會計政策與截至2025年12月31日止年度的年度財務報表所載的會計政策一致。

(a) 本集團採納的經修訂準則

本集團已於2026年1月1日開始的財政年度首次應用下列修訂：

		Effective for accounting periods beginning on or after **於以下日期或之後開始的會計期間生效**
IFRS 7 and IFRS 9 (Amendment)	Amendments to the Classification and Measurement of Financial Instruments	January 1, 2026
國際財務報告準則第7號及國際財務報告準則第9號(修訂)	金融工具的分類及計量的修訂	2026年1月1日
IFRS 7 and IFRS 9 (Amendment)	Amendments to contracts Referencing Nature-dependent Electricity	January 1, 2026
國際財務報告準則第7號及國際財務報告準則第9號(修訂)	對涉及依賴自然能源生產電力的合約的修訂	2026年1月1日
Annual Improvements to IFRS Accounting Standards – Volume 11	Amendments to IFRS 1, IFRS 7, IFRS 9, IFRS 10 and IAS 7	January 1, 2026
國際財務報告準則會計準則年度改進－第11冊	國際財務報告準則第1號、國際財務報告準則第7號、國際財務報告準則第9號、國際財務報告準則第10號及國際會計準則第7號之修訂	2026年1月1日

The adoption of the amended standard does not have significant impact on the condensed consolidated interim financial information of the Group.

採納經修訂準則並未對本集團簡明合併中期財務資料產生重大影響。

3 NEW STANDARDS AND INTERPRETATIONS *(Continued)*

(b) Amendments to existing standards have not yet been adopted

The followings new standards and amendments to standards have not come into effect for the financial year beginning January 1, 2026 and have not been early adopted by the Group in preparing the condensed consolidated interim financial information. None of these is expected to have a significant effect on the condensed consolidated interim financial information of the Group.

3 新訂準則及詮釋*(續)*

(b) 尚未採納的現有準則修訂

以下為於2026年1月1日開始的財政年度尚未生效，且本集團於編製簡明合併中期財務資料時並無提早採納的新訂準則及準則修訂。預期該等準則及修訂概不會對本集團簡明合併中期財務資料構成重大影響。

		Effective for accounting periods beginning on or after **於以下日期或之後開始的會計期間生效**
HKFRS 19 (Amendments)	Subsidiaries without public accountability: disclosures	January 1, 2027
香港財務報告準則第19號（修訂）	非公共受託責任附屬公司：披露	2027年1月1日
HKFRS 18 (Amendments)	Presentation and disclosure in financial statements	January 1, 2027
香港財務報告準則第18號（修訂）	財務報表中的列報及披露	2027年1月1日
IAS 21 (Amendments)	Translation to a Hyperinflationary Presentation Currency	January 1, 2027
國際會計準則第21號（修訂）	換算為惡性通脹呈列貨幣	2027年1月1日
IAS 28 (Amendments)	Amendments to the Fair Value Option	January 1, 2027
國際會計準則第28號（修訂）	公允價值選擇權之修訂	2027年1月1日
IFRS 20	Regulatory Assets and Regulatory Liabilities	January 1, 2029
國際財務報告準則第20號	管制資產及管制負債	2029年1月1日
IFRS 10 and IAS 28 (Amendments)	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture	To be determined
國際財務報告準則第10號及國際會計準則第28號（修訂）	有關投資者與其聯營公司或合營企業之間的資產出售或投入	待定

3 NEW STANDARDS AND INTERPRETATIONS *(Continued)*

(b) Amendments to existing standards have not yet been adopted *(Continued)*

The Group is assessing the full impact of the new standards, new interpretations and amendments to standards and interpretations.

According to the assessment made by the directors of the Company, these new and amended standards are either not relevant to the Group or not significant to the financial performance and positions of the Group when they become effective, except for IFRS 18 which will mainly impact the presentation of the consolidated income statement.

IFRS 18 will replace IAS 1 Presentation of financial statements, introducing new requirements that will help to achieve comparability of the financial performance of similar entities and provide more relevant information and transparency to users. Even though IFRS 18 will not impact the recognition or measurement of items in the financial statements, its impacts on presentation and disclosure are expected to be pervasive, in particular those related to the statement of financial performance and providing management-defined performance measures within the financial statements.

Management is currently assessing the detailed implications of applying the new standard on the Group's consolidated financial statements. From the high-level preliminary assessment performed, although the adoption of IFRS 18 will have no impact on the group's loss, the Group expects that grouping items of income and expenses in the income statement into the new categories will impact how operating loss is calculated and reported, such as fair value gains/losses.

3 新訂準則及詮釋*(續)*

(b) 尚未採納的現有準則修訂*(續)*

本集團現正評估該等新訂準則、新詮釋以及準則及詮釋修訂的全面影響。

根據本公司董事作出的評估，該等新訂及經修訂準則與本集團無關或於生效時對本集團的財務表現及狀況並無重大影響，惟國際財務報告準則第18號除外，其將主要影響合併收益表的呈列。

國際財務報告準則第18號將取代國際會計準則第1號財務報表的列報，引入新規定以助實現類近實體的財務表現可比性及向使用者提供更多相關資料及透明度。儘管國際財務報告準則第18號將不會影響財務報表項目的確認或計量，但預計其將普遍影響列報及披露，尤其是與財務業績報表有關的影響，以及在財務報表範圍內提供管理層界定的績效計量。

管理層目前正評估應用新準則對本集團合併財務報表的具體影響。根據進行的高層次初步評估，儘管採納國際財務報告準則第18號將不會對本集團的虧損產生影響，但本集團預期將收益表中的收入及開支項目分組為新的類別將影響經營虧損的計算及列報(例如公允價值收益／虧損)方式。

3 NEW STANDARDS AND INTERPRETATIONS *(Continued)*

(b) Amendments to existing standards have not yet been adopted *(Continued)*

The Group does not expect there to be a significant change in the information that is currently disclosed in the notes because the requirement to disclose material information remains unchanged; however, the way in which the information is grouped might change as a result of the aggregation/disaggregation principles.

The Group will apply the new standard from its mandatory effective date of January 1, 2027. Retrospective application is required, and so the comparative information for the financial year ending December 31, 2026 will be restated in accordance with IFRS 18.

4 FAIR VALUE MEASUREMENT OF FINANCIAL INSTRUMENTS

This note provides an update on the judgements and estimates made by the Group in determining the fair values of the financial instruments since the last annual financial report.

(a) Fair value hierarchy

To provide an indication about the reliability of the inputs used in determining fair value, the Group has classified its financial instruments into the three levels prescribed under the accounting standards. An explanation of each level follows underneath the table.

3 新訂準則及詮釋*(續)*

(b) 尚未採納的現有準則修訂*(續)*

本集團預期，目前在附註中披露的資料將不會出現重大變動，原因為披露重大資料的要求維持不變；然而，由於其匯總／分解原則，披露資料的歸類方式可能會有所調整。

本集團將於強制生效日期(即2027年1月1日)採用該新準則。由於要求追溯應用，因此截至2026年12月31日止財政年度的可比資料將按照國際財務報告準則第18號進行重述。

4 金融工具的公允價值計量

本附註載列本集團自上一年度財務報告起於釐定金融工具公允價值時所作出的判斷及估計的最新資料。

(a) 公允價值層級

為說明用於釐定公允價值的輸入數據的可靠性，本集團已將其金融工具分為會計準則規定的三個級別。各級別於下表進行闡述。

4 FAIR VALUE MEASUREMENT OF FINANCIAL INSTRUMENTS *(Continued)*

4 金融工具的公允價值計量*(續)*

(a) Fair value hierarchy *(Continued)*

(a) 公允價值層級*(續)*

The following table presents the Group's financial assets and financial liabilities measured and recognised at fair value at June 30, 2026 and December 31, 2025 on a recurring basis:

下表呈列本集團於2026年6月30日及2025年12月31日按經常性基準以公允價值計量及確認的金融資產及金融負債：

		Level 1 第1級 RMB'000 人民幣千元	Level 2 第2級 RMB'000 人民幣千元	Level 3 第3級 RMB'000 人民幣千元	Total 總計 RMB'000 人民幣千元
(Unaudited)	**（未經審計）**				
At June 30, 2026	**於2026年6月30日**				
Assets:	資產：				
– Financial assets at FVPL	－按公允價值計量且其變動計入當期損益的金融資產	–	–	34,587	34,587
Liabilities:	負債：				
– Warrant liabilities	－認股權證負債	–	–	33,667	33,667

		Level 1 第1級 RMB'000 人民幣千元	Level 2 第2級 RMB'000 人民幣千元	Level 3 第3級 RMB'000 人民幣千元	Total 總計 RMB'000 人民幣千元
(Audited)	**（經審計）**				
At December 31, 2025	**於2025年12月31日**				
Assets:	資產：				
– Financial assets at FVPL	－按公允價值計量且其變動計入當期損益的金融資產	–	–	55,451	55,451
Liabilities:	負債：				
– Warrant liabilities	－認股權證負債	–	–	34,443	34,443

The Group's policy is to recognise transfers into and transfers out of fair value hierarchy levels as at the end of the reporting period.

本集團的政策乃於報告期末確認公允價值層級的轉入及轉出。

4 FAIR VALUE MEASUREMENT OF FINANCIAL INSTRUMENTS *(Continued)*

(a) Fair value hierarchy *(Continued)*

Level 1: The fair value of financial instruments traded in active markets (such as publicly traded derivatives, and trading securities) is based on quoted market prices at the end of the reporting period. The quoted market price used for financial assets held by the Group is the current bid price. These instruments are included in level 1.

Level 2: The fair value of financial instruments that are not traded in an active market (for example, over-the-counter derivatives) is determined using valuation techniques which maximise the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2.

Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3. This is the case for unlisted debt and equity investment.

(b) Valuation techniques used to determine fair values

Specific valuation techniques used to value financial instruments include:

- Quoted market prices or dealer quotes for similar instruments; and
- Other techniques, such as discounted cash flow analysis, are used to determine fair value for the remaining financial instruments.

The fair value of trade and notes receivables, other receivables, long-term receivables, short-term treasury investments, short-term bank deposits, restricted cash, cash and cash equivalents, trade and other payables approximated to their carrying amounts.

4 金融工具的公允價值計量*(續)*

(a) 公允價值層級*(續)*

第1級：於活躍市場買賣的金融工具(如公開買賣的衍生工具及交易證券)的公允價值基於各報告期末的市場報價。本集團持有的金融資產採用的市場報價為當前買方出價。該等工具列入第1級。

第2級：並非於活躍市場買賣的金融工具(如場外衍生工具)的公允價值採用估值技術釐定，該等估值技術盡量使用可觀察市場數據，並盡可能少倚賴特定實體的估計。倘計算工具公允價值所需全部重大輸入數據均為可觀察數據，則該工具列入第2級。

第3級：倘一項或多項重大輸入數據並非基於可觀察市場數據，則該工具列入第3級。此為非上市債務及股本投資的情況。

(b) 釐定公允價值使用的估值技術

金融工具估值使用的特定估值技術包括：

- 同類工具的市場報價或交易商報價；及
- 其他技術(如貼現現金流量分析)亦用於釐定餘下金融工具的公允價值。

貿易應收款項及應收票據、其他應收款項、長期應收款項、短期國債投資、短期銀行存款、受限制現金、現金及現金等價物、貿易及其他應付款項的公允價值與其賬面值相若。

4 FAIR VALUE MEASUREMENT OF FINANCIAL INSTRUMENTS *(Continued)*

4 金融工具的公允價值計量*（續）*

(c) Fair value measurements using significant unobservable inputs (level 3)

(c) 使用重大不可觀察輸入數據的公允價值計量（第3級）

The following table presents the changes in level 3 instruments for the six months ended June 30, 2026:

下表呈列截至2026年6月30日止六個月的第3級工具變動：

		Short-term investment measured at fair value through profit and loss 按公允價值計量且其變動計入當期損益的短期投資 RMB'000 人民幣千元	Warrant liabilities 認股權證負債 (Note 26) （附註26） RMB'000 人民幣千元	Total 總計 RMB'000 人民幣千元
(Unaudited)	**（未經審計）**			
At January 1, 2026	**於2026年1月1日**	**55,451**	**(34,443)**	**21,008**
Disposals	出售	**(20,296)**	**–**	**(20,296)**
Fair value changes	公允價值變動	**507**	**776**	**1,283**
Foreign exchange losses	外匯虧損	**(1,075)**	**–**	**(1,075)**
At June 30, 2026	**於2026年6月30日**	**34,587**	**(33,667)**	**920**
(Unaudited)	**（未經審計）**			
At January 1, 2025	**於2025年1月1日**	120,792	(35,347)	85,445
Disposals	出售	(121,915)	–	(121,915)
Fair value changes	公允價值變動	1,123	29	1,152
At June 30, 2025	於2025年6月30日	–	(35,318)	(35,318)

4 FAIR VALUE MEASUREMENT OF FINANCIAL INSTRUMENTS *(Continued)*

4 金融工具的公允價值計量*(續)*

(c) Fair value measurements using significant unobservable inputs (level 3) *(Continued)*

(c) 使用重大不可觀察輸入數據的公允價值計量(第3級)*(續)*

(i) Valuation inputs and relationships to fair value

(i) 估值輸入數據及與公允價值的關係

The following table summarises the quantitative information about the significant unobservable inputs used in level 3 fair value measurements:

下表概述第3級公允價值計量中重大不可觀察輸入數據的量化資料：

At June 30, 2026 *於2026年6月30日*

Description 說明	Unobservable inputs 不可觀察輸入數據	Range of inputs 輸入數據範圍	Relationship of unobservable inputs to fair value 不可觀察輸入數據與公允價值的關係
Wealth management products 理財產品	Expected rate of return 預期回報率	2.30%–2.60%	The higher the expected rate of return, the higher the fair value 預期回報率越高，公允價值越高
Warrant liabilities 認股權證負債	Discount rate 折扣率	1.06%–1.18%	The higher the discount rate, the lower the fair value 折扣率越高，公允價值越低

At December 31, 2025 *於2025年12月31日*

Description 說明	Unobservable inputs 不可觀察輸入數據	Range of inputs 輸入數據範圍	Relationship of unobservable inputs to fair value 不可觀察輸入數據與公允價值的關係
Wealth management products 理財產品	Expected rate of return 預期回報率	2.30%–2.60%	The higher the expected rate of return, the higher the fair value 預期回報率越高，公允價值越高
Warrant liabilities 認股權證負債	Discount rate 折扣率	1.34%–1.36%	The higher the discount rate, the lower the fair value 折扣率越高，公允價值越低

4 FAIR VALUE MEASUREMENT OF FINANCIAL INSTRUMENTS *(Continued)*

(c) Fair value measurements using significant unobservable inputs (level 3) *(Continued)*

(i) Valuation inputs and relationships to fair value *(Continued)*

If the discount rate of warrant liabilities which measured at fair value through profit or loss held by the Group had been 1% lower/higher, the loss before income tax for the six months ended June 30, 2026 would have been approximately RMB328,000 higher/lower (for six months ended June 30, 2025: RMB344,000).

4 金融工具的公允價值計量*(續)*

(c) 使用重大不可觀察輸入數據的公允價值計量(第3級)*(續)*

(i) 估值輸入數據及與公允價值的關係*(續)*

倘本集團持有的按公允價值計量且其變動計入當期損益的認股權證負債的折扣率降低／升高1%，截至2026年6月30日止六個月的除所得税前虧損將分別增加／減少約人民幣328,000元(截至2025年6月30日止六個月：人民幣344,000元)。

5 SEGMENT INFORMATION

The Group's business activities are mainly in providing cloud-based software products including software-as-a-service and AI products ("**SaaS and AI products**") and customised products, digital services and others, for which discrete financial information is available, are regularly reviewed and evaluated by the executive directors of the Company, who are the chief operating decision makers. As a result of this evaluation, the executive directors of the Company consider that the Group's operation is operated and managed as a single segment and no segment information is presented, accordingly.

For the six months ended June 30, 2026, there was no revenue derived from transactions with a single external customer which amounted to 10% or more of the Group's revenue.

5 分部資料

本集團的業務活動主要包括提供軟件即服務及AI產品(「**SaaS及AI產品**」)及定製產品、數字化服務等雲端軟件產品，其可得獨立財務資料由本公司執行董事(為主要經營決策者)定期審閱及評估。基於該項評估，本公司執行董事認為，本集團的營運乃作為單一分部營運及管理；因而並無呈列分部資料。

截至2026年6月30日止六個月，概無與單一外部客戶進行交易產生的收入佔本集團收入的10%或以上。

5 SEGMENT INFORMATION *(Continued)*

(a) Geographical information

The Group mainly operates its businesses in mainland China. The following table shows the Group's total consolidated revenue by location of the customers during the six months ended June 30, 2026:

5 分部資料*（續）*

(a) 地區資料

本集團主要在中國內地經營業務。下表載列截至2026年6月30日止六個月本集團按客戶位置劃分的綜合收入總額：

		Six months ended June 30, 截至6月30日止六個月	
		2026 **2026年** **RMB'000** **人民幣千元** **(Unaudited)** **（未經審計）**	2025 2025年 RMB'000 人民幣千元 (Unaudited) （未經審計）
Mainland China	中國內地	**258,004**	238,577
Korea	韓國	**1,001**	1,058
Singapore	新加坡	**1,975**	1,872
Europe	歐洲	**912**	1,360
Others	其他	**1,747**	1,354
		263,639	244,221

5 SEGMENT INFORMATION *(Continued)*

5 分部資料*(續)*

(b) Non-current assets

(b) 非流動資產

The total of the non-current assets including property, plant and equipment, right-of-use assets and intangible assets as at June 30, 2026, broken down by the location of the assets, is as follows:

於2026年6月30日，按資產位置劃分的非流動資產(包括物業、廠房及設備、使用權資產及無形資產)總值如下：

		As at June 30, 2026 於2026年6月30日 RMB'000 人民幣千元 (Unaudited) (未經審計)	As at December 31, 2025 於2025年12月31日 RMB'000 人民幣千元 (Audited) (經審計)
Mainland China	中國內地	**72,556**	76,673
The United States	美國	**38**	58
Singapore	新加坡	**–**	260
		72,594	76,991

6 REVENUE

Revenue for the six months ended June 30, 2026 is as follows:

6 收入

截至2026年6月30日止六個月收入如下：

Six months ended June 30, 2026	**截至2026年6月30日止六個月**	**AI Clinical Development Platforms AI臨床開發平台 RMB'000 人民幣千元 (Unaudited) （未經審計）**	**AI-enabled CRO AI賦能的臨床開發服務 RMB'000 人民幣千元 (Unaudited) （未經審計）**	**Total 總計 RMB'000 人民幣千元 (Unaudited) （未經審計）**
SaaS and AI products	SaaS及AI產品	**92,316**	**67**	**92,383**
Customised products	定製產品	**15,968**	**–**	**15,968**
Digital services	數字化服務	**50,182**	**104,790**	**154,972**
Other services	其他服務	**316**	**–**	**316**
		158,782	**104,857**	**263,639**

Six months ended June 30, 2025	截至2025年6月30日止六個月	AI Clinical Development Platforms AI臨床開發平台 RMB'000 人民幣千元 (Unaudited) （未經審計）	AI-enabled CRO AI賦能的臨床開發服務 RMB'000 人民幣千元 (Unaudited) （未經審計）	Total 總計 RMB'000 人民幣千元 (Unaudited) （未經審計）
SaaS and AI products	SaaS及AI產品	82,139	286	82,425
Customised products	定製產品	12,171	–	12,171
Digital services	數字化服務	35,324	114,047	149,371
Other services	其他服務	254	–	254
		129,888	114,333	244,221

6 REVENUE *(Continued)*

6 收入（續）

Disaggregation of revenue from contracts with customers by the timing of revenue recognition is as follows:

按收入確認時間劃分的客戶合約收入分拆如下：

		Six months ended June 30, 截至6月30日止六個月	
		2026 **2026年** **RMB'000** **人民幣千元** **(Unaudited)** **（未經審計）**	2025 2025年 RMB'000 人民幣千元 (Unaudited) （未經審計）
Revenue	收益		
– recognised over time	－於某一時段確認	**252,832**	238,162
– recognised point in time	－於某一時點確認	**10,807**	6,059
		263,639	244,221

(a) Contract assets

(a) 合約資產

Contract assets are reclassified to trade receivables when the Group's right to the considerations becomes unconditional. The Group has recognised the following contract assets with customers:

當本集團收取對價的權利成為無條件時，合約資產重新分類至貿易應收款項。本集團已與客戶確認以下合約資產：

		As at June 30, 2026 **於2026年6月30日** **RMB'000** **人民幣千元** **(Unaudited)** **（未經審計）**	As at December 31, 2025 於2025年12月31日 RMB'000 人民幣千元 (Audited) （經審計）
Current assets	流動資產	**21,930**	21,799
Loss allowance	虧損撥備	**(1,708)**	(1,663)
		20,222	20,136

6 REVENUE *(Continued)*

(b) Contract liabilities

The Group has recognised the following liabilities related to contracts with customers:

6 收入*（續）*

(b) 合約負債

本集團已確認下列與客戶合約有關的負債：

		As at June 30, 2026 於2026年6月30日 RMB'000 人民幣千元 (Unaudited) （未經審計）	As at December 31, 2025 於2025年12月31日 RMB'000 人民幣千元 (Audited) （經審計）
Current liabilities	流動負債	60,830	68,941

7 EXPENSES BY NATURE

The expenses charged to cost of sales, selling expenses, administrative expenses and research and development expenses are analysed below:

7 按性質劃分的開支

銷售成本、銷售開支、行政開支及研發開支之開支分析如下：

		Six months ended June 30, 截至6月30日止六個月	
		2026 **2026年** **RMB'000** **人民幣千元** **(Unaudited)** **（未經審計）**	2025 2025年 RMB'000 人民幣千元 (Unaudited) （未經審計）
Employee benefit expenses (excluding share-based payments)	僱員福利開支（不包括以股份為基礎的付款）	**163,872**	152,050
Clinical research related costs	臨床研究相關成本	**56,918**	70,322
Costs of IT infrastructure and data service	IT基礎設施及數據服務成本	**17,900**	14,423
Share-based payments *(Note 28(c))*	以股份為基礎的付款 *（附註28(c)）*	**17,254**	613
Office, business development and travelling expenses	辦公、業務發展及差旅開支	**15,373**	11,708
Consulting and professional service fees	諮詢及專業服務費	**4,640**	6,827
Depreciation of right-of-use assets *(Note 15(c))*	使用權資產折舊 *（附註15(c)）*	**4,610**	5,223
Depreciation of property, plant and equipment *(Note 14)*	物業、廠房及設備折舊 *（附註14）*	**2,657**	3,068
Amortisation of intangible assets *(Note 16)*	無形資產攤銷 *（附註16）*	**2,191**	2,115
Short-term rental expenses	短期租賃開支	**856**	644
Other expenses	其他開支	**13,696**	9,997
		299,967	276,990

8 OTHER INCOME

8 其他收入

		Six months ended June 30, 截至6月30日止六個月	
		2026	2025
		2026年	2025年
		RMB'000	RMB'000
		人民幣千元	人民幣千元
		(Unaudited)	(Unaudited)
		（未經審計）	（未經審計）
Government grants *(a)*	政府補助*(a)*	**5,945**	1,734
Others	其他	**305**	711
		6,250	2,445

(a) Governments grants received during the period primarily comprised the financial subsidies received from various local government authorities in mainland China. There are no unfulfilled conditions or contingencies relating to these income.

(a) 期內收取的政府補助主要包括自中國內地各地方政府機關收取的財政補貼。概無有關該等收入的未達成條件或或有事項。

9 OTHER LOSSES – NET

9 其他虧損淨額

		Six months ended June 30, 截至6月30日止六個月	
		2026	2025
		2026年	2025年
		RMB'000	RMB'000
		人民幣千元	人民幣千元
		(Unaudited)	(Unaudited)
		（未經審計）	（未經審計）
Fair value gains on financial assets at fair value through profit or loss *(Note 4(c))*	按公允價值計量且其變動計入當期損益的金融資產的公允價值收益*（附註4(c)）*	**507**	1,123
Net foreign exchange losses	外匯虧損淨額	**(28,891)**	(16,075)
Fair value gains of warrant liabilities *(Note 4(c))*	認股權證負債的公允價值收益*（附註4(c)）*	**776**	29
Others	其他	**367**	1,991
		(27,241)	(12,932)

10 FINANCE INCOME – NET

10 財務收入淨額

		Six months ended June 30, 截至6月30日止六個月	
		2026	2025
		2026年	2025年
		RMB'000	RMB'000
		人民幣千元	人民幣千元
		(Unaudited)	(Unaudited)
		(未經審計)	(未經審計)
Finance income	***財務收入***		
Interest income	利息收入	**15,001**	19,775
Accretion income for long-term receivables	長期應收款項的累計收入	**194**	205
		15,195	19,980
Finance costs	***融資成本***		
Interest expenses on bank borrowings	銀行借款的利息開支	**(741)**	(130)
Interest charges on lease liabilities *(Note 15)*	租賃負債的利息支出*(附註15)*	**(246)**	(449)
		(987)	(579)
Finance income – net	**財務收入淨額**	**14,208**	19,401

11 INCOME TAX EXPENSE

(i) Corporate income tax in mainland China ("CIT")

The income tax provision of the Group in respect of its operations in the mainland China was subject to statutory tax rate of 25% on the assessable profits, based on the existing legislation, interpretations and practices in respect thereof.

11 所得稅開支

(i) 中國內地企業所得稅(「企業所得稅」)

根據相關現行法律、詮釋及慣例，本集團有關其中國內地業務的所得稅撥備須就應課稅溢利按25%的法定稅率繳稅。

11 INCOME TAX EXPENSE *(Continued)*

(i) Corporate income tax in mainland China ("CIT") *(Continued)*

The Company, Taimei Intelligence Pharmaceutical R&D Co., Ltd., Hangzhou Taimei Xingcheng Pharmaceutical Technology Co., Ltd., Shanghai Taimei Xingyun Digital Technology Co., Ltd. and Shanghai Taimei Digital Technology Co., Ltd. were qualified as "High and New Technology Enterprises" ("**HNTEs**") under the relevant PRC laws and regulations. Accordingly, these entities were entitled to a preferential income tax rate of 15% on the assessable profits during the six months ended June 30, 2026.

During the six months ended June 30, 2026, certain subsidiaries in the mainland China that qualified as "small low-profit enterprises" under the Enterprise Income Tax Law of the PRC enjoyed a preferential income tax rate of 20% (for the six months ended June 30, 2025: 20%).

(ii) Singapore income tax

Singapore income tax rate is 17%. No Singapore profits tax was provided for as there was no estimated assessable profit that was subject to Singapore profits tax during the six months ended June 30, 2026 (for the six months ended June 30, 2025: 17%).

(iii) The United States income tax

The United States income tax rate divided into federal tax and state tax. The Federal CIT is 21% and the State CITs range from 1% to 12%. No United States profits tax was provided for as there was no estimated assessable profit that was subject to the United States profits tax during the six months ended June 30, 2026 (for the six months ended June 30, 2025: 21% and 1%-12% respectively).

11 所得稅開支*(續)*

(i) 中國內地企業所得稅(「企業所得稅」)*(續)*

根據中國相關法律法規，本公司、太美智研醫藥研發(上海)有限公司、杭州太美星程醫藥科技有限公司、上海太美星雲數字科技有限公司及上海太美數字科技有限公司均符合「高新技術企業」資格。因此，截至2026年6月30日止六個月，該等實體有權就應課稅溢利享有15%的優惠所得稅稅率。

截至2026年6月30日止六個月，根據中華人民共和國企業所得稅法符合「小型微利企業」資格的若干中國內地附屬公司享有20%(截至2025年6月30日止六個月：20%)的優惠所得稅稅率。

(ii) 新加坡所得稅

新加坡所得稅稅率為17%。由於截至2026年6月30日止六個月並無須繳納新加坡利得稅的估計應課稅溢利，故並無就新加坡利得稅計提撥備(截至2025年6月30日止六個月：17%)。

(iii) 美國所得稅

美國所得稅稅率分為聯邦稅及州稅。聯邦企業所得稅稅率為21%，而州企業所得稅稅率則介乎1%至12%。由於截至2026年6月30日止六個月並無須繳納美國利得稅的估計應課稅溢利，故並無就美國利得稅計提撥備(截至2025年6月30日止六個月：分別為21%及1%至12%)。

12 LOSS PER SHARE

Basic

The basic loss per share is calculated by dividing the loss attributable to owners of the Company by the weighted average number of shares outstanding during the six months ended June 30, 2026.

12 每股虧損

基本

每股基本虧損按本公司擁有人應佔虧損除以截至2026年6月30日止六個月期間發行在外股份的加權平均數計算。

		Six months ended June 30, 截至6月30日止六個月	
		2026 2026年 (Unaudited) （未經審計）	2025 2025年 (Unaudited) （未經審計）
Loss attributable to owners of the Company (RMB’000)	本公司擁有人應佔虧損（人民幣千元）	**(45,107)**	(22,802)
Weighted average number of ordinary shares outstanding (thousand shares)	發行在外普通股的加權平均數（千股）	**563,569**	563,779
Basic loss per share (expressed in RMB per share)	每股基本虧損（以每股人民幣元表示）	**(0.08)**	(0.04)

Diluted

Diluted loss per share is calculated by adjusting the weighted average number of ordinary shares outstanding to assume conversion of all dilutive potential ordinary shares. As the Group incurred losses during the six months ended June 30, 2026, the potential ordinary shares, i.e. restricted shares issued under the Company’s and the subsidiary’s share incentive plan, were not included in the calculation of diluted loss per share as their inclusion would be anti-dilutive. Accordingly, diluted loss per share for the six months ended June 30, 2026 is the same as basic loss per share (for the six months ended June 30, 2025: same as basic loss per share).

攤薄

每股攤薄虧損乃透過調整發行在外普通股加權平均數以假設轉換所有潛在攤薄普通股計算。由於本集團於截至2026年6月30日止六個月產生虧損，計算每股攤薄虧損時並無計入潛在普通股（即根據本公司及附屬公司的股份激勵計劃發行的受限制股份），原因是計入該等股份會有反攤薄作用。因此，截至2026年6月30日止六個月的每股攤薄虧損與每股基本虧損相同（截至2025年6月30日止六個月：與每股基本虧損相同）。

13 DIVIDENDS

No dividend had been declared or paid by the Company during the six months ended June 30, 2026 (for the six months ended June 30, 2025: nil).

13 股息

截至2026年6月30日止六個月，本公司並無宣派或派付任何股息（截至2025年6月30日止六個月：無）。

14 PROPERTY, PLANT AND EQUIPMENT 14 物業、廠房及設備

		Server and electronic equipment 服務器及電子設備	Furniture and office equipment 傢俬及辦公設備	Transportation equipment and vehicles 運輸設備及汽車	Leasehold improvements 租賃物業裝修	Total 總計
(Audited)	**(經審計)**					
At December 31, 2025	**於2025年12月31日**					
Cost	成本	16,880	5,088	2,318	51,703	75,989
Accumulated depreciation	累計折舊	(12,769)	(3,796)	(1,771)	(48,306)	(66,642)
Net book amount	**賬面淨值**	4,111	1,292	547	3,397	9,347
(Unaudited)	**(未經審計)**					
Six months ended June 30, 2026	**截至2026年6月30日止六個月**					
Opening net book amount	期初賬面淨值	4,111	1,292	547	3,397	9,347
Additions	添置	740	1,071	313	359	2,483
Disposals	出售	(5)	–	–	–	(5)
Depreciation charge *(Note 7)*	折舊費用*(附註7)*	(885)	(261)	(111)	(1,400)	(2,657)
Currency translation differences	貨幣換算差額	–	–	(1)	(1)	(2)
Closing net book amount	**期末賬面淨值**	3,961	2,102	748	2,355	9,166
(Unaudited)	**(未經審計)**					
At June 30, 2026	**於2026年6月30日**					
Cost	成本	17,453	6,159	2,619	52,375	78,606
Accumulated depreciation	累計折舊	(13,492)	(4,057)	(1,871)	(50,020)	(69,440)
Net book amount	**賬面淨值**	3,961	2,102	748	2,355	9,166

14 PROPERTY, PLANT AND EQUIPMENT *(Continued)*

During the six months ended June 30, 2026, depreciation charges were expensed off in the following categories in the interim condensed consolidated income statement:

14 物業、廠房及設備*（續）*

截至2026年6月30日止六個月，折舊費用於中期簡明合併收益表中按以下類別支銷：

		Six months ended June 30, 截至6月30日止六個月	
		2026 **2026年** **RMB'000** **人民幣千元** **(Unaudited)** **（未經審計）**	2025 2025年 RMB'000 人民幣千元 (Unaudited) （未經審計）
Cost of sales	銷售成本	**398**	295
Selling expenses	銷售開支	**453**	462
Administrative expenses	行政開支	**1,720**	2,126
Research and development expenses	研發開支	**86**	185
		2,657	3,068

15 RIGHT-OF-USE ASSETS AND LEASE LIABILITIES

15 使用權資產及租賃負債

Right-of-use assets is leased buildings.

使用權資產為租賃樓宇。

(a) Amounts recognised in the interim condensed consolidated balance sheet

(a) 於中期簡明合併資產負債表中確認的金額

The interim condensed consolidated balance sheet shows the following amounts relating to leases:

中期簡明合併資產負債表載列與租賃有關的以下金額：

		As at June 30, 2026 於2026年6月30日 RMB'000 人民幣千元 (Unaudited) （未經審計）	As at December 31, 2025 於2025年12月31日 RMB'000 人民幣千元 (Audited) （經審計）
Right-of-use assets	**使用權資產**		
Leased buildings	租賃樓宇	10,636	12,982
Lease liabilities	**租賃負債**		
Current	流動	8,746	10,062
Non-current	非流動	1,152	3,070
		9,898	13,132

15 RIGHT-OF-USE ASSETS AND LEASE LIABILITIES *(Continued)*

15 使用權資產及租賃負債*(續)*

(b) Amounts recognised in the interim condensed consolidated income statement

The interim condensed consolidated income statement shows the following amounts relating to leases:

(b) 於中期簡明合併收益表中確認的金額

中期簡明合併收益表載列與租賃有關的以下金額：

		Six months ended June 30, 截至6月30日止六個月	
		2026 **2026年** **RMB'000** **人民幣千元** **(Unaudited)** **(未經審計)**	2025 2025年 RMB'000 人民幣千元 (Unaudited) (未經審計)
Depreciation charge of right-of-use assets	**使用權資產折舊費用**		
Leased buildings	租賃樓宇	**4,610**	5,223
Interest expense (included in finance income – net)	利息開支(計入財務收入淨額)	**246**	449

The total cash outflow for leases for the six months ended June 30, 2026 was RMB6,602,000 (for the six months ended June 30, 2025: RMB7,075,000).

截至2026年6月30日止六個月的租賃現金流出總額為人民幣6,602,000元(截至2025年6月30日止六個月：人民幣7,075,000元)。

15 RIGHT-OF-USE ASSETS AND LEASE LIABILITIES *(Continued)*

15 使用權資產及租賃負債*(續)*

(c) The movement in right-of-use assets in the interim condensed consolidated balance sheet are as follows:

(c) 中期簡明合併資產負債表中使用權資產變動如下：

		Total 總計 RMB'000 人民幣千元
(Audited)	**（經審計）**	
At December 31, 2025	**於2025年12月31日**	
Cost	成本	28,033
Accumulated depreciation	累計折舊	(15,051)
Net book amount	**賬面淨值**	12,982
(Unaudited)	**（未經審計）**	
Six months ended June 30, 2026	**截至2026年6月30日止六個月**	
Opening net book amount	期初賬面淨值	**12,982**
Additions	添置	**2,266**
Depreciation charge *(Note 7)*	折舊費用*(附註7)*	**(4,610)**
Currency translation differences	貨幣換算差額	**(2)**
Closing net book amount	**期末賬面淨值**	**10,636**
(Unaudited)	**（未經審計）**	
At June 30, 2026	**於2026年6月30日**	
Cost	成本	**27,649**
Accumulated depreciation	累計折舊	**(17,013)**
Net book amount	**賬面淨值**	**10,636**

15 RIGHT-OF-USE ASSETS AND LEASE LIABILITIES *(Continued)*

15 使用權資產及租賃負債*(續)*

(c) The movement in right-of-use assets in the interim condensed consolidated balance sheet are as follows: *(Continued)*

(c) 中期簡明合併資產負債表中使用權資產變動如下：*(續)*

During the six months ended June 30, 2026, depreciation charges were expensed off in the following categories in the interim condensed consolidated income statement:

截至2026年6月30日止六個月，折舊費用於中期簡明合併收益表中按以下類別支銷：

		Six months ended June 30, 截至6月30日止六個月	
		2026	2025
		2026年	2025年
		RMB'000	RMB'000
		人民幣千元	人民幣千元
		(Unaudited)	(Unaudited)
		（未經審計）	（未經審計）
Cost of sales	銷售成本	**2,157**	1,801
Selling expenses	銷售開支	**539**	627
Administrative expenses	行政開支	**1,026**	1,834
Research and development expenses	研發開支	**888**	961
		4,610	5,223

16 INTANGIBLE ASSETS 16 無形資產

		Goodwill (a) 商譽(a) RMB'000 人民幣千元	Software 軟件 RMB'000 人民幣千元	Patent 專利 RMB'000 人民幣千元	Total 總計 RMB'000 人民幣千元
(Audited)	**（經審計）**				
At December 31, 2025	**於2025年12月31日**				
Cost	成本	161,126	13,674	29,900	204,700
Accumulated amortisation	累計攤銷	–	(5,586)	(19,130)	(24,716)
Accumulated impairment	累計減值	(124,118)	–	(1,204)	(125,322)
Net book amount	**賬面淨值**	37,008	8,088	9,566	54,662
(Unaudited)	**（未經審計）**				
Six months ended June 30, 2026	**截至2026年6月30日止六個月**				
Opening net book amount	期初賬面淨值	**37,008**	**8,088**	**9,566**	**54,662**
Additions	添置	**–**	**321**	**–**	**321**
Amortisation charge *(Note 7)*	攤銷費用*（附註7）*	**–**	**(791)**	**(1,400)**	**(2,191)**
Closing net book amount	**期末賬面淨值**	**37,008**	**7,618**	**8,166**	**52,792**
(Unaudited)	**（未經審計）**				
At June 30, 2026	**於2026年6月30日**				
Cost	成本	**161,126**	**13,912**	**29,900**	**204,938**
Accumulated amortisation and impairment	累計攤銷及減值	**(124,118)**	**(6,294)**	**(21,734)**	**(152,146)**
Net book amount	**賬面淨值**	**37,008**	**7,618**	**8,166**	**52,792**

16 INTANGIBLE ASSETS *(Continued)*

During the six months ended June 30, 2026, amortization charges were expensed off in the following categories in the interim condensed consolidated income statement:

16 無形資產*（續）*

截至2026年6月30日止六個月，攤銷費用於中期簡明合併收益表中按以下類別支銷：

		Six months ended June 30, 截至6月30日止六個月	
		2026 **2026年** **RMB'000** **人民幣千元** **(Unaudited)** **（未經審計）**	2025 2025年 RMB'000 人民幣千元 (Unaudited) （未經審計）
Cost of sales	銷售成本	**149**	87
Selling expenses	銷售開支	**22**	22
Administrative expenses	行政開支	**1,836**	1,819
Research and development expenses	研發開支	**184**	187
		2,191	2,115

16 INTANGIBLE ASSETS *(Continued)*

(a) Goodwill

The goodwill balance arose from the acquisitions of Taimei Xinghuan on June 28, 2019 and Beijing Nuoming Technology Co., Ltd ("**Beijing Nuoming**") on November 29, 2019, amounting to RMB139,646,000 and RMB21,480,000, respectively. Taimei Xinghuan is primarily engaged in provision of pharmaceutical marketing solutions. Beijing Nuoming is mainly engaged in provision of institution digitalisation solutions. The following is a summary of goodwill allocation for CGUs:

16 無形資產*(續)*

(a) 商譽

商譽餘額產生於2019年6月28日收購太美星環及2019年11月29日收購北京諾銘科技有限公司(「**北京諾銘**」)，分別為人民幣139,646,000元及人民幣21,480,000元。太美星環主要從事提供醫藥營銷解決方案。北京諾銘主要從事提供機構數字化解決方案。下表載列現金產生單位的商譽分配概要：

		As at June 30, 2026 於2026年6月30日 RMB'000 人民幣千元 (Unaudited) (未經審計)	As at December 31, 2025 於2025年12月31日 RMB'000 人民幣千元 (Audited) (經審計)
Cost	**成本**		
Taimei Xinghuan	太美星環	139,646	139,646
Beijing Nuoming	北京諾銘	21,480	21,480
		161,126	161,126
Accumulated impairment	**累計減值**		
Taimei Xinghuan	太美星環	(102,638)	(102,638)
Beijing Nuoming	北京諾銘	(21,480)	(21,480)
		(124,118)	(124,118)
Closing net book amount	**期末賬面淨值**	37,008	37,008

17 DEFERRED INCOME TAX

17 遞延所得稅

The analysis of deferred income tax assets and deferred income tax liabilities is as follows:

遞延所得稅資產及遞延所得稅負債分析如下：

		As at June 30, 2026 於2026年6月30日 RMB'000 人民幣千元 (Unaudited) （未經審計）	As at December 31, 2025 於2025年12月31日 RMB'000 人民幣千元 (Audited) （經審計）
Deferred income tax assets:	遞延所得稅資產：		
– to be recovered within 12 months	一於12個月內收回	2,762	3,134
– to be recovered after more than 12 months	一於超過12個月之後收回	175	420
Offset by deferred income tax liabilities	被遞延所得稅負債抵銷	(2,937)	(3,554)
Net deferred income tax assets	遞延所得稅資產淨值	–	–
Deferred income tax liabilities:	遞延所得稅負債：		
– to be recovered within 12 months	一於12個月內收回	(836)	(1,460)
– to be recovered after more than 12 months	一於超過12個月之後收回	(2,101)	(2,094)
Offset by deferred income tax assets	被遞延所得稅資產抵銷	2,937	3,554
Net deferred income tax liabilities	遞延所得稅負債淨額	–	–

17 DEFERRED INCOME TAX *(Continued)*

17 遞延所得稅*（續）*

The gross movements on the deferred income tax account is as follows:

遞延所得稅賬目的總變動如下：

Deferred income tax assets	遞延所得稅資產	Tax losses 稅項虧損 RMB'000 人民幣千元	Credit loss allowance 信貸虧損撥備 RMB'000 人民幣千元	Lease liabilities 租賃負債 RMB'000 人民幣千元	Total 總計 RMB'000 人民幣千元
(Unaudited)	**（未經審計）**				
At January 1, 2026	**於2026年1月1日**	**–**	**1,623**	**1,931**	**3,554**
Charged to the interim condensed consolidated income statement	扣除自中期簡明合併收益表	**2**	**(173)**	**(446)**	**(617)**
At June 30, 2026	**於2026年6月30日**	**2**	**1,450**	**1,485**	**2,937**
(Unaudited)	**（未經審計）**				
At January 1, 2025	**於2025年1月1日**	149	1,860	3,482	5,491
Credit to the interim condensed consolidated income statement	計入中期簡明合併收益表	(149)	(181)	(819)	(1,149)
At June 30, 2025	**於2025年6月30日**	–	1,679	2,663	4,342

17 DEFERRED INCOME TAX *(Continued)* 17 遞延所得稅*(續)*

Deferred income tax liabilities	遞延所得稅負債	Fair value adjustment on assets upon acquisition 收購時資產的公允價值調整 RMB'000 人民幣千元	Right-of-use assets 使用權資產 RMB'000 人民幣千元	Fair value changes on financial assets carried at FVPL 按公允價值計量且其變動計入當期損益的金融資產的公允價值變動 RMB'000 人民幣千元	Total 總計 RMB'000 人民幣千元
(Unaudited)	**（未經審計）**				
At January 1, 2026	**於2026年1月1日**	**(1,435)**	**(1,951)**	**(168)**	**(3,554)**
Credit to the interim condensed consolidated income statement	計入中期簡明合併收益表	**210**	**355**	**52**	**617**
At June 30, 2026	**於2026年6月30日**	**(1,225)**	**(1,596)**	**(116)**	**(2,937)**
(Unaudited)	**（未經審計）**				
At January 1, 2025	**於2025年1月1日**	(1,855)	(3,517)	(119)	(5,491)
Credit/(charged) to the interim condensed consolidated income statement	計入╱(扣除自)中期簡明合併收益表	210	820	119	1,149
At June 30, 2025	**於2025年6月30日**	(1,645)	(2,697)	–	(4,342)

18 CONTRACT FULFILMENT COST

18 合約履約成本

		As at June 30, 2026 於2026年6月30日 RMB'000 人民幣千元 (Unaudited) （未經審計）	As at December 31, 2025 於2025年12月31日 RMB'000 人民幣千元 (Audited) （經審計）
Contract fulfilment cost	合約履約成本	6,532	4,339
Less: allowance for impairment of inventories	減：存貨減值撥備	–	–
		6,532	4,339

Contract fulfilment cost are recognised from the costs incurred to fulfill contracts of customised software, which will be recognised to cost of sales mainly within 2–6 months when the Group's related performance obligations are satisfied and hence the related revenue is recognised.

合約履約成本自履行定製軟件的合約所產生的成本中確認，其將主要於本集團相關履約責任獲履行後2至6個月內確認為銷售成本，並因此確認相關收入。

19 TRADE AND NOTES RECEIVABLES

19 貿易應收款項及應收票據

		As at June 30, 2026 於2026年6月30日 RMB'000 人民幣千元 (Unaudited) （未經審計）	As at December 31, 2025 於2025年12月31日 RMB'000 人民幣千元 (Audited) （經審計）
Notes receivables *(a)*	應收票據*(a)*	**1,021**	1,439
Provision for impairment	減值撥備	**–**	–
		1,021	1,439
Trade receivables *(b)*	貿易應收款項*(b)*	**229,105**	201,238
Provision for impairment	減值撥備	**(26,491)**	(21,588)
		202,614	179,650
		203,635	181,089

(a) Notes receivables

The aging of notes receivables is within 180 days, which is within the Group's credit terms.

(a) 應收票據

應收票據的賬齡為180天內，處於本集團的信貸期內。

19 TRADE AND NOTES RECEIVABLES *(Continued)*

(b) Trade receivables

The credit terms given to trade customers are determined on an individual basis with normal credit period mainly around 30 to 120 days. The aging analysis of the trade receivables based on date of revenue recognition is as follows:

19 貿易應收款項及應收票據*（續）*

(b) 貿易應收款項

授予貿易客戶的信貸期按個別基準釐定，正常信貸期主要約為30至120天。貿易應收款項基於收入確認日期的賬齡分析如下：

		As at June 30, 2026 於2026年6月30日 RMB'000 人民幣千元 (Unaudited) （未經審計）	As at December 31, 2025 於2025年12月31日 RMB'000 人民幣千元 (Audited) （經審計）
Up to 3 months	不超過3個月	**101,382**	99,294
3 months to 6 months	3個月至6個月	**44,556**	38,776
6 months to 1 year	6個月至1年	**42,592**	23,194
1 to 2 years	1至2年	**20,794**	24,108
2 to 3 years	2至3年	**10,804**	9,043
More than 3 years	3年以上	**8,977**	6,823
		229,105	201,238

20 OTHER RECEIVABLES AND PREPAYMENTS 20 其他應收款項及預付款項

		As at June 30, 2026 於2026年6月30日 RMB'000 人民幣千元 (Unaudited) （未經審計）	As at December 31, 2025 於2025年12月31日 RMB'000 人民幣千元 (Audited) （經審計）
Other receivables	其他應收款項		
– refundable deposits	－可退還按金	6,831	8,005
– others	－其他	576	782
Gross other receivables	其他應收款項總額	7,407	8,787
Less: provision for impairment	減：減值撥備	(239)	(307)
		7,168	8,480
Prepayments for products and services	產品及服務之預付款項	39,427	45,782
Deductible input VAT	可抵扣進項增值稅	15,539	18,342
		62,134	72,604

As at June 30, 2026, the fair values of other receivables of the Group, except for the prepayments and deductible input VAT which are not financial assets, approximated their carrying amounts.

於2026年6月30日，本集團其他應收款項(預付款項及可抵扣進項增值稅除外，其並非金融資產)的公允價值與其賬面值相若。

21 LONG-TERM RECEIVABLES

Long-term receivables represented the receivables due for settlement by instalments, which are generally between 1 to 5 years. Long-term receivables contain significant financing components. Accordingly, these receivables are recognised initially at fair value and subsequently at amortised cost using the effective interest method. The portion due for settlement within 1 year is reclassified to trade receivables. The balance of long-term receivables was analysed in the following table.

21 長期應收款項

長期應收款項指須分期支付的應收款項，一般為期1至5年。長期應收款項包含重大融資部分。因此，該等應收款項初始按公允價值確認，隨後使用實際利率法按攤銷成本確認。於1年內到期須結算的部分重新分類為貿易應收款項。長期應收款項的餘額於下表分析。

		As at June 30, 2026 於2026年6月30日 RMB'000 人民幣千元 (Unaudited) （未經審計）	As at December 31, 2025 於2025年12月31日 RMB'000 人民幣千元 (Audited) （經審計）
Payment by instalment sales contract	分期付款銷售合約	**13,230**	13,530
Less: due within one year	減：於一年內到期	**(4,114)**	(4,269)
		9,116	9,261
Less: provision for impairment	減：減值撥備	**(56)**	(58)
		9,060	9,203

22 SHORT-TERM TREASURY INVESTMENTS　22 短期國債投資

		As at June 30, 2026 於2026年6月30日 RMB'000 人民幣千元 (Unaudited) （未經審計）	As at December 31, 2025 於2025年12月31日 RMB'000 人民幣千元 (Audited) （經審計）
Short-term treasury investments *(a)*	短期國債投資*(a)*		
– principal deposits	－本金存款	**135,222**	133,644
– interest receivable	－應收利息	**1,190**	5,802
Gross short-term treasury investments	短期國債投資總額	**136,412**	139,446
Less: provision for impairment	減：減值撥備	**(161)**	(205)
		136,251	139,241

(a) Short-term treasury investments included several fund products. These products were all redeemable at any time with a fixed interest return of 3.00%. The underlying assets of these products were primary short-term United States treasury bonds.

(a) 短期國債投資包括多項基金產品。該等產品均可隨時贖回，固定利息回報為3.00%。該等產品的相關資產為主要短期美國國債。

23 INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD

23 按權益法列賬的投資

		As at June 30, 2026 於2026年6月30日 RMB'000 人民幣千元 (Unaudited) (未經審計)	As at December 31, 2025 於2025年12月31日 RMB'000 人民幣千元 (Audited) (經審計)
– Associate	一聯營公司	**41,000**	–

The movements of investments accounted for using the equity method are as follows:

採用權益法入賬之投資變動如下：

		Associate 聯營公司 RMB'000 人民幣千元
(Unaudited)	（未經審計）	
At January 1, 2026	**於2026年1月1日**	**–**
Additions	添置	**41,000**
At June 30, 2026	**於2026年6月30日**	**41,000**

24 CASH AND CASH EQUIVALENTS, RESTRICTED CASH AND SHORT-TERM BANK DEPOSITS

24 現金及現金等價物、受限制現金及短期銀行存款

Cash and cash equivalents

現金及現金等價物

		June 30, 2026 2026年6月30日 RMB'000 人民幣千元 (Unaudited) （未經審計）	December 31, 2025 2025年12月31日 RMB'000 人民幣千元 (Audited) （經審計）
Cash at bank and in hand	銀行及手頭現金	912,722	997,273
Less: restricted cash *(a)*	減：受限制現金*(a)*	(1,718)	(70)
Less: short-term bank deposits with initial term of over three months *(b)*	減：初始期限超過三個月的短期銀行存款*(b)*	(433,680)	(372,018)
Cash and cash equivalents	現金及現金等價物	477,324	625,185

(a) Restricted cash

As at June 30, 2026, RMB1,718,000 was restricted guarantee deposits at bank for letters of guarantee (As at December 31, 2025, restricted cash of RMB70,000 was disclosed in current assets according to their maturity date).

(b) Short-term bank deposits were deposits with initial terms of over three months and were neither past due nor impaired. The directors of the Company considered that the carrying amount of the short-term bank deposits with initial terms of over three months approximated to their fair values as at June 30, 2026.

(a) 受限制現金

於2026年6月30日，共有受限制擔保存款人民幣1,718,000元為銀行擔保函作擔保(於2025年12月31日，共有受限制現金人民幣70,000元按其到期日於流動資產披露)。

(b) 短期銀行存款是指初始期限超過三個月的存款，既無逾期亦無減值。本公司董事認為，於2026年6月30日，初始期限超過三個月的短期銀行存款的賬面值與其公允價值相若。

25 SHARE CAPITAL 25 股本

		Number of ordinary shares 普通股數目	Share capital 股本 RMB'000 人民幣千元 (Unaudited) （未經審計）
At January 1, 2026, and June 30, 2026	**於2026年1月1日及2026年6月30日**	**563,779,000**	**563,779**
At January 1, 2025, and June 30, 2025	**於2025年1月1日及2025年6月30日**	563,779,000	563,779

26 OTHER RESERVES 26 其他儲備

		Share premium 股份溢價 RMB'000 人民幣千元	Capital reserve 股本儲備 RMB'000 人民幣千元	Treasury shares 庫存股份 RMB'000 人民幣千元	Share-based payments 以股份為基礎的付款 RMB'000 人民幣千元	Total 總計 RMB'000 人民幣千元
(Unaudited)	**（未經審計）**					
At January 1, 2026	**於2026年1月1日**	**1,388,579**	**295,295**	**(643)**	**612,541**	**2,295,772**
Share-based payments *(Note 28)*	以股份為基礎的付款 *（附註28）*	**–**	**–**	**–**	**17,254**	**17,254**
Repurchase of ordinary shares	購回普通股	**–**	**–**	**(5,699)**	**–**	**(5,699)**
At June 30, 2026	**於2026年6月30日**	**1,388,579**	**295,295**	**(6,342)**	**629,795**	**2,307,327**
(Unaudited)	**（未經審計）**					
At January 1, 2025	**於2025年1月1日**	1,388,579	295,295	–	611,315	2,295,189
Share-based payments *(Note 28)*	以股份為基礎的付款 *（附註28）*	–	–	–	613	613
As at June 30, 2025	**於2025年6月30日**	1,388,579	295,295	–	611,928	2,295,802

27 WARRANT LIABILITIES

27 認股權證負債

		As at June 30, 2026 於2026年6月30日 RMB'000 人民幣千元 (Unaudited) （未經審計）	As at December 31, 2025 於2025年12月31日 RMB'000 人民幣千元 (Audited) （經審計）
Warrant liabilities *(a)*	認股權證負債*(a)*	33,667	34,443

(a) During the year ended December 31, 2022, third-party investors (the "**Non-controlling Shareholders**") subscribed for 21.49% of the equity interest in one subsidiary of the Group, by way of capital injection for an aggregate amount of USD50,000,000 (equivalent to RMB330,140,000). Pursuant to the agreement entered into between the Non-controlling Shareholders and the subsidiary, a warrant was issued to the Non-controlling Shareholders that they had right to subscribe new shares (an aggregate amount of subscription price being less than USD20,000,000) in the subsequent round of the subsidiary's equity financing with an 80% financing price of any other investors in such round. Proceeds received from the Non-controlling Shareholders were recorded in the capital reserve, the non-controlling interests and warrant liabilities. Since the directors believe that the subsidiary of the Group will not start the subsequent round of equity financing before June 30, 2026, the warrant liabilities is classified as non-current liabilities with maturity of over 1 year.

(a) 截至2022年12月31日止年度，第三方投資者（「**非控股股東**」）以注資方式認購本集團一家附屬公司21.49%的股權，總金額為50,000,000美元（相當於人民幣330,140,000元）。根據非控股股東與附屬公司之間簽訂的協議，向非控股股東發出認股權證，其有權於下一輪附屬公司股權融資中認購新股（認購價總額低於20,000,000美元），該輪融資價為任何其他投資者的80%。從非控股股東處收到的所得款項已計入資本儲備、非控股權益及認股權證負債。由於董事認為本集團附屬公司於2026年6月30日之前不會啟動下一輪股權融資，認股權證負債被歸類為到期日超過1年的非流動負債。

Warrant liabilities were initially recognised at fair value of RMB28,796,000 and subsequently re-measured to their fair values at June 30, 2026. Changes of fair value were recorded in "Other losses – net" in interim condensed consolidated income statements (Note 9).

認股權證負債最初按人民幣28,796,000元的公允價值確認，隨後於2026年6月30日重新計量為其公允價值。公允價值變動計入中期簡明合併收益表的「其他虧損－淨額」（附註9）。

28 SHARE-BASED PAYMENTS

Starting from 2016, the board of directors approved share award schemes ("**restricted shares**") for the purpose of providing incentive for certain directors, senior management members and employees contributing to the Group. The Group receives services from employees as consideration for equity instruments of the Company or a certain subsidiary under the above schemes.

The restricted shares awarded vest in tranches from the grant date over the longer of certain service period and the period certain market capitalization condition is met. Once the vesting conditions of restricted shares are met, ordinary shares are considered duly and validly issued to the holder, and free of restrictions on transfer.

(a) Restricted shares granted by the Company

(i) 2023 Share Award Scheme

Movements in the number of restricted shares granted under 2023 Share Award Scheme are as below:

28 以股份為基礎的付款

自2016年起，董事會准予了股份獎勵計劃(「**受限制股份**」)，以激勵若干董事、高級管理人員及為本集團做出貢獻的員工。本集團根據上述計劃從員工處獲得服務，作為本公司或某附屬公司權益工具的對價。

授出的受限制股份自授出日期起於若干服務期間及特定市值條件達成期間之較長者內分批歸屬。各受限制股份的歸屬條件一經滿足，則視為正式有效地向持有人發出普通股，且轉讓不受限制。

(a) 由本公司授出的受限制股份

(i) 2023年股份獎勵計劃

根據2023年股份獎勵計劃授出的受限制股份數目變動如下：

		Number of restricted shares 受限制股份數目
(Unaudited)	**（未經審計）**	
At January 1, 2026	**於2026年1月1日**	**174,001**
Granted	授出	–
Vested	歸屬	–
Forfeited	沒收	–
At June 30, 2026	**於2026年6月30日**	**174,001**

28 SHARE-BASED PAYMENTS *(Continued)*

(a) Restricted shares granted by the Company *(Continued)*

(ii) 2026 H Share Award Scheme

Movements in the number of restricted shares granted under 2026 H Share Award Scheme are as below:

28 以股份為基礎的付款*（續）*

(a) 由本公司授出的受限制股份*（續）*

(ii) 2026年H股獎勵計劃

根據2026年H股獎勵計劃授出的受限制股份數目變動如下：

		Number of restricted shares 受限制股份數目
(Unaudited)	**（未經審計）**	
At January 1, 2026	**於2026年1月1日**	**–**
Granted	授出	**20,042,494**
Vested	歸屬	**–**
Forfeited	沒收	**–**
At June 30, 2026	**於2026年6月30日**	**20,042,494**

The fair value of restricted shares at the grant date was determined by reference to the fair value of the underlying ordinary shares of the Company on the respective dates of grant.

受限制股份於授出日期的公允價值乃參考本公司的相關普通股於各自授出日期的公允價值釐定。

28 SHARE-BASED PAYMENTS *(Continued)*

28 以股份為基礎的付款*(續)*

(a) Restricted shares granted by the Company *(Continued)*

(a) 由本公司授出的受限制股份*(續)*

Restricted shares of the Company outstanding at the end of the period have the following vesting period and exercise prices:

本公司於期末尚未歸屬的受限制股份的歸屬期及行使價如下：

	Vesting period 歸屬期	Exercise price 行使價 (RMB) （人民幣元）	Number of restricted shares 受限制股份數目 As at June 30, 2026 於2026年6月30日 (Unaudited) （未經審計）	As at December 31, 2025 於2025年12月31日 (Audited) （經審計）
2023 Share Award Scheme 2023年股份獎勵計劃	3 years 3年	0.86	**174,001**	174,001
1st batch of 2026 H Share Award Scheme 第一批2026年H股獎勵計劃	1.18 years 1.18年	1.00	**6,680,831**	–
2nd batch of 2026 H Share Award Scheme 第二批2026年H股獎勵計劃	1.33 years 1.33年	1.00	**6,680,831**	–
3rd batch of 2026 H Share Award Scheme 第三批2026年H股獎勵計劃	1.45 years 1.45年	1.00	**6,680,832**	–
			20,216,495	174,001

(b) Restricted shares granted by a subsidiary

(b) 由附屬公司授出的受限制股份

Movements in the number of outstanding restricted shares of a subsidiary during the six months ended June 30, 2026 are as follows:

截至2026年6月30日止六個月，附屬公司尚未歸屬受限制股份數目變動如下：

		Number of restricted shares 受限制股份數目
(Unaudited)	（未經審計）	
At January 1, 2026	**於2026年1月1日**	**450,500**
Granted	授出	**–**
Vested	歸屬	**–**
Forfeited	沒收	**–**
At June 30, 2026	**於2026年6月30日**	**450,500**

28 SHARE-BASED PAYMENTS *(Continued)*

(b) Restricted shares granted by a subsidiary *(Continued)*

The fair value of restricted shares at the grant date was determined by reference to the fair value of the underlying ordinary shares of a subsidiary on the dates of grant.

Restricted shares of a subsidiary outstanding at the end of the period have the following vesting period and exercise prices:

28 以股份為基礎的付款*(續)*

(b) 由附屬公司授出的受限制股份*(續)*

受限制股份於授出日期的公允價值乃參考附屬公司的相關普通股於授出日期的公允價值釐定。

附屬公司於期末尚未歸屬的受限制股份的歸屬期及行使價如下：

Grant date 授出日期	Vesting period 歸屬期	Exercise price 行使價 (RMB) （人民幣元）	Number of restricted shares 受限制股份數目 As at June 30, 2026 於2026年6月30日 (Unaudited) （未經審計）	As at December 31, 2025 於2025年12月31日 (Audited) （經審計）
November 18, 2021 2021年11月18日	5 years 5年	2.00	**50,500**	50,500
November 8, 2022 2022年11月8日	5 years 5年	1.00	**400,000**	400,000
			450,500	450,500

28 SHARE-BASED PAYMENTS *(Continued)*

(c) Share-based payments recorded during six months ended June 30, 2026

During the six months ended June 30, 2026, the amounts of share-based payments to employees were charged in the following categories in the interim condensed consolidated income statements:

28 以股份為基礎的付款*（續）*

(c) 截至2026年6月30日止六個月入賬的以股份為基礎的付款

截至2026年6月30日止六個月，向僱員作出的以股份為基礎的付款金額於中期簡明合併收益表中按以下類別扣除：

		Six months ended June 30, 截至6月30日止六個月	
		2026 **2026年** **RMB'000** **人民幣千元** **(Unaudited)** **（未經審計）**	2025 2025年 RMB'000 人民幣千元 (Unaudited) （未經審計）
Cost of sales	銷售成本	**1,072**	–
Selling expenses	銷售開支	**1,112**	–
Administrative expenses	行政開支	**12,121**	599
Research and development expenses	研發開支	**2,949**	14
		17,254	613

29 TRADE AND OTHER PAYABLES

29 貿易及其他應付款項

		As at June 30, 2026 於2026年6月30日 RMB'000 人民幣千元 (Unaudited) （未經審計）	As at December 31, 2025 於2025年12月31日 RMB'000 人民幣千元 (Audited) （經審計）
Trade payables – third parties	貿易應付款項－第三方	**102,953**	104,126
Staff salaries and welfare payables	應付員工薪金及福利	**47,539**	74,127
Other payables – third parties	其他應付款項－第三方	**8,352**	11,058
VAT payables related to contract liabilities	有關合約負債的應付增值税	**4,452**	6,172
Accrued taxes other than income tax	應計税項(所得税除外）	**4,679**	4,977
Others	其他	**541**	492
		168,516	200,952

(a) The carrying amounts of trade and other payables are considered to be approximated their fair values, due to their short-term nature.

(a) 由於屬短期性質，貿易及其他應付款項的賬面值被視為與其公允價值相若。

29 TRADE AND OTHER PAYABLES *(Continued)*

Aging analysis of the trade payables based on purchase date at the end of June 30, 2026 are as follows:

29 貿易及其他應付款項*（續）*

於2026年6月30日，貿易應付款項基於購買日期的賬齡分析如下：

		As at June 30, 2026 於2026年6月30日 RMB'000 人民幣千元 (Unaudited) （未經審計）	As at December 31, 2025 於2025年12月31日 RMB'000 人民幣千元 (Audited) （經審計）
Up to 3 months	不超過3個月	**28,888**	41,233
3 months to 6 months	3個月至6個月	**14,874**	13,450
6 months to 1 year	6個月至1年	**20,722**	20,962
1 to 2 years	1至2年	**29,314**	24,746
More than 2 years	超過2年	**9,155**	3,735
		102,953	104,126

30 BORROWINGS

30 借款

		As at June 30, 2026 於2026年6月30日 RMB'000 人民幣千元 (Unaudited) （未經審計）	As at December 31, 2025 於2025年12月31日 RMB'000 人民幣千元 (Audited) （經審計）
Unsecured	**無抵押**		
Short-term bank borrowing	短期銀行借款	**75,489**	48,000
Interest payable	應付利息	**–**	–
		75,489	48,000

30 BORROWINGS *(Continued)*

30 借款*（續）*

The Group's borrowings are all denominated in RMB.

本集團的借款均以人民幣計值。

As at June 30, 2026, the Group's borrowings were repayable as follows:

於2026年6月30日，本集團的借款償還情況如下：

		As at June 30, 2026 於2026年6月30日 RMB'000 人民幣千元 (Unaudited) （未經審計）	As at December 31, 2025 於2025年12月31日 RMB'000 人民幣千元 (Audited) （經審計）
Up to 6 months	不超過6個月	71,617	30,000
6 months to 1 year	6個月至1年	3,872	18,000
		75,489	48,000

The aggregate principal amounts of bank borrowings and applicable interest rates were as follows:

銀行借款本金總額及適用利率如下：

		As at June 30, 2026 於2026年6月30日		As at December 31, 2025 於2025年12月31日	
		Amount 金額 RMB'000 人民幣千元	Interest rate 利率 Per annum 每年	Amount 金額 RMB'000 人民幣千元	Interest rate 利率 Per annum 每年
RMB bank borrowings	人民幣銀行借款	75,489	2.20%–2.40%	48,000	2.30%–2.40%

The fair values of short-term bank borrowings approximate their carrying amount as the discounting impact is not significant.

由於貼現影響不大，短期銀行借款的公允價值與其賬面值相若。

31 RELATED PARTY TRANSACTIONS

Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operation decisions. Parties are also considered to be related if they are subject to common control. Members of key management and their close family members of the Group are also considered as related parties.

31 關聯方交易

如一方有能力直接或間接控制另一方或對另一方在作出財務和經營決策方面有重大影響力，則雙方即被視為有關聯。如雙方受共同控制，則亦會被視為有關聯。本集團主要管理層成員及其近親家庭成員亦被認為是關聯方。

(a) Transactions with related parties

In the opinion of the Company's directors, the related party transactions were conducted in the ordinary course of business and based on terms mutually agreed by the underlying parties. Related party transactions of the Group during the six months ended June 30, 2026 include:

(a) 與關聯方的交易

本公司董事認為，關聯方交易乃於日常業務過程中按有關雙方共同協定的條款進行。本集團截至2026年6月30日止六個月的關聯方交易包括：

(i) Key management compensations

Key management includes directors (executive and non-executive) and senior management of the Company. The compensation paid or payable to key management for employee services is shown below:

(i) 主要管理層薪酬

主要管理層成員包括董事（執行董事和非執行董事）及本公司的高級管理層。就僱員服務已付或應付主要管理層的薪酬如下所示：

		Six months ended June 30, 截至6月30日止六個月	
		2026	2025
		2026年	2025年
		RMB'000	RMB'000
		人民幣千元	人民幣千元
		(Unaudited)	(Unaudited)
		（未經審計）	（未經審計）
Wages, salaries and bonuses	工資、薪金及花紅	**12,426**	8,043
Contributions to pension plans	退休金計劃供款	**490**	305
Other social security costs, housing benefits and other employee benefits	其他社會保障成本、住房福利及其他僱員福利	**358**	321
Share-based payments	以股份為基礎的付款	**11,450**	–
		24,724	8,669

31 RELATED PARTY TRANSACTIONS *(Continued)*

(a) Transactions with related parties *(Continued)*

(i) Key management compensations *(Continued)*

As at June 30, 2026, compensation of RMB14,625,600 has not been paid to key management (for the six months ended June 30, 2025: RMB2,190,000).

31 關聯方交易*(續)*

(a) 與關聯方的交易*(續)*

(i) 主要管理層薪酬*(續)*

於2026年6月30日，尚未向主要管理層支付的薪酬為人民幣14,625,600元(截至2025年6月30日止六個月：人民幣2,190,000元)。

32 CONTINGENCIES AND COMMITMENTS

(a) Contingencies

As at June 30, 2026, there were no significant contingencies items for the Group.

(b) Commitments

As at June 30, 2026, the Group did not have any significant capital commitments.

32 或有事項及承諾

(a) 或有事項

於2026年6月30日，本集團並無任何重大或有事項。

(b) 承諾

於2026年6月30日，本集團並無任何重大資本承諾。

33 EVENTS AFTER THE BALANCE SHEET DATE

Subsequent to the Reporting Period and up to the date of this report, the Company repurchased H Shares on the Stock Exchange pursuant to the general mandate to repurchase H Shares granted by the Shareholders on June 23, 2026 at an aggregate consideration of HK$20.6 million. All such repurchased H Shares were held by the Company as Treasury Shares.

In addition, the trustee (the "**Trustee**") of the H Share Award Scheme (Existing Shares) approved and adopted by the Shareholders on June 8, 2026 (the "**Share Award Scheme**") purchased H Shares on the Stock Exchange pursuant to the rules of the Share Award Scheme and the terms of the trust deed at an aggregate consideration of HK$90.0 million. Such H Shares are held by the Trustee on trust for the purposes of the Share Award Scheme.

33 資產負債表日期後事項

於報告期後及直至本報告日期，本公司根據股東於2026年6月23日授出的購回H股的一般授權於聯交所購回H股，總代價為20.6百萬港元。所有該等已購回H股由本公司作為庫存股份持有。

此外，股東於2026年6月8日批准及採納的H股獎勵計劃(現有股份)(「**股份獎勵計劃**」)的受託人(「**受託人**」)根據股份獎勵計劃的規則及信託契約的條款於聯交所購回H股，總代價為90.0百萬港元。該等H股由受託人為股份獎勵計劃的目的以信託方式持有。

Taimei
太美医疗科技